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Abstract 
The thesis addresses the potential application of ruthenium(II)-cobalt(III) 
heterodinuclear complexes as a new selective cancer treatment. The selectivity is to be 
achieved through the use of visible light to trigger activation of the drug. 
The majority of work conducted relates to the design and synthesis of the bridging 
ligand for the final ruthenium(II)-cobalt(III) heterodinuclear complex. In Chapter 2, a potential 
bridging ligand based on a functionalised terpyridine is described. The intention was to bind 
the ruthenium(II) metal centre to the terpyridine end of the bridging ligand and have a 
secondary binding domain available for coordination of the cobalt(III) metal centre. However, 
a reductive step in the synthetic pathway failed to produce the desired product and this 
potential bridging ligand had to be abandoned. 
In Chapter 3, two series of bridging ligands are described. The first of these series is 
based on Jurgen Sauer’s ‘LEGO’ system. In addition to describing the free synthesis of these 
ligands, their synthesis on a ruthenium(II) metal centre is described. The second series is based 
on disubstituted-1,2,4,5-tetrazines. These compounds are only able to be directly synthesised 
as the non-coordinated ligand. Coordination of these ligands to a single ruthenium(II) metal 
centre is then described. Ruthenium(II) complexes of both ligand series are then exposed to 
several transition metals and their ability to coordinate a second metal centre investigated. 
The formation of ruthenium(II)-cobalt(III) heterodinuclear complexes, using the ligand 
series detailed in Chapter 3, is described in Chapter 4. These complexes are formed by 
reacting the ruthenium(II) complex of the bridging ligand with either [Co(en)2(OTf)2](OTf) or 
[Co(tren)(OTf)2](OTf). These heterodinuclear complexes exhibit photo-activated ligand 
release, which makes them candidates for development as a potential cancer treatment. 
Abstract 
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The non-bridging ligands coordinated to the cobalt(III) metal centre in Chapter 4 were 
not cytotoxic. In order to make the system biologically active these ligands need to be 
changed. Chapter 5 describes how nitrogen mustards (a class of cytotoxic DNA alkylators) 
could be introduced as the non-bridging ligands. This involves the synthetic strategy of 
forming the cobalt(III) complex of the alcohol precursor of a nitrogen mustard. This precursor 
complex is then converted into the nitrogen mustard complex and coordinated to the 
ruthenium(II) bound bridging ligand. 
The synthetic strategies outlined in this thesis can be applied to a wide range of 
potential bridging ligands and could potentially lead to a large number of ruthenium(II)-
cobalt(III) heterodinuclear complexes being synthesised. 
One journal article based on this research has been accepted for publication, in the 
Australian Journal of Chemistry. Three more articles are in preparation. 
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1.1. Introduction 
During 2005 there were 18,610 new cancer registrations and 7,971 deaths from cancer 
recorded in New Zealand.[1] This means that in 2005 cancer accounted for 29.4 % of all deaths 
and was the leading cause of death in New Zealand. This makes research into new methods of 
cancer treatment both topical and important. 
The development of new cancer treatments provides medical practitioners with more 
options when treating a cancerous growth. Additional benefit may also be gained through a 
decrease in the negative side effects generally associated with cancer treatments. 
1.2. Differences between Malignant Tumours and Healthy 
Tissue 
A tumour is an abnormal tissue growth or mass that serves no useful purpose. In the 
case of a malignant tumour there is rapid growth of the mass and destruction of normal cells. 
The tumour may also spread to other parts of the body and is life threatening. The rapid 
growth causes the structure of the tumour to be highly irregular; blood vessels within the mass 
are a mixture of those that originally belonged to healthy tissue that the tumour invaded, and 
the tumour’s own microvessels. Therefore the blood vessels within the tumour are highly 
irregular, tortuous and develop abnormalities such as arterio-venous shunts, blind ends, a lack 
of smooth muscle, and incomplete endothelial linings and basement membranes. The end 
result is that the tumour has poor vasculature throughout and the vessels are ‘leaky’ when 
compared to blood vessels in normal tissue.[2] 
The poor vasculature results in insufficient amounts of oxygen being able to diffuse to 
all cells in the tumour and the formation of hypoxic and even necrotic regions (Figure  1.1). 
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Figure  1.1 Hypoxia in tumours, the more hypoxic regions are shaded darker
[3]
 
In addition to a decrease in oxygen levels associated with an increase in distance to 
nearest blood vessel, there is also a decrease in pH. It is believed that the main reason for this 
decrease in pH is the hydrolysis of adenosine triphosphate.[4, 5] Unfortunately some drugs, such 
as doxorubicin, are absorbed less readily and are less cytotoxic at lower pH.[6] This means that 
these treatments are less effective against the hypoxic regions of the tumour. In addition to 
this, because the drug needs to diffuse further to reach these areas the dose received is also 
lower. Unfortunately, exposure to non-lethal concentrations of a chemotherapeutic agent can 
also result in the development of resistant tumours. 
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Figure  1.2 Oxygen concentration and pH in relation to distance to nearest blood vessel
[7]
 
A further consideration when targeting a cancerous growth is the leaky vasculature. 
The incomplete endothelial lining and basement membranes result in the tumour vessels being 
more permeable to large molecules. It has been observed that these defects result in the tumour 
being permeable by liposomes 400 nm in diameter, but not by liposomes 600 nm in 
diameter.[8] This suggests that the average size of the pores in tumour vessels is between 400 
and 600 nm. It is possible that the pore size is smaller than this and that the liposomes are 
deforming to pass through. However, prior measurements of the average pore size in rat liver 
tissue using a scanning electron microscope found that the periportal fenestrae (pores around 
the portal veins) have an average diameter of 106 nm. The same study found that the 
hepatocytes will take up liposomes up to around 100 nm in diameter and that larger liposomes 
are taken up by the macrophagic Kupffer cells.[9] These observations are consistent with the 
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proposal that pore diameter can be estimated to be the same as the diameter of the largest 
liposome that can pass through. 
These differences between healthy tissue and malignant tumours provide both an 
impediment to effective treatment, as well as a possible basis for targeting the cancerous 
growth through chemotherapy. 
1.3. Origins of Chemotherapy 
Chemotherapy is the use of highly toxic drugs to treat or control cancer cells, either by 
interfering with their growth or preventing their reproduction.[10] The origins of modern 
chemotherapeutic agents date back to the First World War. Mustard gas was used as a 
chemical warfare agent, causing severe irritation to the skin, eyes, and respiratory system and 
resulting in blistering and skin ulcers. However, after the war ended, it was discovered that in 
addition to its vesicant properties, mustard gas was toxic towards blood and bone marrow.[11] 
The active ingredient of mustard gas is the sulfur mustard bis(2-chloroethyl)sulfide, a 
colourless odourless liquid in its pure form. However, the impure form is coloured, usually 
yellow, and has an odour resembling mustard plants, hence the name. 
Cl
S
Cl 
Figure  1.3 bis(2-chloroethyl)sulfide (mustard gas) 
The 1925 Geneva Protocol banned the war time use of toxic gases. However, this did 
not stop military studies with the gas from continuing. In 1946, after the end of the Second 
World War, Goodman et al[12] revealed that they had been conducting war time studies 
involving the effects of nitrogen mustards on lymphomas. The publication of their results had 
to be delayed because of war time secrecy and when finally published gave medical 
practitioners a method of treatment besides surgery and radiation therapy.[13] In addition to 
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providing medical practitioners with a new treatment regime, the publication gave rise to the 
concept that a chemical which shows toxicity towards normal tissues could potentially be used 
in the treatment of neoplastic disease. 
The drug Mitotane (1.1), used in the treatment of adrenocortical carcinoma, is another 
example of observed toxicity towards normal cells resulting in the discovery of an effective 
treatment for abnormal cells. Nelson and Woodard,[14] while evaluating the toxicity of 
insecticides, observed that crude dichlorodiphenyldichloroethane (DDD) caused atrophy of the 
adrenal cortex. DDD, which is very similar to the insecticide DDT (1.2) 
(dichlorodiphenyltrichloroethane), was then studied for use as a chemotherapeutic agent. The 
active compounds were found to be the o,pʹ isomers of DDD, which are now marketed as the 
drug Mitotane (Figure  1.4).[15] 
Cl Cl
Cl
Cl
Cl Cl
Cl
Cl Cl  
Figure  1.4 Mitotane and the related insecticide DDT 
Because of the well established history of poisoning associated with metal based 
treatments, especially with heavy metals, many prejudices had to be overcome before the field 
of medicinal metal complexes would come into its own. One of the earliest metal containing 
treatments for cancer, dating back to 1786, was a 1% solution of potassium arsenite known as 
Fowler’s solution. This is a highly toxic solution which causes cirrhosis of the liver as well as 
other cancers to form.[16] 
The origins of the first successful metal based chemotherapeutic agents lie not in war 
or toxicity trials but rather in serendipity. Barnett Rosenberg, while examining the influence of 
an electric field on bacterial growth, observed that the E. coli bacteria grew up to 300 times 
1.1 1.2 
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their own length without cell division. The platinum electrodes being used in these studies 
were submerged in an electrolyte solution containing ammonium chloride. This resulted in the 
formation a range of platinum species, including ammonium hexachloroplatinate(IV), which 
could be then photochemically converted into cis-diamminetetrachloroplatinum(IV). Through 
additional experiments with platinum complexes and E. coli, Rosenberg was able to 
demonstrate that it was cis-diamminetetrachloroplatinum(IV) that was causing the abnormal 
cell growth (Figure  1.5). [17, 18] 
  
Figure  1.5 Rosenberg’s phase contrast photomicrographs of E. coli cultures with less than 6 ppm [PtCl6]
2
¯ 
and with 8 ppm cis-[PtCl4(>H3)2] 
Following on from this, Rosenberg synthesised a range of simple platinum complexes, 
including cis-diamminedichloroplatinum(II) (cisplatin). Using these complexes he was able to 
achieve a reduction in tumour weight and increase the lifespan of the animal test subjects.[19] 
Cisplatin is still used today and is highly effective against testicular and ovarian carcinomas as 
well as bladder, head and neck tumours.[16] 
Thanks to the work of Rosenberg, the reluctance to use metals in the treatment of 
disease was overcome and the field of metal-based chemotherapy was opened up. Today a 
wide range of compounds containing metals such as ruthenium, gold, gallium, titanium, tin, 
iron and cobalt are used and/or examined as possible cancer treatments. 
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1.4.  Effect of Chemotherapeutic Agents on DNA 
Most chemotherapeutic agents interact with DNA in some manner. These interactions 
can be either indirect or direct. Indirect interactions involve interference with the precursors 
and biochemical apparatus necessary for DNA synthesis while direct interactions can be 
summarised as occurring through intercalation, outer-sphere binding, inner-sphere binding and 
strand breakage. 
Intercalation involves the insertion of a planar molecule between two DNA base pairs; 
this process is primarily driven by π stacking and electrostatic interactions.[20] This binding 
mode distorts the DNA structure; however, the actual mechanism by which intercalating 
chemotherapeutic agents operate is through strand breakages resulting from the inhibition of 
the religation step of DNA topoisomerase II.[20, 21] 
Outer sphere binding occurs through the interaction of the negatively charged 
backbone of the DNA double helix and positively charged molecules.[22] It has been well 
established that octahedral cobalt(III) complexes are capable of these types of interactions.[23]  
Inner sphere binding involves the formation of covalent bonds to the bases of DNA. 
This interaction is a very common between transition metals and DNA.[22] 
Strand breakage can occur for a variety of reasons. As mentioned previously, 
intercalation can cause strand breakage through its interaction with DNA topoisomerase II. In 
addition to this, strand breakage can occur through redox and hydrolytic reactions. 
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1.4.1. Nitrogen Mustards 
Nitrogen mustards are a class of DNA alkylating agents and were the first clinically 
effective cancer chemotherapeutic agents. The first nitrogen mustard drug was 
mechlorethamine and it is still in use today (Figure  1.6). 
N
Cl
CH3
Cl  
Figure  1.6 Mechlorethamine 
Mechlorethamine’s major clinical use is in the treatment of Hodgkin’s disease. The 
cytotoxicity results from its ability to crosslink DNA. All nitrogen mustards either mono-
alkylate or crosslink DNA and this can often trigger apoptosis. This alkylation occurs in a two 
step process. First a cationic cyclic intermediate is formed by the lone pair on the nitrogen 
atom displacing a chloride ion, followed by nucleophilic attack from DNA onto the cyclic 
intermediate (Figure  1.7). 
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Figure  1.7 Alkylation of D>A by a nitrogen mustard 
The biggest problem associated with nitrogen mustards is their lack of specificity for 
cancerous growths. Instead, they result in a high degree of DNA alkylation in the major 
groove at the N7 position of guanine.[24] In order to try and improve the selectivity of nitrogen 
mustards there has been a lot of work conducted on the development of prodrugs; compounds 
that will be selectively transformed into nitrogen mustards after administration. 
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1.4.2. Cisplatin 
Cisplatin is the gold standard of metal based chemotherapeutic agents. Its activity was 
first discovered in 1969, and it has since become established as a highly effective drug for the 
treatment of testicular tumours (Figure  1.8), ovarian carcinomas, bladder tumours and head 
and neck cancer. In addition to this, it has also shown activity towards lung cancers, 
lymphomas, breast cancer, and oesophageal cancer as well as several other tumour types.[25] 
 
Figure  1.8 Lung metastases of a testicular cancer patient before and after receiving 4 cycles of cisplatin-
containing chemotherapy
[16]
 
An additional benefit of cisplatin is the marked synergy shown when combined with 
other chemotherapeutic agents; thus enabling more flexibility in the design of drug regimens. 
The major disadvantage associated with the use of cisplatin is the persistence of severe toxic 
side effects.[26] A review of 32 chemotherapeutic agents for nephrotoxicity found that cisplatin 
posed the highest risk.[27] This risk can be minimised by the use of hydration, diuretics and 
sulfur nucleophiles, as this lowers the concentration of the active drug in the kidneys. 
Because of the success of cisplatin, a lot of work has gone into testing analogous 
chemicals to develop structure-activity relationships. The primary aim of these studies is to 
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develop active complexes that are less toxic than cisplatin; an example of such a drug is 
carboplatin (Figure  1.9). 
O
O
O
O
Pt
H3N
H3N
 
Figure  1.9 Carboplatin 
The toxic side effects of carboplatin are much milder than those associated with 
cisplatin; there is no neurotoxicity, gastrointestinal effects are milder and there is considerably 
less damage to the kidneys. Because of the reduced nephrotoxicity, and therefore lack of need 
for hydration, carboplatin can be administered on an outpatient basis. 
The platinum-based chemotherapeutic agents all interact with DNA in the same 
manner. The first step is aquation, where at least one of the leaving groups is replaced with 
water. The platinum then binds to DNA, initially forming a monofunctional adduct. Platinum 
binding to DNA is irreversible and as such any observed selectivity must arise through 
preassociation and kinetic control. The platinum then binds to the DNA a second time, 
possibly after a second aquation step, resulting in the formation of both interstrand and 
intrastrand bifunctional adducts. This cross-linking results in the deformation of the DNA 
strand and ultimately results in cell death, most probably via apoptosis.[28] 
1.4.3. Ruthenium Complexes 
Platinum group transition metals have a relatively high affinity for the lone pairs on 
most nitrogen ligands; this includes those which occur in important classes of biomolecules 
such as proteins and nucleic acids. The wide variety of complexes capable of being formed 
makes ruthenium a very promising chemotherapeutic agent.[29] 
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The observed mutagenic effects of ruthenium complexes indicated to early researchers 
that DNA was the target molecule for ruthenium based anticarcinogens and provided a 
valuable working hypothesis for the design of new drugs.[30] Since then, ruthenium complexes 
have been shown to interact with DNA through a variety of mechanisms such as coordination 
to the base pairs, or as a groove binder, metallointercalator (complexes that unwind DNA in 
order to π-stack between two base pairs) or metalloinsertor (complexes that eject the bases of a 
single base-pair, with their planar ligand acting as a π -stacking replacement in the DNA base 
stack) (Figure  1.10). The type of interaction is determined by the coordinated ligands. 
Ruthenium complexes with monodentate ligands, such as [Ru(NH3)5Cl]Cl2, coordinate to 
DNA. However, the formation of coordination bonds between nucleic acids and cationic 
ruthenium compounds is likely to be preceded by electrostatic interactions, such as outer 
sphere binding to the negatively charged phosphate backbone. Ruthenium(II) complexes with 
three bidentate aromatic ligands are more likely to non-covalently interact with DNA. 
Depending on the ligands that are coordinated to the ruthenium centre, the complex may be 
chiral, and this chirality can in turn affect the way that the metal interacts with the DNA.[31, 32] 
 
Figure  1.10 >on covalent binding modes of metal complexes to D>A
[32]
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It has also been shown that many diruthenium complexes will associate with non-
duplex DNA and RNA structures such as bulges, junctions and hairpin loops. These studies 
have shown that the nature of the bridging ligand, flexible or rigid, as well as the terminal 
ligands and their coordination geometry all affect the selectivity of the complex for a specific 
feature.[33] 
There are several key differences between ruthenium and most of the platinum based 
anticancer drugs. Firstly, ruthenium complexes are usually six coordinate with an octahedral 
geometry as opposed to the square planar arrangement of platinum(II) complexes. Secondly, 
the facility with which electron transfer takes place for ruthenium(II)-ruthenium(III) as 
opposed to platinum(II)-platinum(IV), which undergoes both a change in coordination number 
and bond distance, means that ruthenium complexes are more capable of causing strand 
cleavage through a redox pathway. Finally, ruthenium compounds are known to be less toxic 
than their platinum counterparts.[34] 
Two ruthenium-based anticancer drugs, NAMI-A and KP1019 (Figure  1.11), have 
successfully completed phase I clinical trials for the treatment of metastatic tumours and colon 
cancers. It is believed that these drugs select for cancerous tissue by mimicking iron ions. 
Since rapidly dividing cells have a greater demand for iron, this results in the ruthenium 
complexes being more effectively delivered. In the case of NAMI-A, the dose-limiting toxicity 
was the formation of painful blisters, while KP1019 had comparatively mild side effects. 
Although the mechanism of cytotoxic action is not known, it is believed to involve activation 
of the complex by reduction from ruthenium(III) to ruthenium(II) inside the tumour.[34, 35, 36] 
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Figure  1.11 Structure of >AMI-A and KP1019 
1.5. Targeted Treatment of Cancerous Cells 
Since chemotherapy uses highly toxic chemicals, the targeting of cancerous cells in 
preference to non-cancerous cells is essential for developing successful treatments. In order to 
achieve this selectivity, most traditional treatments have focused on exploiting the differences 
between healthy and cancerous cells. For most chemotherapeutic agents the primary form of 
discrimination is achieved by targeting the rapid proliferation of the cancerous cells.[2, 3, 37] 
However, there are limitations associated with this type of selectivity. The dosage is 
limited by the cytotoxic effects of the drug on normal cells, especially bone marrow, hair 
follicles, and epithelial cells lining the gastrointestinal tract.[2] Over time, tumours can develop 
a resistance to the drug, which can arise through mutations, changes in uptake, metabolism, or 
the limited ability of the drug to penetrate the tumour.[7] Also, not all tumours, or parts of 
tumours, are fast growing and may not be targeted by traditional chemotherapy agents. 
One way to circumvent the problems associated with chemotherapy is through the 
development of prodrugs, compounds that become active after administration. The advantage 
of using a prodrug is that it can lead to optimisation of the absorption, distribution and 
metabolism of the active compound. In addition, the use of prodrugs often results in an 
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increase in selectivity towards the intended target, which can reduce the negative side effects 
associated with treatment. 
An example of a prodrug currently being used in chemotherapy is cyclophosphamide. 
Cyclophosphamide is oxidized in the liver by the mixed function oxidase system[38] into 4-
hydroxycyclophosphamide, and the ring opened aldophosphamide. The biologically active 
nitrogen mustard phosphoramide is then produced by a β elimination of the aldophosphamide 
(Figure  1.12).[39, 40] This mustard then alkylates and crosslinks DNA and this ultimately leads 
to apoptosis. 
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Figure  1.12 Conversion of the prodrug cyclophosphamide into the phosphoramide mustard alkylating 
agent 
Unfortunately most prodrugs activate non-specifically, usually in the liver, and as such 
are still limited by their negative effects on healthy tissue. In order to develop a truly selective 
treatment, more of the differences between cancerous and non-cancerous cells need to be 
exploited. 
Chapter 1 Introduction 
Photo-activated Cytotoxins Alan Downward 16 
Prodrugs which become active by a reductive mechanism and can be easily back 
oxidised by molecular oxygen should show an increase in selectivity for the hypoxic regions 
of tumours, where the concentration of oxygen is lower. Tirapazamine (3-
aminobenzo[1,2,4]triazine-1,4-di--oxide), which shows a 2 to 3 fold selectivity for hypoxic 
regions in vivo, promises to be the first hypoxia selective drug with clinical applications and is 
currently undergoing stage III trials. The drug is activated by an enzymatic one electron 
reduction, forming a radical intermediate which, if not back oxidised, causes DNA breakages 
(Figure  1.13).[37] However, limitations such as lower hypoxia selectivity in vivo compared to 
in vitro mean that the usefulness of tirapazamine could be more related to its use as a lead 
compound for future hypoxia selective drugs, rather than as a final treatment.[41] 
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Figure  1.13 Activation of tirapazamine by a reductive mechanism 
Another way to target the hypoxic region of the tumour is through the use of pH 
sensitive drugs. The exact effect of pH is complicated because pH can influence the transport, 
uptake and metabolism of a drug.[4] However, neutral species are often more readily taken up 
by cells than charged species and, if the pKa of the drug is low, then it will be more readily 
absorbed at low pH. Chlorambucil, 4-[bis(2-chloroethyl)amino]benzenebutanoic acid (Figure 
 1.14), is an example of such a drug. With a pKa of 5.8, chlorambucil exists primarily in the 
deprotonated form at physiological pH, but at lower pH the neutral form will be prevalent, 
resulting in an increase in uptake.[3] 
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Figure  1.14 Chlorambucil 
Because tumours have leaky vasculature, another way to specifically target them is 
through the use of drug-carrying nanoparticles or liposomes. The drug doxorubicin (Figure 
 1.15) is used in the treatment of a variety of neoplastic diseases, and the liposomal formulation 
has also been approved for use in the treatment of ovarian cancer under the name DOXIL. 
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Figure  1.15 Doxorubicin 
DOXIL places the chemical doxorubicin inside a liposome, which is then coated in 
methoxypolyethylene glycol to give the pegylated liposome (Figure  1.16). One of the 
advantages of DOXIL is that it shows reduced cardiotoxicity in comparison to the non-
liposomal form of the drug.[42] 
 
Figure  1.16 Schematic representation of DOXIL
[43]
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1.6. Hypoxia Selective Cobalt(III) Cytotoxins 
In order to develop new hypoxia selective cancer treatments, Denny and his group 
have conducted work relating to prodrugs activated by a reductive mechanism.[44, 45, 46, 47, 48] 
While much of the work dealt with the development of organic drugs that were activated in a 
manner similar to that of tirapazamine, they also conducted work using cobalt(III) complexes. 
The d6 low-spin electronic configuration of octahedral cobalt(III) complexes renders 
them kinetically inert. For example, the aquation of [Co(NH3)6]
3+ has a rate constant of 
5.8x10-12 s-1, which corresponds to a half-life of ~3800 years.[49] This is in stark contrast to 
cobalt(II), a labile metal ion where the rate constant for the aquation of the first ethane-1,2-
diamine from [Co(en)3]
2+ is 6.8x102 s-1, a half-life of ~0.001 s.[50] 
Since the cobalt(III)-cobalt(II) reduction potential can fall within the range of cellular 
reductants, it is reasonable to expect that the one-electron reduction needed to facilitate this 
massive change in behaviour can occur in vivo. Hypoxia selectivity is achieved through 
reoxidation of the labile cobalt(II) species to the inert cobalt(III) species, by molecular oxygen 
before ligand release occurs. 
Binding a nitrogen mustard such as ,-bis(2-chloroethyl)ethane-1,2-diamine to an 
inert cobalt(III) metal centre effectively renders it much less active, as the lone pair on the 
nitrogen atom needed to form the highly reactive aziridinium is involved in binding to the 
metal. Following reduction of the metal centre in the hypoxic region of the cell, the mustard 
may be released. The lone pair of the nitrogen is now no longer involved in binding and the 
drug is active (Figure  1.17). 
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Figure  1.17 Reductive activation of cobalt(III) complexes as hypoxia selective cytotoxins 
The activity of these complexes was tested in vitro against both the AA8 and UV4 cell 
lines. The UV 4 cell line is hypersensitive to alkylating agents and is used to confirm that the 
cytotoxicity is due to alkylation and not some other process. The degree of hypoxia selectivity 
was also assessed using the UV4 cell line. The concentration multiplied by the time taken to 
reduce cell survival to 10% (CT10) was measured under both aerobic and hypoxic conditions. 
Table  1.1 Cytotoxic data for alkylating ligands and their cobalt(III) complexes
[45]
 
Compound IC50 (air) 
AA8 
HF (air) 
AA8/UV4 
Aerobic CT10/hypoxic CT10 
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890 µM 14 1.6 
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Although the study showed that the cobalt(III) was being reduced to cobalt(II) and 
releasing the bound mustards, the small variation in the CT10 values under aerobic and 
hypoxic conditions means that the complexes exhibit only modest hypoxia selectivity in vitro. 
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Additional in vivo studies showed little activity against hypoxic cells and the series has not 
been developed further.[37] 
1.7. Photodynamic Therapy 
Photodynamic therapy is a cancer treatment where light and a photosensitizer interact 
to destroy tumour tissue. Patients are injected with a light-activated photosensitizer that makes 
their body sensitive to light. The drug is more readily retained by cancerous cells than normal 
tissue, so that following exposure to light the photosensitizer produces a toxic reaction that 
selectively destroys the tumour.[10] 
The use of visible or near-IR light to trigger cytotoxicity presents both advantages and 
disadvantages in cancer therapy. The main advantage is the ability to localise the toxicity to a 
selected site, reducing the damage done to normal cells. One of the disadvantages is the 
limited depth of effect due to problems associated with penetration of the light into tissues. 
Another disadvantage is the inability to treat widespread metastases.[51] 
Photodynamic reactions were first studied in 1900 when Raab used acridine and light 
to facilitate the killing of paramecium. The first photosensitizer used in humans was 
hematoporphyrin derivative (Hpd), which is a series of hematoporphyrin (Hp) oligomers, 
joined by a mixture of ether and ester linkages, ranging up to six units long. Hpd was first 
prepared by acetylating Hp and then dissolving the mixture in an aqueous alkali solution.[51] 
Hpd is now sold under the trade name of Photofrin and is used to treat obstructing 
endobroncial non-small lung carcinoma and obstructing oesophageal cancer. 
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Figure  1.18 Hematoporphyrin and the oligomer hematoporphyrin derivative (Photofrin) 
The mechanism by which a photosensitizer operates is believed to involve the 
sensitizer first absorbing a photon and going to an excited singlet state, from this singlet state 
intersystem crossing gives rise to an excited triplet state. The excited triplet state is able to 
interact with molecular oxygen, which results in the photosensitizer relaxing back to the 
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ground state and the formation of singlet oxygen (Figure  1.19). Singlet oxygen is highly 
reactive and the damage it causes to DNA can result in cell death.[51] 
Sen + hv
1Sen*
3Sen* + O2
1Sen* + hv
3Sen*
Sen + 1O2
*
ISC
 
Figure  1.19 Generation of singlet oxygen by photodynamic therapy 
1.8. Photo-activated Cytotoxins 
The purpose of this project was to synthesise a system in which heteronuclear metal 
centres are connected by a bridging ligand. When light strikes one of the metal centres, it 
excites an electron through the bridging ligand onto the other metal, which causes it to be 
reduced to a labile state. In this labile state it will swap its current ligands for water. By 
choosing to have a cytotoxic molecule as one of the ligands a photo-activated release is 
achieved (Figure  1.20). Provided the cytotoxin is relatively inactive while bound to the metal 
centre, the light induced release will serve as the trigger for enhanced anti-cancer activity. 
D L A C
Electron Transfer
Cytotoxin
Release
hv
Light
Absorption
 
Figure  1.20 Schematic of a photo-activated cytotoxin: Photo-induced electron transfer from the donor (D) 
to the acceptor (A) through the bridging ligand (L) results in release of the cytotoxin (C) 
Several aspects were considered when selecting a donor site. Firstly, the chosen donor 
must be able to undergo photo-oxidation, for example by a metal-to-ligand-charge-transfer 
process, as well as being relatively stable in both oxidation states. Ruthenium polypyridyl 
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complexes are an example of a class of compounds which could be used for this purpose. 
Another option is to use zinc porphyrin complexes, where the excitation would involve a π to 
π* transition instead of a MLCT. Ruthenium polypyridyl complexes have often been used in 
studies involving intramolecular electron transfer between two metal sites,[52] and are the main 
focus of this study. 
The acceptor site must be able to accept the electron generated by the donor and in 
doing so change from an inert to labile state. Metal ions such as cobalt(III) and chromium(III) 
are capable of doing this. The fact that most cobalt(III) complexes are diamagnetic makes 
them a great deal more convenient to study than the related paramagnetic chromium(III) 
species, principally because diamagnetic compounds are more readily studied by NMR 
techniques. 
As soon as more than one kind of metal ion binding site is present in an unsymmetrical 
bridging ligand, a synthetic problem arises, in that the binding of the first metal to the ligand 
could, in principle, occur at either site. There are two ways that selective binding can be 
achieved: either the ligand can be synthesised on one of the metal centres, or synthetic 
strategies designed to introduce exploitable differences between the binding sites can be used. 
Synthetic differentiation between the sites can be achieved by controlling the binding 
geometries of the sites, as well as the number of donor atoms at each binding domain. For 
example, a tridentate ligand can bind either meridionally or facially. If a metal atom is already 
bound by a tridentate ligand, in either manner, then this will restrict the coordination geometry 
of a second tridentate ligand, since a meridional ligand prohibits the binding of a facial ligand 
and vice versa. It is therefore possible, through the use of tridentate ligands with appropriate 
geometry, to control the end to which the donor and acceptor metals will bind. 
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The bridging ligand used must allow for the transfer of the electron from the donor to 
the acceptor site. This is best achieved by transmission of the electron through the bridging 
ligand. Bridging ligands with conjugated π-bonds are better suited to allowing this electron 
transfer to occur. Since the bridging ligand also heavily influences the structure of the final 
system, especially the distances between the donor and accepter sites, rigidity is desirable. 
Spacers with aromatic ring systems satisfy both of these criteria and were the focus of this 
project.[53] 
1.9. Ruthenium 
The element ruthenium was discovered in 1844 by Karl Klaus, who was examining the 
residues being produced by the St. Petersburg platinum refinery. These residues were the 
insoluble parts of the mineral which remained after treatment with aqua regia. Klaus treated 
the residue with a variety of reagents and examined the resulting compounds by smell, taste, 
and appearance under a microscope. Eventually, from the 8 kg of crude residue originally 
given to him, Klaus was able to isolate 6 g of pure ruthenium metal. Klaus sent the samples of 
his ruthenium compounds to Jöns Berzelius who initially proclaimed them to be dirty iridium 
salts. Klaus responded by sending additional salts as well as his most recent publications to 
Berzelius who finally accepted it as being a new element.[54, 55] 
The name ruthenium is taken from Ruthenia, the Latin name for an historical area of 
Europe comprised of Western Russia, Ukraine, Belarus, and small regions of Poland and 
Slovakia. The name ruthenium had first been proposed by Gottfried Osann in 1827 when he 
believed he had discovered three new metals in platinum residues, this claim was rejected by 
Berzelius causing Osann to withdraw his claim. Klaus chose to reuse the name ruthenium as 
an acknowledgment to Osann as well as to honour his native land of Russia. 
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Ruthenium is observed in a number of oxidation states, with +2, +3 and +4 being the 
most common (Table  1.2). The raw metal is not oxidised by cold air but will readily form 
RuO2 on heating. The metal is not soluble in either hot or cold acids; it was this insolubility 
that led to its discovery. However, if potassium perchlorate is added to an acid in contact with 
ruthenium metal the resulting oxidation is explosive. 
Table  1.2 Ruthenium complexes of various oxidation states
[55]
 
Complex Oxidation 
State 
[RuO4] 8 
[RuO4]¯ 7 
[RuO2Cl4]
2¯ 6 
[RuF6]¯ 5 
[Ru(bpy)Cl4] 4 
[RuO2] 4 
[Ru(NH3)6]
3+ 3 
[Ru(bpy)3]
2+ 2 
[Ru(C6H6)2]
2+ 2 
[Ru(CO)5] 0 
 
Ruthenium is in group 8 of the periodic table and has an atomic electron configuration 
of [Kr](4d)7(5s)1. As a second row transition metal, the ligand field is substantially larger than 
that encountered in first row metals. Because of this, higher temperatures are needed to 
facilitate ligand exchange and the obtained compounds are very stable. This stability extends 
to the reaction conditions normally utilised in synthetic organic chemistry. The ligands on a 
ruthenium metal centre can be exchanged in a systematic manner. In addition, after binding to 
a ruthenium metal centre, the properties of a ligand do not differ greatly from its 
uncoordinated form. These characteristics of ruthenium compounds mean that they can be 
tailored to form designer compounds.[56] 
The two oxidation states of ruthenium that are of interest to us in our study are 
ruthenium(II) and ruthenium(III). Ruthenium(II) is a low spin d6 metal centre which usually 
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forms monomeric, six-coordinate octahedral complexes. Ruthenium(III) is a low spin d5 metal 
centre and like ruthenium(II) will usually form six-coordinate monomers. Because both 
oxidation states of ruthenium are usually low spin they are kinetically inert,[57] which has the 
advantage that complexes of these metals are usually quite stable under laboratory conditions. 
With no unpaired electrons, ruthenium(II) is diamagnetic, meaning that complexes of this 
metal centre can easily be studied by NMR techniques. 
1.9.1. Ruthenium (III) 
The quantity of ruthenium(III) complexes makes an exhaustive discussion of this class 
of compounds and their properties unfeasible in this introduction. Ruthenium(III) forms many 
stable cationic, neutral and anionic complexes. The compound RuCl3.xH2O is the most 
common starting material in ruthenium chemistry. However, this material is actually a mixture 
of monomeric and polymeric ruthenium complexes in various oxidation states coordinated 
with various ligands, and despite being commonly referred to as ruthenium(III) the average 
oxidation state is actually closer to four than three.[55] RuCl3.xH2O is usually prepared by 
evaporation of a solution of RuO4 in HCl, while true ruthenium(III) chloride is prepared by 
heating ruthenium metal in an atmosphere of chlorine and carbon monoxide.[58] 
RuCl3.xH2O is used as a starting material in the synthesis of most ruthenium(II) 
polypyridyl complexes. This is because when RuCl3.xH2O is reacted with polypyridyl ligands, 
the resulting ruthenium(III) polypyridyl complexes are usually unstable and readily reduce to 
the corresponding ruthenium(II) complexes.  
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1.9.2. Ruthenium(II) 
The field of ruthenium(II) complexes is even more extensive than that of 
ruthenium(III) complexes. I shall restrict the discussion to polypyridyl complexes, since these 
have the most relevance to this project. The electrochemical and photophysical properties of 
these compounds, combined with their chemical stability, make them an ideal subject for 
study. In fact [Ru(bpy)3]
2+ and its derivatives have been the subject of more attention than any 
other class of ruthenium compound.[55] 
These polypyridyl complexes have many applications: In dye-sensitised solar cells, 
ruthenium complexes are used to facilitate the generation of electricity at longer 
wavelengths.[59, 60, 61] Ruthenium(II) complexes have shown potential for use in the splitting of 
water into hydrogen and oxygen.[62, 63] Because their photophysical properties can be altered 
by their surroundings complexes such as [Ru(bpy)2(dppz)]
2 have been used as luminescent 
DNA probes.[64, 65] Ruthenium complexes are also used in organic light emitting diodes.[66] 
1.9.2.1. Photochemistry of Ruthenium(II) Complexes 
Ruthenium polypyridyl complexes are the most studied class of transition metals from 
a photochemical viewpoint. In addition to being good absorbers of visible light, they exhibit 
long-lived excited states, luminescence, and can undergo reversible redox processes in both 
their ground and excited states.[67] 
The highly coloured nature of these complexes is due to their ability to absorb energy 
in the visible region, often through a metal-to-ligand-charge-transfer transition (MLCT). The 
MLCT gives rise to a singlet excited state, which quickly undergoes intersystem crossing to a 
triplet excited state. For most ruthenium(II) polypyridyl complexes, this 3MLCT is the lowest 
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excited state, and relaxation back to the ground state is usually accompanied by an intense 
luminescent emission that often falls in the visible region (Figure  1.21).[68, 69] 
 
Figure  1.21 Energy diagram showing the emissive pathway for ruthenium(II) complexes 
The MLCT involves an electron from the πM metal orbital being excited to the 
antibonding πL
* orbital, which is more or less delocalised about the aromatic rings of the 
ligand. The intense colour is due to the large transition dipole associated with this transfer. 
The lifetime of the excited state can be extended if the electron can be delocalised over several 
aromatic rings, and such species can participate in photochemical redox reactions.[70] 
In addition to the MLCT excited states, both metal-centred (MC) and ligand-centred 
(LC) excited states can be obtained. These involve promotion of an electron from the πM to 
σM
* and πL to πL
* respectively (Figure  1.22). These excited states may have singlet or triplet 
multiplicity. However, spin-orbit coupling can cause large singlet-triplet mixing, especially in 
the MC and MLCT excited states.[71, 72] 
hv 
hv 
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Figure  1.22 Simplified molecular orbital diagram showing the three low energy electronic transitions in 
ruthenium(II) polypyridine complexes
[67]
 
The lifetime of the 3MLCT is heavily influenced by the energy level of the metal-
centred triplet state (3MC). This is because 3MC excited states of d6 metal centres are strongly 
displaced with respect to the ground state geometry along metal-ligand vibrational coordinates 
and relaxation to the ground state is both fast and radiationless.[73] One of the mechanisms for 
non-radiative decay from the 3MLCT is through this thermally accessible 3MC. A rough rule 
of thumb is that the lifetime of the 3MLCT state in ruthenium(II) polypyridyl complexes is 
determined by the thermal accessibility of the 3MC state. This is why the lifetime for 
[Ru(tpy)2]
2+ is much shorter than [Ru(bpy)3]
2+, the 2,2ʹ:6ʹ,2ʹʹ-terpyridine (tpy) ligands cause a 
greater distortion from the ideal octahedral geometry and as a result the ligand field strength is 
weaker, lowering the 3MC energy level (Figure  1.23).[68, 69] 
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Figure  1.23 Effect of ligands on the 
3
MC energy level. In the case of [Ru(bpy)3]
2+
 (left) there is a larger gap 
between the 
3
MC and 
3
MLCT energy levels than in the [Ru(tpy)2]
2+
 case (right).
[68]
 
In the absence of deactivation via the 3MC, the lowest 3MLCT excited state often lives 
long enough to encounter other solute molecules and, in doing so, can act as an energy donor, 
electron donor or electron acceptor. For example, the energy available to *[Ru(bpy)3]
2+ for 
energy transfer processes is 2.21 eV and its reduction and oxidation potentials are +0.84 and -
0.84 V. This means that through interactions with other species the excited state can be 
quenched (Figure  1.24).[67] 
*
[Ru(bpy)3]
2+
 + Q → [Ru(bpy)3]
2+
 + 
*
Q 
*
[Ru(bpy)3]
2+
 + Q → [Ru(bpy)3]
3+
 + Q¯ 
*
[Ru(bpy)3]
2+
 + Q → [Ru(bpy)3]
+
 + Q
+ 
Figure  1.24 Mechanisms for the quenching of 
*
[Ru(bpy)3]
2+ 
Usually the redox products of such interactions rapidly decay, either through back 
electron transfer into the starting materials or through secondary reactions. 
hv hv 
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1.10. Cobalt 
Cobalt containing pigments have been used since ancient times; it is present in 
Egyptian pottery dated from around 2600 BCE and in Iranian glass beads of 2250 BCE. 
However, it was not until 1735 that cobalt metal was first prepared by Georg Brandt. The 
name comes from the German word kobold, meaning goblin. Miners had used the name 
kobold ore long before the metal was discovered. The reason for this name is that miners 
found that smelting these ores would not only fail to give the expected metal, but also produce 
highly toxic fumes, this phenomenon was blamed on goblins.[74, 75] 
Cobalt is in Group 9 of the periodic table, and has an atomic electron configuration of 
[Ar]3d74s2. The most common oxidation states for cobalt complexes are 2+ and 3+, although 
compounds with 1+ and 4+ oxidation states are also known. The reduction potential of the 
cobalt(III)-cobalt(II) couple is highly sensitive to the nature of the coordinated ligands (Table 
 1.3). The complex [Co(H2O)6]
3+ is highly oxidising, capable of oxidising water, and for this 
reason few simple cobalt(III) salt hydrates are able to be isolated. 
Table  1.3 Selected Co(III)/Co(II) reduction potentials
[75]
 
Couple E/V 
[Co(H2O)6]
3+ + e- Ý [Co((H2O)6]2+ 1.83 
[Co(C2O4)3]
3- + e- Ý [Co(C2O4)3]4- 0.57 
[Co(EDTA)]- + e- Ý [Co(EDTA)]2- 0.37 
[Co(bpy)3]
3+ + e- Ý [Co(bpy)2]2+ 0.31 
[Co(en)3]
3+ + e- Ý [Co(en)3]
2+ 0.18 
[Co(NH3)6]
3+ + e- Ý [Co(NH3)6]2+ 0.108 
[Co(CN)6]
3- + e- Ý [Co(CN)5(H2O)]
3- + CN- -0.8 
1.10.1. Cobalt(III) 
The d6 cobalt(III) oxidation state is able to form a wide range complexes, particularly 
with nitrogen donor ligands. Complexes of cobalt(III) are almost exclusively octahedral, low 
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spin and kinetically inert.[76] The kinetic inertness of these complexes is primarily due to the 
low spin nature of these complexes resulting in a high crystal field splitting energy associated 
with the (t2g)
6 electronic configuration. 
Because cobalt(III) complexes are so kinetically inert, they are usually prepared by 
indirect methods. The most common method involves adding the ligand to an aqueous solution 
on the appropriate cobalt(II) salt; the resulting complex is oxidised into the cobalt(III) state. It 
is quite common for molecular oxygen to be used as the oxidant. This is often achieved by 
simply drawing a stream of air through the solution. The low-spin diamagnetic nature of 
cobalt(III) complexes means that they can easily be characterised by NMR techniques. 
1.10.2. Cobalt(II) 
Cobalt(II) complexes have seven d electrons and are much more labile than cobalt(III) 
complexes.[76] However, despite being less numerous, cobalt(II) complexes show a greater 
diversity of types than cobalt(III) complexes. Cobalt(II) complexes are usually high-spin 
octahedral, although certain complexes, such as [Co(tpy)2]X2.nH2O, exhibit an equilibrium 
between the high-spin and low-spin states.[77] Both high-spin and low-spin states of a 
cobalt(II) complex are paramagnetic and as such cannot be easily analysed by NMR 
techniques. 
Because of the potential for cobalt(II) to oxidise to cobalt(III), the possibility of 
oxidation must always be considered when synthesising a cobalt(II) complex. However, as 
long as the solution is not alkaline and the ligands not too high on the electrochemical series, a 
wide range of complexes can be isolated without the need for special precautions.[75] 
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The main feature of cobalt(II) complexes that we intend to utilise in our study is their 
highly labile nature. This can be exploited to facilitate ligand release following reduction of an 
inert cobalt(III) complex into the labile cobalt(II) complex. 
1.11. Metal-to-Metal-Charge-Transfer 
A metal-to-metal-charge-transfer (MMCT) is ‘an electronic transition of a bi- or poly-
nuclear metal complex that corresponds to excitation populating an electronic state in which 
considerable electron transfer between two metal centres has occurred.’[78] A subset of this is 
intervalence charge transfer where the two metal sites differ only in oxidation states. Often 
this transfer results in the two metal centres swapping oxidation states. 
Mixed valence ruthenium complexes provide an insight into the barriers relating to 
intramolecular charge transfers. The first reported mixed valence complex was the Creutz-
Taube ion [(µ-pyz){Ru(NH3)5}2]
5+ (Figure  1.25), where, despite having an odd charge and 
neutral ligands, spectroscopic studies showed the two ruthenium centres to be equivalent. This 
equivalence is not what would be expected for a complex containing a ruthenium(II) and 
ruthenium(III) metal centre.[79, 80, 81] 
NN(NH3)5Ru Ru(NH3)5
+5
 
Figure  1.25 Creutz-Taube ion 
The equivalence of the two ruthenium metal centres shows the ease with which the 
electron is transferred between the two metals. The extent of the electronic coupling is 
measured by the comproportionation constant Kc. Comproportionation is the unification of the 
oxidation numbers of two atoms of the same element with different oxidation numbers. The 
comproportionation constant is a reflection of the stability of the mixed-valence state as 
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opposed to the isovalent state. In the absence of any coupling the two metal centres will 
undergo reduction or oxidation at the same potential. The value of Kc, and hence the degree of 
communication, can be easily calculated experimentally through the use of electrochemistry. 
By measuring the values of Ef associated with each step of the reduction: 
Ru(III), Ru(III) Ru(III), Ru(II) Ru(II), Ru(II)  
Kc can then be calculated by the equation: Kc=exp((E≨-E≩)F/RT) 
The bridging ligand in such a system controls the distance and orientation of the two 
metal centres. There are a large number of studies which investigate the effect of the bridging 
ligand on Kc. In addition to this, there are studies showing the effect of the non-bridging 
ligands as well as solvent and environmental effects on the value of Kc. While this does not 
relate directly to the work that we conducted, such studies could, in principle, be used to gain 
an insight into how well a particular bridging ligand might perform in a photo-activated 
cytotoxin. 
1.12. Ruthenium(II)-Cobalt(III) Systems 
During his research on inner sphere electron transfer reactions, Taube examined 
ruthenium(II)-cobalt(III) bridged systems.[82, 83, 84, 85] In these experiments dinuclear complexes 
of ruthenium(III) and cobalt(III) were bridged by functionalised pyridyl and polypyridyl 
ligands (Figure  1.26). The ruthenium(III) was then reduced to ruthenium(II), either by addition 
of [Ru(NH3)6]
2+ or ascorbate, and the rate of the electron transfer between the two metal 
centres was measured in each case. 
E≨ E≩ 
Chapter 1 Introduction 
Photo-activated Cytotoxins Alan Downward 36 
N N
N
N
N
O
OH
N
HO
O
N
O
HO
N
N
 
Figure  1.26 Examples of bridging ligands used by Taube 
During these studies Taube was able to examine the effects of distance, type of 
bridging ligand, solvent and orientation on the rate of electron transfer. Taube observed that 
after the formation of the ruthenium(II) species, the cobalt(III) metal centre would be reduced 
to the cobalt(II) state. There are two possible explanations for this observation, either the 
transfer is intermolecular, occurring through an outer sphere interaction, or alternatively the 
reaction could be intramolecular (Figure  1.27). 
(NH3)5Co
III(L)RuII(NH3)4H2O (NH3)5*Co
II(L)Ru III(NH3)4H2O
Products
k1
k-1
k2
a)
b)
k3
k-3
Products
k4
(NH3)5*Co
II(L)Ru II(NH3)4H2O(NH3)5Co
III(L)RuII(NH3)4H2O
(NH3)5Co
III(L)RuII(NH3)4H2O (NH3)5Co
III(L)RuIII(NH3)4H2O
+ +
 
Figure  1.27 General reaction scheme for a) the intramolecular reaction and b) the intermolecular 
reaction
[83]
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By a consideration of the rate and its lack of dependence on the concentration of the 
products Taube was able to deduce that the transfer was intramolecular. However, this did not 
determine if the measured rate is k1 or K1k2 (K1 is the equilibrium constant for the 
intramolecular electron transfer). If the reaction establishes an equilibrium between the 
ruthenium(II)-cobalt(III) and ruthenium(III)-cobalt(II) states, with the latter slowly going to 
form the final products, then the measured rate corresponds to K1k2. The alternative is that the 
formation of the final products (k2) is fast, in which case the rate is determined by k1. At the 
time of first publication Taube was not able to conclusively say which was the case, although 
the evidence favoured k1 being the rate determining step. 
In addition to this Taube also noted a relationship between the rate of electron transfer 
in the heterodinuclear complexes and the intensity of the intervalence band measured for the 
corresponding ruthenium(II)-ruthenium(III) mixed-valence complexes. Since these 
measurements were first made, the reaction has shown to be dependent on k1, and a correlation 
has been observed between the electronic factors (κe1) for ruthenium(II)-cobalt(III) reactions 
and κe1 for diruthenium complexes; this suggests a common mechanism for the electronic 
coupling.[86] 
1.13. Prior Work on Photo-activated Cytotoxins 
This thesis carries on from the work conducted by Ramin Zibaseresht for his PhD, 
titled “Approaches to Photo-activated Cytotoxins”.[87] Zibaseresht synthesised and examined 
the coordination of eleven bridging ligands based on the tridentate terpyridyl system. The two 
metal ion binding sites in these ligands were differentiated by the number of atoms in each 
site, the configuration of the binding domain or the types of donor atoms present. 
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Zibaseresht synthesised many ruthenium(II) complexes where the ruthenium ion was 
bound to the terpyridyl sites of the ligands. These mono-ruthenium complexes were reacted 
with a range of other metal ions, which enabled the complexes to be classified into three main 
types: ruthenium(II) complexes which can react with cobalt(III) ions; ruthenium(II) complexes 
which react only with silver (I) ions; and ruthenium(II) complexes that have no detectable 
ability to coordinate other common metal ions.[88, 89, 90, 91, 92, 93] 
These studies provided us with a starting point for our research and more details on the 
ruthenium(II)-cobalt(III) heterodinuclear systems synthesised by Zibaseresht are given in 
 2.1.3. 
1.14. Thesis Overview 
The purpose of this thesis is to outline challenges and strategies associated the 
synthesis of several photo-activated cytotoxins. These photo-activated cytotoxins utilise a 
ruthenium(II) metal centre as the electron donor and a cobalt(III) metal centre as the electron 
acceptor. Selectivity with respect to the coordination of different metal centres to different 
binding domains was achieved through the use of different steric arrangements of the binding 
domains, pre-binding the ruthenium(II) metal centre before completing the synthesis of the 
bridging ligand and in the case of symmetrical bridging ligands an excess of ligand was used 
to minimise the formation of the homodinuclear complex. 
Chapter 2 describes our initial work with terpyridine-based ligands, carrying on from 
that of Zibaseresht. The primary target system that this chapter is concerned with involved a 
bridging ligand with one terpyridine-based binding domain and one cyclam-based binding 
domain. 
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Chapter 3 introduces bridging ligands in which there is either no or limited steric 
differentiation between the two binding domains, and outlines how the mono-ruthenium(II) 
complexes of these ligands can be synthesised. In addition to this, the binding of a second 
metal centre is explored through the use of silver(I), zinc(II) and copper(I) metal salts. 
Chapter 4 relates to the synthesis of ruthenium(II)-cobalt(III) heterodinuclear systems, 
with non-cytotoxic ligands coordinated to the cobalt(III) metal centre. This chapter also 
describes the photo-activated ligand release of the cobalt bound ligands, showing that such 
systems could potentially be used as photo-activated cytotoxins. 
Chapter 5 takes the heterodinuclear systems described in chapter 4 and attempts to 
replace the non-cytotoxic ligands on the cobalt(III) metal centre with cytotoxic ones. Finally 
this chapter details the results of the cytotoxicity tests we conducted during our study. 
Chapter 6 outlines the prospects for future study in this field. In some cases we have 
already conducted preliminary experiments towards these studies, the details of which are also 
given in this chapter. 
 
Chapter 2 Terpyridine-Based Systems 
Photo-activated Cytotoxins Alan Downward 40 
Chapter 2: Terpyridine-
Based Systems 
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2.1. Introduction 
The key component in the design and synthesis of our photo-activated cytotoxin 
system is the bridging ligand. It is the bridging ligand which must be able to bind both metal 
centres as well as facilitate the transition of an electron between these two metals. We began 
our study by continuing from the previous experiments of Zibaseresht, who was working 
towards synthesising a bridging ligand, based on functionalised terpyridines, for use as a 
photo-activated cytotoxin.[87, 88] 
In this chapter the synthetic strategies involved in the synthesis of functionalised 
terpyridines will be outlined. This will be followed by an explanation of the results achieved 
by Zibaseresht that served as a starting point for our research. Finally the results of our work 
with cyclam functionalised ttp and its possible use as a bridging ligand will be discussed. 
2.1.1. Methods for Synthesis of 4ʹ-p-Tolylterpyridine Ligands 
When synthesising an aryl-terpyridine, such as ttp (2.2), the key step is the 
condensation of two equivalents of 2-acetylpyridine with the appropriate aryl aldehyde (in this 
case 4-methylbenzaldehyde), followed by ring closure with an ammonia source at high 
temperatures. Various strategies for the synthesis of ttp have been described in the 
literature.[94, 95, 96, 97, 98, 99, 100] A brief review of the synthetic strategies we explored during our 
research is given below. 
2.1.1.1. The Kröhnke Methodology 
The synthetic strategy employed in the Kröhnke methodology[95] assembles a 
substituted terpyridine over multiple steps. In the synthesis of ttp, the first step is the formation 
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of the enone 2.1 by an aldol condensation between 2-acetylpyridine and 4-
methylbenzaldehyde (Figure  2.1). 
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Figure  2.1 Mechanism for the formation of (E)-1-(pyridin-2-yl)-3-p-tolylprop-2-en-1-one 
2.1 is isolated and then reacted with (2-pyridacyl)pyridinium iodide (synthesised by 
reacting 2-acetylpyridine with iodine in pyridine)[101] which results in the formation of a 1,5-
diketone via a Michael addition. Finally, ring closure is achieved by the addition of 
ammonium acetate, and the resulting dihydropyridine is oxidised by O2 to give ttp (2.2) 
(Figure  2.2). 
2.1 
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Figure  2.2 Mechanism for the formation of ttp by the Kröhnke Methodology 
The advantage of the Kröhnke methodology is that it can be adapted to generate a wide 
variety of terpyridines. This is achieved by using appropriately substituted 2-acetylpyridines 
and aromatic aldehydes in the synthesis of the enone, which can then be reacted with a range 
of pyridinium ions.[102] This means that the Kröhnke methodology can be used to tune and 
adjust the terpyridines to suit their application. The major disadvantage is that synthesising a 
ligand where the non central pyridine rings of the terpyridine are identical, such as ttp, is more 
time consuming because of the multiple steps involved. Additionally, the overall yield is lower 
than that of other methods. 
2.2 
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2.1.1.2. Collin-Balzani-Sauvage Methodology 
The symmetrical nature of ttp means that the stepwise Kröhnke methodology is not 
required for its synthesis, and one-pot reactions can be used instead. The one-pot scheme 
initially selected for use was that of Collin-Balzani-Sauvage.[99] Two equivalents of 2-
acetylpyridine were reacted with 4-methylbenzaldehyde in the presence of acetamide and 
ammonium acetate. After basification and cooling to room temperature, the crude products 
were precipitated out. 
Even after recrystallisation the product is a mixture of two isomers with ttp (2.2) as the 
major isomer and 6ʹ-p-tolyl-2,2ʹ:4ʹ,2ʹʹ-terpyridine (2.3) as the minor isomer. The major isomer 
is formed by a 1,4-Michael addition and follows the same general mechanism as described in 
Figure 2.2. However, a 1,2-aldol reaction results in the formation of the minor isomer as 
detailed in Figure  2.3. 
The two isomers are separated by exploiting the difference in their binding domains. 
Ttp has a tridentate binding domain, while the sterically hindered minor isomer 2.3 has only a 
bidentate binding domain. The addition of iron(II) results in the preferential binding of ttp to 
form the highly stable [Fe(ttp)2](PF6)2 complex as a purple precipitate, which is isolated by 
vacuum filtration. The minor isomer can then be recovered by extraction of the filtrate with 
toluene. The complexed ttp is then liberated from the iron by the addition of hydrogen 
peroxide under alkali conditions. The peroxide oxidizes the iron from iron(II) to iron(III), 
forming a precipitate of iron oxides; this brown precipitate is then removed by filtration to 
leave pure ttp.[103] 
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Figure  2.3 Mechanism for the formation of 6ʹ-p-tolyl-2,2ʹ:4ʹ,2ʹʹ-terpyridine 
The advantage of using this method is that it can be carried out in a single reaction 
vessel and can be easily scaled up; the disadvantage is that it forms the minor isomer 2.3, 
which has to be separated from the desired product. 
2.1.1.3. Hanan Methodology 
A revised one-pot synthesis was developed and optimised by Hanan in order to easily 
obtain large amounts of pure 4ʹ-aryl substituted terpyridines, such as ttp.[100] This synthesis 
involves the addition of an aryl aldehyde to two equivalents of 2-acetylpyridine in ethanol 
with potassium hydroxide and aqueous ammonia. When 4-methoxybenzaldehyde is used as 
2.3 
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the aryl aldehyde ttp is produced in a 49% yield after only two hours of reaction time, with no 
other isomers present. 
2.1.2. Functionalisation of 4ʹ-p-Tolylterpyridine Ligands 
Ttp needs to be further functionalised in order to introduce the second binding domain 
necessary for it to act as the bridging ligand in our final system. This could be achieved either 
by using various funtionalised aryl aldehydes during ligand synthesis, or by introducing 
functionality after the ligand is synthesised. 
One of the most versatile methods of introducing functionality to an unfunctionalised 
centre is through radical bromination. In the case of ttp, the methyl group can be brominated 
by reacting ttp with -bromosuccinimide in either carbon tetrachloride or benzene, with a 
catalytic amount of dibenzoyl peroxide under an inert atmosphere. Although the bromination 
is successful in both solvents, we found that a slightly higher yield was achieved when using 
carbon tetrachloride. 
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Figure  2.4 Propagation steps of the radical bromination of ttp 
The high reactivity of the bromomethyl group towards nucleophiles means that it can 
be reacted with a variety of nitrogen or oxygen containing molecules in basic solution (Figure 
 2.5).[104, 105, 106, 107] This provides an easy route to synthesise various ligands with multiple 
2.4 2.2 
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binding domains. It was this synthetic strategy of bromination, followed by substitution to 
introduce functionality, that Zibaseresht used in his research. 
HN
N N
H
N
N
N+
N
N N
N
NH2
H2N N
NH N
HNNH
O
NN
NN
N
N
N
N N
Br
N
N N
R
 
Figure  2.5 Examples of functionalised 4ʹ-p-tolylterpyridine ligands 
2.1.3. Some Ligand Systems and Coordination Compounds 
Synthesised by Zibaseresht 
Using the method described above, Zibaseresht synthesised a variety of functionalised 
ttp ligands (Figure  2.6) and examined their binding to different metal ions. His intentions were 
to gain an understanding of how these ligands bind to different metals, as well as produce a 
2.4 
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heterodinuclear ruthenium-cobalt species which could then be evaluated for use as a photo-
activated cytotoxin. 
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Figure  2.6 Bridging ligands synthesised by Zibaseresht 
Zibaseresht reacted the ligand 2.5 with ruthenium(II), iron(II), copper(II), zinc(II) and 
silver(I) ions. By forming these homonuclear complexes, Zibaseresht was able to examine the 
affinity of each of the binding domains towards various metals. However, with the exception 
of the silver(I) ions, the only observed binding in the products was through the terpyridine end 
of the molecule. In the silver(I) case, the silver ion was bound in a planar tridentate fashion to 
the terpyridine site of one ligand and to a single pyrazole donor group from a second ligand, 
2.6 2.7 2.5 
2.9 2.10 2.8 
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forming a [2 + 2] complex. This demonstrated that the terpyridine portion of the molecule is a 
better binding domain than the pyrazole, but that it still might be possible to form 
heterodinuclear complexes. 
Attempts were then made to produce heterodinuclear metal complexes. This was done 
by taking the previously synthesised mononuclear iron and ruthenium complexes of 2.5 and 
reacting them with various metal salts. The resulting products were examined with 1H NMR 
and ESI-MS. Of all the metal ions trialled, only silver(I) ions showed evidence of binding to 
the pyrazole donors. This means that 2.5 is not an appropriate bridging ligand because it 
cannot bind to both cobalt(III) and ruthenium(II) ions at the same time. 
However, Zibaseresht was able to generate heterodinuclear ruthenium(II)-cobalt(III) 
complexes by using the ligand 2.8. First 2.8 was reacted with Ru(ttp)Cl3 in ethanol to form the 
ruthenium(II) complex 2.11. The cobalt(III) ion was then coordinated by reaction of 2.11 with 
Na3[Co(NO2)6] and the complex 2.12 was isolated as its PF6
- salt. The dinitrito complex 2.12 
could then be converted into the dichlorido complex 2.13 by treatment with 6 M HCl. (Figure 
 2.7) 
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Figure  2.7 
Finally Zibaseresht exposed the system to the cytotoxin analogue ethane-1,2-diamine 
(en). Reaction of the dichlorido complex 2.13 with an excess of en resulted in removal of the 
cobalt ion from the macrocycle and re-isolation of the parent complex 2.11. This was a 
disappointing result because the en complex would have been very useful in monitoring any 
light induced ligand release. This result was also unusual because cyclam complexes are 
generally considered to be quite stable. Use of less en and milder reaction conditions resulted 
in the majority of the sample undergoing no reaction. However, a small amount of cobalt(III) 
was still lost from the macrocycle and a trace amount of the protonated ruthenium-cobalt 
complex with en bound was detected by mass spectrometry. 
One possible explanation for the poor binding of en is the binding geometry of the 
cobalt(III) metal centre, which could prohibit the coordination of a bidentate ligand. Cyclam is 
able to bind to an octahedral metal, such as cobalt(III), in such a way that the two remaining 
2.13 
2.12 
2.11 
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coordination sites are either in a cis or trans arrangement, giving rise to two different possible 
isomers (Figure  2.8). 
 
Figure  2.8 Cyclam bound to an octahedral metal centre in a trans (left) and cis (right) fashion. The yellow 
balls identify the remaining free coordination sites 
When acting as a bidentate ligand for an octahedral metal centre, en binds to two cis 
related positions. A trans arrangement of the complex could be counterproductive as it would 
require isomerisation to occur before binding. However, attempts by Zibaseresht to 
definitively identify which isomers of the dinitrito and dichlorido complexes had been formed 
proved unsuccessful. Cobalt complexes show well-established changes in the d-d transitions of 
their UV-visible spectra when in different binding geometries. However, the UV-visible 
spectra of 2.11, 2.12 and 2.13 were all very similar in appearance, with the dominant peak at 
490 nm being the MLCT transition characteristic of the ruthenium(II)polypyridyl systems. The 
presence of these large MLCT bands obscured the cobalt(III) d-d bands. The shape and 
location of the d-d bands could not, therefore, be used to determine which of the cis or trans 
isomers were formed. 
Poon and Tobe suggest that trans isomers of cobalt(III) complexes of cyclam and two 
monodentate ligands, such as in 2.12 and 2.13, are the dominant products in aqueous 
solution.[108, 109] They have also reported that cis complexes with monodentate ligands 
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eventually isomerise to a trans configuration in aqueous solution.[110] The similarities between 
the cobalt bound cyclam end of the systems 2.12, 2.13 and the systems of Poon and Tobe lead 
us to conclude that the product complexes are most likely trans isomers. 
2.1.4. Synthesis of Strapped Cyclams 
Since Zibaseresht’s inability to bind en to the heterodinuclear ruthenium-cobalt 
complex 2.13 in more than trace amounts was potentially due to the cobalt being bound to the 
cyclam with the vacant sites in a trans arrangement, we began our research by looking for an 
established way to force the vacant sites into a cis geometry. Such a restriction can be 
achieved by strapping the cyclam molecule with an ethyl bridge between two of the nitrogen 
atoms. Depending on which nitrogen atoms are connected to the strap, different coordination 
geometries can be realised.[111, 112] 
The synthetic route for a strapped cyclam with the vacant sites in a cis relationship is 
reported by Weisman and Wong.[111] First the cyclam is reacted with aqueous glyoxal in 
acetonitrile to give the tetra cyclic bis aminal product 2.15. 2.15 is then dialkylated in a single 
step before reduction with sodium borohydride (Figure  2.9). 
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Figure  2.9 Synthesis of cross strapped cyclam 
Weisman and Wong also report that particular R groups can be removed by 
hydrogenation using gaseous hydrogen and 10% palladium on carbon. This means that it is 
2.17 2.16 2.15 2.14 
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possible to synthesise an unsubstituted cross strapped cyclam. This unsubstituted cross 
strapped cyclam can then be reacted with alkyl halides to give a wide range of products. 
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Figure  2.10 Reduction of cyclam based tetracycles 
The dialkylation is important because it ensures that the double reductive ring 
expansion gives the cross strapped product and not the piperazine 2.18, which is the observed 
product from the reduction of either the mono or unalkylated tetracycle (Figure  2.10). The 
piperazine 2.18 can also be directly synthesised by reaction of cyclam with 1,2-
dibromoethane. If the reaction is carried out with a large excess of 1,2-dibromoethane, the 
doubly bridged species 2.19 is formed (Figure  2.11). These bridges provide a steric barrier 
which should be sufficient to prohibit the ligand binding in such a way that the other 
coordination sites are cis to each other.[112] 
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Figure  2.11 Reactions of 1,2-dibromoethane with cyclam 
Therefore, by using the synthetic strategies outlined above, it is possible to synthesise 
ligands based on the cyclam macrocycle which can only exhibit specific binding geometries. 
2.2. Results and Discussion 
2.2.1. Synthesis of Strapped Cyclam with a 4ʹ-p-
Tolylterpyridine Substituent 
We began our experimental work with the intention of synthesising a ligand similar to 
2.8, with the difference being that the cyclam end would be strapped in such a way so as to 
force cis binding. Such a synthesis would involve the formation of a dialkylated tetracycle, as 
outlined in Figure  2.9 and Figure  2.10, where at least one of the alkyl arms is ttp. The 
tetracycle could then be reduced to give the final ligand. 
2.18 
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2.2.1.1. Formation of the Dialkylated Tetracyclic Intermediate 
The first step was to alkylate the tetracycle with ttp. This was done by reacting 2.15 
with 2.4 in THF and resulted in the formation of an off white solid. 1H NMR in D2O was then 
used to identify the product as the monoalkylated product 2.20. Although the experimental 
method reported by Weisman and Wong[111] exclusively resulted in double alkylation of the 
tetracycle, 2.15, only the monoalkylated product could be observed. However, it should be 
noted that the method reported by Weisman and Wong only used benzyl bromide and 
iodomethane as alkylating agents. 
Since, as detailed in  2.1.4, reduction of a monoalkylated tetracycle results in the 
formation of a piperazine, the product needs to be alkylated a second time. However, the mono 
substituted product had a poor solubility profile and a satisfactory reaction scheme for direct 
alkylation with iodomethane to give the dialkylated product 2.21 could not be found. We 
propose that it was this poor solubility which prevented the formation of any dialkylated 
product in the initial reaction, as the monoalkylated form is no longer soluble in THF. 
In order to improve the solubility profile of 2.20 we decided to coordinate the 
monoalkylated ligand to ruthenium. To do this 2.20 was heated at reflux with [Ru(ttp)Cl3] in 
dry methanol for 4 hours, after which the solution was cooled to room temperature, water was 
added and the complex 2.22 was precipitated out as the PF6
- salt (Figure  2.12). The newly 
synthesised complex was soluble in acetonitrile and therefore reaction with iodomethane was 
now possible. 
The complex 2.23, bearing a dialkylated macrocycle, was synthesised by methylating 
2.22 with an excess of iodomethane in acetonitrile. The product 2.23 was identified through 
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the appearance of a new singlet at approximately 3.5ppm in the 1H NMR spectrum, assigned 
to the new methyl group. 
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Figure  2.12 
2.2.1.2. Reduction of the Tetracyclic Intermediate 
After completing the synthesis of 2.23, the next step in our proposed synthetic route 
was to reduce the macrocycle and produce the cross strapped ligand 2.24. In order to achieve 
this, we carried out a reduction reaction using sodium borohydride. The 1H NMR spectrum of 
the reduced product showed fewer peaks than expected in the aromatic region and only one in 
the aliphatic region, which was a singlet. This indicated that the cyclam group had been 
removed. The 1H NMR spectrum of the reduced product was then compared to that of 
[Ru(ttp)2](PF6)2, and appeared to be identical. From this result we concluded that the product 
of the reduction reaction was the complex [Ru(ttp)2]
2+, 2.25, instead of the desired product, 
2.24 (Figure  2.13). There are two possible explanations for how 2.25 was formed: either the 
sodium borohydride was breaking the carbon nitrogen bond between the ttp and the cyclam, or 
the ligands on the ruthenium were exchanging and we were only seeing one of several 
products. Since the latter of these two explanations both fails to explain what was happening 
2.20 2.21 
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to the other ligands and does not conform to the classification of ruthenium as an inert metal, 
we suspect that it was the sodium borohydride breaking the carbon nitrogen bond that was 
responsible for the formation of 2.25. 
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Figure  2.13 
In order to assess whether the final product, 2.25, was being directly formed by the 
reduction of 2.23 or was formed by a further reduction of the desired product 2.24, the 
reaction was monitored by TLC. This revealed that two products were initially formed; 
however, after 5 minutes only one product was left, presumably [Ru(ttp)2]
2+. From this we 
hypothesise that although some of the borohydride was reducing the macrocycle to give the 
desired product, this species was short lived because the ttp-cyclam bond was also easily 
broken by the borohydride. 
2.2.2. Reduction of a Related Ruthenium Complex 
Because the observed product from the reduction of 2.23 could potentially be formed 
by ligand exchange, an additional experiment with the ruthenium complex 2.26 was carried 
2.23 
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out. In 2.26 there is a carbon oxygen bond analogous to the carbon nitrogen bond in 2.23. If 
this carbon oxygen bond was broken by reaction with sodium borohydride, the product, 2.27, 
could be definitively identified as being formed by this method as the two ligands on the 
ruthenium(II) metal centre would not be identical (Figure  2.14). 
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Figure  2.14 
The complex 2.26 was subjected to the same reaction conditions as 2.23 and the 1H 
NMR and mass spectra were recorded. 1H NMR spectroscopy was not as definitive in this case 
as it was for 2.25, due to the complex having two different ligands and less internal symmetry, 
which made the change less obvious. Mass spectrometry showed a major peak with m/z of 
375. Both this mass and the observed isotope pattern around it agree with what would be 
predicted for 2.27 and led us to conclude that the same type of reaction was occurring (Figure 
 2.15). 
2.26 
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Figure  2.15 Predicted and experimental isotope pattern for 2.27 
Because the two ligands are not the same, this result, unlike the previous one, could 
only have resulted from the breaking of the bond between the carbon atom and the uncharged 
oxygen atom. From this we concluded that a sodium borohydride reduction of a ruthenium 
complex containing a carbon-hetero atom single bond can result in the breaking of the bond. 
One possible way to circumvent this problem would be to cross strap the cyclam 
molecule before reaction with ttp, as this would remove the need for treatment with sodium 
borohydride. Unsubstituted cross strapped cyclam can be synthesised in three steps from 2.16. 
The first step involves the double alkylation of 2.16 with benzyl bromide; this is then followed 
by reduction with sodium borohydride before the benzyl groups are removed by 
hydrogenation (Figure  2.16). This unsubstituted cross strapped cyclam could then be reacted 
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with 2.4 to give a ligand with potential application in our study. However, we decided to 
explore other methods for synthesising potential bridging ligands rather than pursue this 
further. 
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Figure  2.16 Synthesis of unsubstituted cross strapped cyclam 
2.2.3. Binding of 6ʹ-p-tolyl-2,2ʹ:4ʹ,2ʹʹ-terpyridine to 
Ruthenium(II) 
When ttp is synthesised using the Collin-Balzani-Sauvage method, the side product 2.3 
can also be isolated.[99] Although ttp has been featured in 109 peer reviewed journal articles, 
the minor product has only been featured in 7. We therefore took the opportunity to look into 
the binding properties of a relatively ignored ligand. 
In order to further study the binding of the minor isomer, 2.3 was heated at reflux with 
RuCl3.xH2O in ethanol for 3 hours. Slowly cooling the reaction mixture to room temperature 
caused a deep red crystalline solid to form, from which a crystal was selected and examined 
by X-ray diffraction (Figure  2.17). 
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Figure  2.17 X-ray crystal structure of [Ru(6ʹ-p-tolyl-2,2ʹ:4ʹ,2ʹʹ-terpyridine)2Cl2]; solvent molecules have 
been omitted for clarity 
In the obtained structure the ruthenium(II) atom is bound to two ligands of 2.3 as well 
as two chloride ligands. 2.3 is bound in a bidentate manner through the nitrogen atoms of the 
central and 2ʹ pyridine rings. The structure shows intramolecular π-π stacking between the 
bound singly substituted pyridine ring and the tolyl ring of the other ligand, as well as 
intermolecular π-π stacking between the unbound and central pyridine rings. Unfortunately 
additional electron density, which can be attributed to solvent channels existing in the crystal 
lattice, meant that the ethanol solvent molecules could not be satisfactorily modelled. 
However, since we obtained this crystal structure, Bray has reported an X-ray crystal structure 
with copper bound to 6ʹ-p-tolyl-2,2ʹ:4ʹ,2ʹʹ-terpyridine instead of ruthenium, which shows the 
same binding motif.[113] 
Since 2.3 has similar binding to bpy and can be functionalised in the same manner as 
outlined for ttp in section 2.1.2, there are many potential applications for this ligand and its 
derivatives which could be studied in the future. 
Chapter 2 Terpyridine-Based Systems 
Photo-activated Cytotoxins Alan Downward 62 
2.3. Conclusion 
The synthesis of the ruthenium bound potential bridging ligand 2.24, consisting of ttp 
with an appended strapped cyclam molecule, was attempted. The synthesis of the precursor 
2.20 was achieved by reacting the tetracycle 2.15 with the brominated form of ttp (2.4). 
However, due to the poor solubility of 2.20, it could not be methylated directly. To circumvent 
this problem, 2.20 was complexed to [Ru(ttp)Cl3] to give 2.22, and then this was methylated to 
give 2.23. Unfortunately, sodium borohydride reduction of 2.23 resulted in the breaking of the 
bond between the nitrogen atom of the cyclam and methyl carbon of the ttp, resulting in the 
formation of [Ru(ttp)2]
2+ instead of the desired product 2.24. 
Although the problem associated with the reductive step could, in principle, be 
circumvented by synthesis of the strapped cyclam molecule prior to it being appended to the 
ttp ligand, we decided that it would be more productive to pursue new bridging ligands rather 
than adding additional steps to this synthetic route. 
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Chapter 3: Two Bridging 
Ligand Series and Their 
Ruthenium Complexes 
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3.1.  Introduction 
The bridging ligand of a photo-activated cytotoxin would ideally be able to selectively 
bind two different metal centres, as well as permitting electron transfer between these two 
metals. In Chapter 2 we examined ligands with different coordination numbers and binding 
geometries at each of the binding domains. In this chapter we will demonstrate that ligands 
with little or no variation between the binding geometry of their domains can also be used as 
potential bridging ligands. 
First we will outline the process for the synthesis of two series of bridging ligands. We 
will then discuss how to form ruthenium(II) complexes of these ligands with one vacant 
binding domain. Finally the coordination and interactions of these ruthenium(II) complexes 
with various metals, excluding cobalt(III), will be discussed. The formation and reactivity of 
ruthenium-cobalt heterodinuclear complexes of these ligands is discussed in Chapter 4. 
3.1.1. Jurgen Sauer’s ‘LEGO’ System 
In 1998 Jurgen Sauer first published details of his ‘LEGO’ system.[114, 115, 116, 117, 118] 
This system provides a synthetic strategy for the formation of a wide range of oligopyridines 
over two steps (Figure  3.1). 
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Figure  3.1 Examples of ligands produced by the ‘LEGO’ system 
Step one is a condensation reaction between a hydrazonamide and a 1,2-dicarbonyl 
compound. After the product from the condensation reaction is isolated, it undergoes an 
inverse-type Diels-Alder reaction (Figure  3.2) to give the final product. 
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Figure  3.2 Mechanism for an inverse-type Diels-Alder reaction 
The paper which was of particular interest to us related to the synthesis of 6-
oligopyridyl-1,5,12-triazatriphenylenes (3.4).[114] However, it was not the final product that we 
3.1 3.2 
3.3 3.4 
3.5 3.6 
3.7 3.8 
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intended to use in our research, but rather the triazine intermediate 3.3. In addition to the 1,10-
phenanthroline binding domain in 3.3, a second binding domain can be formed by having an 
appropriate R group, such as 2-pyridine (Figure  3.3). 
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Figure  3.3 3-(pyridin-2-yl)-[1,2,4]triazino[5,6-f][1,10]phenanthroline (pytp) and its potential binding 
domains 
One way to achieve selective binding of a ruthenium metal centre to a ligand such as 
pytp is to synthesise the ligand on the metal centre. Such a synthesis involves coordinating the 
phendione to a ruthenium(II) metal centre before reaction with the hydrazonamide.[119] 
3.1.2. 3,6-Disubstituted-1,2,4,5-Tetrazines 
The carboxamidrazones used in the ‘LEGO’ system are prepared by the reaction of 
hydrazine with an aryl nitrile (3.9). However, while these reactions result in the formation of a 
hydrazonamide under mild conditions, more vigorous reaction conditions result in the 
formation of a dihydrotetrazine (3.10). Oxidation of this generates a 1,2,4,5-tetrazine 
(3.10).[120, 121, 122, 123, 124] 
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Figure  3.4 Formation of disubstituted-1,2,4,5-tetrazines 
These tetrazines are of interest to the wider academic community because they can 
undergo inverse-type Diels-Alder reactions to generate a variety of complexes. However, our 
interest in these ligands relates to the possibility of generating bidentate binding domains. This 
3.9 
3.10 3.11 
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can be achieved through the incorporation of a nitrogen containing substituent, such as 
pyridine, to the tetrazine core (Figure  3.5). 
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Figure  3.5 3,6-di(pyridin-2-yl)-1,2,4,5-tetrazine (pytz) and its potential binding domains 
Ligands such as pytz (3.12) are of interest to us because the low-lying π* orbitals of the 
ligand enable longer wavelength MLCT absorption events to occur. Diruthenium complexes 
of pytz have previously been reported to have an unusually long wavelength MLCT band at 
685 nm.[124] Since longer wavelengths of light are not as readily absorbed by the body, if the 
MLCT band for a ruthenium-cobalt heterodinuclear complex of pytz is at a similar wavelength 
to that of the diruthenium complex, this could add additional benefit to our photo-activated 
cytotoxin. 
3.2. Results and Discussion 
The ligands we selected for further investigation were based on the 1,2,4,8,9-
pentaazatriphenylene intermediates (3.3). The first of these triazine intermediates was 3-(1,10-
phenanthrolin-2-yl)-[1,2,4]triazino[6,5-f][1,10]phenanthroline (phtp) (3.13). This ligand has 
two potential binding domains: one is tridentate, utilising the appended phenanthroline group 
and a single nitrogen from the triazine; the other is bidentate and arises from the fused 1,10-
phenathroline. (Figure  3.6) It was this tridentate vs bidentate nature of the two domains that 
we intended to use to achieve selective binding during the formation of metal complexes. The 
3.12 
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intention was to bind ruthenium to the tridentate domain, leaving the bidentate domain free to 
coordinate to another metal. 
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Figure  3.6The ligand phtp and its potential binding domains 
The other series that we selected for study was based around a substituted 1,2,4,5-
tetrazine core. However, because these substituted tetrazines have identical binding domains, 
we could not use coordination geometry to prevent a metal centre from binding to both 
domains. 
3.2.1. 3-(1,10-Phenanthrolin-2-yl)-[1,2,4]triazino[6,5-
f][1,10]phenanthroline 
The first step in the synthesis of phtp (3.13) was to generate 2-cyano-1,10-
phenanthroline (3.16); this was synthesised by first forming the -oxide (3.15) of 1,10-
phenanthroline (3.14) and then treating this with potassium cyanide (Figure  3.7).[125] 
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Figure  3.7 Synthesis of 2-cyano-1,10-phenanthroline 
3.13 
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3.16 was then reacted with hydrazine to give the carboxamidrazone 3.17.[126] Using the 
synthetic strategy outlined by Sauer, the carboxamidrazone is reacted with 1,10-
phenanthroline-5,6-dione to yield the yellow ligand phtp. (Figure  3.8) 
N N
N
N N
N
H2N
H2N
N
N
O
ON
N N
N
N
N
N
H2N NH2
 
Figure  3.8 Synthesis of phtp 
3.2.2. 3-(Pyridin-2-yl)-[1,2,4]triazino[6,5-f][1,10]phenanthroline 
and 3-(Pyrazin-2-yl)-[1,2,4]triazino[6,5-
f][1,10]phenanthroline 
The synthesis of the ligands 3-(pyridin-2-yl)-[1,2,4]triazino[5,6-f][1,10]phenanthroline 
(pytp) (3.18) and 3-(pyrazin-2-yl)-[1,2,4]triazino[5,6-f][1,10]phenanthroline (pztp) (3.19) 
(Figure  3.9) followed the same synthetic pathway as the synthesis of phtp (3.13). However, 
since both 2-cyanopyridine and 2-cyanopyrazine are readily available, they did not need to be 
synthesised prior to the reaction with hydrazine. 
3.16 3.17 
3.13 
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Figure  3.9 The ligands pytp (3.18) and pztp (3.19) 
3.2.2.1. Crystal Structure of Pytp 
Dissolving pytp in a dilute solution of hydrochloric acid and then allowing slow 
evaporation to occur yielded large yellow needles suitable for use in X-ray crystallography. 
The X-ray structure showed the pytp to be in a doubly-protonated form with two chloride ions 
present to balance the charge. The protons are bound to a phenanthroline nitrogen atom and a 
pyridyl nitrogen atom and highlight the intended metal binding domains of the ligand. The 
ligand is planar, with the pyridine ring in the plane of the molecule. 
 
Figure  3.10 X-ray crystal structure of pytp.2HCl. The nitrogen bound H atoms are circled 
There is an average distance of 3.255 Å between the planes of the molecules, which is 
close enough for π-π interactions to occur. However, there is poor overlap between the 
ligands. The main intermolecular interaction is a hydrogen bonding network between the 
protonated nitrogen atoms, chloride ions and water molecule (Figure  3.11). 
3.18 3.19 
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Figure  3.11 Hydrogen bonding network in the X-ray crystal structure of pytp.2HCl 
3.2.3. 3,6-di(pyridin-2-yl)-1,2,4,5-tetrazine and 3,6-di(pyrazin-2-
yl)-1,2,4,5-tetrazine 
The next ligands we synthesised were not from the ‘LEGO’ system but were the 
substituted tetrazines pytz (3.12) and pztz (3.22). These ligands were synthesised in two steps 
from 2-cyanopyridine and 2-cyanopyrazine respectively. The first step was reaction with 
hydrazine to generate the dihydrotetrazines 3.20 and 3.21. This was followed by oxidation 
with NaNO2 in acetic acid to give pytz and pztz. (Figure  3.12) 
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Figure  3.12 Syntheses of pytz (left) and pztz (right) 
In the literature relating to the synthesis of the ligands pytz and pztz, three different 
reaction conditions for the synthesis of the dihydro intermediate are reported. The first of these 
involved heating a mixture of the appropriate nitrile, an excess of hydrazine, and sulfur in 
ethanol at reflux for three hours.[120] The next was simply to heat the nitrile and hydrazine 
together at reflux for 5 hours, with a minimal amount of ethanol added to aid dissolution of the 
nitrile.[122] The final method we evaluated was to heat a solution of the nitrile and hydrazine at 
reflux in THF with a small amount of HCl for five hours.[121] 
All three of these methods gave an orange solid as the product. These orange solids 
were analysed by 1H NMR spectroscopy. In all cases the desired dihydrotetrazine product was 
present. However, the reaction involving sulfur showed a large number of impurities. Of the 
other two, the reaction in THF gave a slightly lower yield but was easier to conduct because it 
lacked the solubility problems associated with the neat nitrile-hydrazine reaction. 
3.12 
3.20   3.21 
  3.22 
Chapter 3 Two Bridging Ligand Series and Their Ruthenium Complexes 
Photo-activated Cytotoxins Alan Downward 73 
The final step in the synthesis of pytz and pztz was using NaNO2 to oxidise the 
dihydrotetrazine to the final product, which had the added benefit of removing any impurities. 
This was true even in the case of the sulfur reaction, although the overall yield was lower. 
Unlike the ‘LEGO’ system ligands, these substituted tetrazines have identical binding 
domains. This could prove problematic during the coordination of a metal centre to these 
ligands as they could easily generate a dinuclear complex. 
3.2.4. Formation of Triazine Based Ligands on Ruthenium 
One way to ensure selective binding of ruthenium to the ligands phtp, pytp and pztp, is 
the synthetic strategy of pre-binding ruthenium to the 1,10-phenanthroline-5,6-dione before 
synthesising the ligands.[119] To achieve this an ethanolic solution of the carboxamidrazone 
was added to a solution of [(bpy)2Ru2(phendione)](PF6)2 in acetonitrile; after heating at reflux 
for 1 hour, the solution was cooled to room temperature and the solvent removed under 
vacuum to give the crude product. The final product was isolated by column chromatography 
on silica. (Figure  3.13)  
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Figure  3.13 Synthesis of the ligand pytp on a ruthenium(II) metal centre 
Characterisation of these complexes was achieved through the use of ESI-MS and 
NMR spectroscopy. gCOSY NMR techniques were employed to identify the various ring 
systems (Figure  3.14), and the assigned spectra are illustrated for [(bpy)2Ru(pytp)](PF6)2 
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(Figure  3.15). The assignment of the 1H NMR peaks proved invaluable during the later 
coordination studies, as detailed in Section  3.2.8. 
 
Figure  3.14 gCOSY >MR spectrum of [(bpy)2Ru(pytp)]
2+
 with the non-bpy spin systems highlighted 
 
Figure  3.15 
1
H >MR spectrum of [(bpy)2Ru(pytp)]
2+
 in CD3C> 
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The visible absorption spectrum was also recorded and showed a maximum absorption 
at 440 nm (Figure  3.16). 
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Figure  3.16 UV-vis absorption spectrum of [(bpy)2Ru(pytp)]
2+
 in CH3C> 
3.2.4.1. Crystal Structure of [(bpy)2Ru(pztp)](PF6)2 
Vapour diffusion of ether into a solution of [(bpy)2Ru(pztp)](PF6)2 in acetonitrile 
produced red crystalline plates that were suitable for use in X-ray crystallography (Figure 
 3.17). The crystal structure confirmed that the ruthenium is bound to the phenanthroline end of 
the bridging ligand in an octahedral geometry. It is also worth noting the position of the 
pyrazine ring. This ring, which can freely rotate about its bond, is in a planar arrangement with 
respect to the rest of the ligand. This alignment, with the pyrazine-triazine rings forming a 
potential bidentate domain, is the desired configuration for binding a second metal centre. 
Chapter 3 Two Bridging Ligand Series and Their Ruthenium Complexes 
Photo-activated Cytotoxins Alan Downward 76 
 
Figure  3.17 X-ray crystal structure of [(bpy)2Ru(pztp)](PF6)2; counter ions and solvent molecules have 
been omitted for clarity 
3.2.4.2. Glycolation of [(bpy)2Ru(phendione)](PF6)2 
The formation of the complex [(bpy)2Ru(phendione)](PF6)2, which involves the 
reaction of [Ru(bpy)2Cl2] with phendione in ethanol, was initially conducted using ethylene 
glycol and water as the solvent, as we believed that conducting the reaction at a higher 
temperature would result in a better yield. The change to ethanol was necessitated by the 
discovery of an impurity in the product. This impurity was the result of the ethylene glycol 
reacting with the phendione to form 3.23 (Figure  3.18). The non-nitrogen containing analogue 
of the free ligand of 3.23 was first reported in 1971 by Erenz et al as part of a series of 
complexes formed by the condensation of cyclic 1,2-diketones with ethylene glycol in the 
presence of an acid catalyst.[127] 
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Figure  3.18 Glycolation of [(bpy)2Ru(phendione)](PF6)2 
3.23 was only a minor product in the formation of [(bpy)2Ru(phendione)](PF6)2, 
presumably because the water can react with 3.23 to regenerate the phendione, and any 3.23 
still present was almost always removed during column chromatography. However, we 
discovered that this was not always the case. When attempting to grow crystals of 
[(bpy)2Ru(pytp)Co(en)2](PF6)5, by diffusion of ether into acetonitrile, the majority of the solid 
formed was an orange-brown precipitate. In addition to this precipitate, there were about half a 
dozen red crystals present, which were examined by X-ray crystal diffraction. The data 
collected from these crystals was very poor, but nevertheless the structure of 3.23 could be 
resolved (Figure  3.19). 
3.23 
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Figure  3.19 X-ray crystal structure of 3.23 
In order to assess if the glycolation was occurring before or after coordination of the 
phendione to the ruthenium metal centre, or both, two additional experiments were conducted. 
The first of these simply involved heating phendione in ethylene glycol at reflux for three 
hours. The product of this reaction was not analysed by 1H NMR spectroscopy due to a poor 
solubility profile. Instead, it was reacted with [Ru(bpy)2Cl2] and the product of this reaction 
examined by 1H NMR spectroscopy. The other experiment was to heat a sample of 
[(bpy)2Ru(phendione)](PF6)2, prepared from ethanol, at reflux in ethylene glycol. In both cases 
the product was substantially different from the pure [(bpy)2Ru(phendione)](PF6)2, with the 
sample prepared by heating phendione in ethylene glycol being the least different. This 
demonstrates that the glycolation is not hindered by the presence of the ruthenium(II) metal 
centre, and may even be promoted by it. 
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3.2.5. Ruthenium Complexes of Pytp and Pztp 
In addition to synthesising the ligands pytp and pztp on ruthenium, the complexation of 
the preformed ligands with [Ru(bpy)2Cl2] was carried out. The 
1H NMR spectrum of the crude 
complex resulting from the reaction (Figure  3.20) had more peaks above 8.5ppm than the 
ruthenium synthesised complex (Figure  3.15). Since these peaks are assigned to the protons on 
pytp, this suggests that the ruthenium is coordinated through the pyridyl-triazine end of the 
molecule. 
 
Figure  3.20 
1
H >MR spectrum of the crude product from the reaction of [Ru(bpy)2Cl2] with pytp in 
CD3C> 
The crude product from the reaction with pztp was examined by 1H NMR 
spectroscopy. The large number of peaks in the aromatic region of the 1H NMR spectrum was 
assessed as being due to a mixture of products (Figure  3.21). We were able to assign some of 
these peaks to the complex with the ruthenium(II) ion bound to the phenanthroline end of the 
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ligand. The remaining peaks were most probably related to the complex with the ruthenium(II) 
ion bound to the pyrazine end of the ligand. 
 
Figure  3.21 
1
H >MR spectrum of the crude product from the reaction of [Ru(bpy)2Cl2] with pztp in 
CD3C> 
Purification of the crude material by column chromatography on silica gel resulted in 
the isolation of one major band. The 1H NMR spectrum of this band still contained the peaks 
that had previously been assigned to the complex with the ruthenium(II) ion bound to the 
phenanthroline end of the ligand (Figure  3.22). However, while the number of peaks in this 
spectrum was fewer than in the spectrum of the crude material, the product still was not pure. 
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Figure  3.22 
 1
H >MR spectrum of the major band from the purification of the reaction of [Ru(bpy)2Cl2] 
with pztp in CD3C> 
3.2.6. Ruthenium Complexes of Pytz and Pztz 
The synthetic pathway for the synthesis of the tetrazine ligands, pytz and pztz, 
prohibits the use of selective binding as a strategy to generate the monoruthenium(II) complex. 
Our intention was to simply carry out the reaction between [Ru(bpy)2Cl2] and the ligand in a 
one to one ratio and remove any diruthenium complexes after the reaction was completed. 
Carrying out the one to one reaction by heating the reactant at reflux in ethylene glycol for 3 
hours gave a blue solution, from which a blue solid could be precipitated by addition of a 
saturated methanolic solution of NH4PF6. Recording the UV-vis spectrum of the product in 
acetonitrile and comparing the recorded spectrum with that reported in the literature for the 
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compound [(bpy)2Ru(pytz)Ru(bpy)2](PF6)4 showed that we had formed the diruthenium 
complex (Figure  3.23).[128] 
Ernst and Kaim describe the ready formation of the diruthenium complex as being due 
to charge transfer assisted polynucleation.[124] Back donation from the first bound ruthenium 
ion increases the electron density of the other binding domain and makes it a better ligand than 
the unbound species. 
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Figure  3.23 Attempted synthesis of [(bpy)2Ru(pytz)](PF6)2 instead resulting in the formation of 
[(bpy)2Ru(pytz)Ru(bpy)2](PF6)4 
The blue colour is due to a maximum absorption of visible light at just under 700 nm 
(Figure  3.24). Usually ruthenium polypyridyl complexes have a maximum absorption in the 
range of 400-500 nm; for example [Ru(bpy)3]
2+ has λmax=451 nm.
[129] This bathochromic shift 
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is due to the complex having an extremely low energy LUMO (π*) associated with the 
bridging ligand.[124, 128, 130] 
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Figure  3.24 UV-vis absorption spectrum of [(bpy)2Ru(pytz)Ru(bpy)2]
4+
 in CH3C> 
In order to obtain the monoruthenium complex, a revised synthetic procedure based on 
that used for the coordination of ruthenium(II) to 2,5-dipyridylpyrazine was used.[131] An 
excess of either pytz or pztz was heated to reflux in methanol; to this a stirred suspension of 
[Ru(bpy)2Cl2] in methanol was slowly added. After being cooled to room temperature, the 
mono-ruthenium complex was isolated through column chromatography on silica gel (Figure 
 3.25). The reason that this method produced the monoruthenium complex while the previous 
method produced the diruthenium complex is because it uses kinetic control instead of 
thermodynamic. 
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Figure  3.25 Formation of [Ru(bpy)2(pytz)](PF6)2 
The absorption of the mono-ruthenium complex [(bpy)2Ru(pytz)]
2+ in acetonitrile was 
recorded with a λmax of 510 nm (Figure  3.26).  
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Figure  3.26 Absorption spectrum of [(bpy)2Ru(pytz)]
2+
 in CH3C> 
3.2.7. Formation of Diruthenium Complexes 
We have already shown that the ligand pytz readily forms diruthenium complexes and 
in addition to our own evidence, there is also a literature example of ruthenium binding to the 
pyridyl end of pytp.[132] In order to further investigate the coordination ability of the second 
binding domain of pytp, we decided to synthesise the diruthenium pytp complex. Heating a 
mixture of [Ru(bpy)2Cl2] and [(bpy)2Ru(pytp)](PF6)2 at reflux in methanol for two weeks gave 
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a red precipitate as the product (Figure  3.27). Because no attempt was made to control the 
configuration of the ruthenium(II) metal centres this product should be a mixture of both the 
meso and rac stereoisomers. 
N
N
N
N
N
N
Ru
N
N
N
N
N
N
N
N
N
N
Ru
N
N
N
N
N
N
N
N
Ru
Cl
Cl
N
N
N
N
Ru+
2+
4+
 
Figure  3.27 Formation of [(bpy)2Ru(pytp)Ru(bpy)2](PF6)4 
The 1H NMR spectrum of the resulting product was recorded and shows that the peaks 
relating to the pytp ligand are shifted by up to about 1ppm from the mononuclear complex 
(Figure  3.28). However, full assignment and characterisation of the products from this reaction 
was not achieved. 
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Figure  3.28 
1
H >MR of [(bpy)2Ru(pytp)Ru(bpy)2](PF6)2 in CD3C> 
3.2.8. Heterodinuclear Complexes of [(bpy)2Ru(pytp)](PF6)2 
[(bpy)2Ru(pytp)](PF6)2 was dissolved in acetonitrile-d3 and its interactions with 
silver(I) were monitored by 1H NMR. An increasing amount of Ag(ClO4) was slowly added 
with the observed result being a gradual shift of the pytp peaks until the ruthenium:silver ratio 
was one to one (Figure  3.29). Further addition of silver had a minimal affect on the position of 
the pytp peaks. This is consistent with one to one binding of silver ions and a fast equilibrium 
between the bound and unbound state. If the silver was irreversibly bound or the rate of 
exchange slow on the NMR timescale, then we would expect to see a new set of peaks 
growing in with the addition of Ag(ClO4). 
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Figure  3.29 
1
H >MR spectra of [(bpy)2Ru(pytp)](PF6)2 in CD3C> with: (a) 0 equivalents of Ag(ClO4); (b) 
0.3 equivalents of Ag(ClO4); (c) 1 equivalent of Ag(ClO4) 
At the conclusion of the silver titration, a small amount of the solution was used to 
prepare a sample suitable for analysis by mass spectrometry. The mass spectrometry showed 
three major isotope patterns that were of interest. These were at m/z ratios of 362, 466, and 
823 corresponding to [(bpy)2Ru(pytp)]
2+, [(bpy)2Ru(pytp)Ag](ClO4)
2+ and 
[(bpy)2Ru(pytp)](ClO4)
+ respectively (Figure  3.30). This was consistent with the 1H NMR 
result in indicating that silver was binding to the vacant site. 
a 
b 
c 
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Figure  3.30 Modelled and experimental isotope patterns for [(bpy)2Ru(pytp)]
2+
, 
[(bpy)2Ru(pytp)Ag](ClO4)
2+
 and [(bpy)2Ru(pytp)](ClO4)+ 
In addition to the 1H NMR study carried out with Ag(ClO4), additional studies were 
conducted using CuSCN and Zn(NO3)2. The addition of Zn(NO3)2 resulted in a similar change 
in the 1H NMR peak positions as was observed for the addition of Ag(ClO4). 
CuSCN was initially observed to behave like silver(I); however, as the experiment 
continued, the pytp peaks broadened as well as shifted. This was potentially due to oxidation 
of the copper(I) to the paramagnetic copper(II). To confirm that it was paramagnetic 
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broadening causing the suppression of the pytp peaks, another experiment was carried out, this 
time with the paramagnetic copper(II) salt copper acetate. The addition of copper(II) resulted 
in the pytp peaks quickly broadening to the point that they could no longer be observed. Since 
both the 1H NMR spectra of the copper(I) and copper(II) experiments show peak broadening, 
we conclude that it was oxidation of the copper(I) metal ions to copper(II) metal ions that 
caused the original result. Oxidation of the copper(I) could have potentially arisen through 
aerial oxidation. 
In order to ensure that it was the transition metal ions that were responsible for the 
observed changes, the non-transition metal-containing salts NaClO4, NH4PF6 and LiCl were 
also tested. In each case they had little or no effect on the recorded 1H NMR spectrum. We 
infer from this that these metal ions are not associating with the pytp ligand, and that the 
observed changes were due to the coordination of the transition metal to the vacant binding 
domain of the pytp ligand. 
3.2.9. Heterodinuclear Complexes of [(bpy)2Ru(pytz)](PF6)2 
The complex [(bpy)2Ru(pytz)](PF6)2 was also dissolved in acetonitrile and the ability 
to coordinate a second metal centre assessed by use of a silver titration. Again the result was a 
gradual shifting of the 1H NMR peaks consistent with the silver being in equilibrium between 
a bound and unbound state. 
3.3. Conclusion 
From our studies we have been able to produce two series of ligands and synthesise 
their ruthenium complexes. In addition, we have been able to show that by prebinding a 
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ruthenium metal centre prior to ligand synthesis, selectivity towards only a single domain can 
be achieved. 
Furthermore, we have shown that all of these complexes are capable of binding a 
second metal centre and that the coordination of the second metal centre can be monitored by 
1H NMR spectroscopy. This promising result meant that each of these complexes was a 
suitable candidate for coordination to a cobalt metal centre, a process which will be detailed 
further in Chapter 4. 
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Chapter 4: Heterodinuclear 
Ruthenium(II)-Cobalt(III) 
Complexes 
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4.1.  Introduction 
We have shown that the free binding domains of the ligand systems described in 
Chapter 3 are able to coordinate a second metal centre. These ligands are therefore potential 
bridging ligands for ruthenium(II)-cobalt(III) heterodinuclear complexes. Ideally an electron 
transfer between the two metal centres would enable these complexes to be further developed 
into photo-activated cytotoxins. 
4.1.1. Applications of Ruthenium(II) Heterodinuclear 
Complexes 
In many cases the synthesis and study of heterodinuclear complexes containing 
ruthenium(II) is motivated by the need for a particular photochemical or electrochemical 
property in a possible application. For example ruthenium(II)-platinum(II) complexes have 
been investigated as possible photosensitisers to enhance the photochemical reduction of water 
to molecular hydrogen by the disodium salt of ethylenediaminetetraacetic acid.[133] Both 
ruthenium(II)-rhenium(I) and ruthenium(II)-rhodium(III) complexes are being investigated for 
use as charge separating sensitisers in dye-sensitised solar cells.[60] 
Recently the first example of photochemical reduction of nitrite into nitrogen 
monoxide by a ruthenium(II)-copper(II) complex was reported (Figure  4.1).[134] 
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Figure  4.1 Ruthenium(II)-copper(II) heterodinuclear species capable of the photochemical reduction of 
>O2
- 
Replacing the copper(II) centre with zinc(II) resulted in the NO2
- no longer being 
reduced to NO. From this, it was therefore concluded that the copper(II) centre is the site for 
the reduction. The proposed mechanism for this photo-reduction is: 
Ru2+-Cu2+ + hv ↓ Ru2+*-Cu2+ 
Ru2+*-Cu2+ ↓ Ru3+-Cu+ 
Ru3+-Cu+ + NO2¯ + 2H
+ ↓ Ru3+-Cu2+ + NO + H2O 
Ru3+-Cu2+ + X(e.g. CH2Cl2) ↓ Ru2+-Cu2+ + X•(e.g. Cl•) 
The first step involves a photo-induced intramolecular electron transfer from the 
ruthenium(II) centre to the copper(II) centre which results in the formation of a 
ruthenium(III)-copper(I) species. The copper(I) metal centre then reduces the nitrite ion into 
nitrogen monoxide, being oxidised back to copper(II) in the process. The final regenerative 
step is the reduction of the ruthenium(III) metal centre back to ruthenium(II); this step is 
proposed to involve the oxidation of a solvent molecule, such as CH2Cl2. The rationale behind 
the regenerative step is that the photo-reduction continued without the need for a sacrificial 
reductant, and the UV-visible absorption spectrum of the solution at the end of the experiment 
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was very similar to that before. This is consistent with the ruthenium metal centre still being in 
the 2+ oxidation state. 
4.1.2. Heterodinuclear Ruthenium(II)-Cobalt(III) Complexes 
The majority of ruthenium(II)-cobalt(III) complexes in the literature were synthesised 
for the purpose of electron transfer studies. The complexes used by Taube in his experiments 
were synthesised first by forming the ruthenium(III)-cobalt(III) complex (Figure  4.2) and then 
reducing it to the ruthenium(II)-cobalt(III) complex with either [Ru(NH3)6]
2+ or ascorbate. [82, 
83, 84, 85] 
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Figure  4.2 Taube synthesis of a ruthenium(III)-cobalt(III) complex 
Toreida et al. synthesised ruthenium(II)-cobalt(III) complexes by heating the 
ruthenium(II) complex with either [Co(tpy)Cl3] or [Co(tpy)(CF3SO3)3] (Figure  4.3).
[135, 136] 
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Figure  4.3 Synthesis of a ruthenium(II)-cobalt(III) heterodinuclear complex 
4.2. Results and Discussion 
4.2.1. Synthetic Strategy 
For our purposes, a modification of the method proposed by Toreida seemed the most 
useful. However, the products which resulted from heating our ruthenium(II) complexes at 
reflux with [Co(en)2Cl2]Cl were unable to be assigned due to paramagnetic contamination. 
This paramagnetism could be due to the ruthenium(II) being oxidised to ruthenium(III) and/or 
the reduction of the cobalt(III) to cobalt(II). 
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By using the triflate salts of selected cobalt(III) complexes (for example 
[Co(tren)(OTf)2](OTF) and [Co(en)2(OTf)2](OTf)) it should be possible to successfully 
synthesise a variety of heterodinuclear complexes simply by stirring equimolar amounts of the 
ruthenium(II) and cobalt(III) complexes in acetonitrile at room temperature (Figure  4.4). The 
reason for using the triflate complex is that in addition to being soluble in acetonitrile, the 
triflate ligands in cobalt(III) triflato complexes are weakly coordinating. For example, the rates 
of aquation for [Co(NH3)5L]
2+ are for L= triflate 2.7 x 10-2 s-1, chloride 1.7 x 10-6 s-1 and nitrite 
1.2 x 10-8 s-1.[49] Since the use of triflate ligands will mitigate the problem of cobalt(III) being 
inert, it is possible that the heterodinuclear complexes will be successfully formed at room 
temperature. 
During the formation of the ruthenium(II)-cobalt(III) heterodinuclear complexes, it is 
important to minimise exposure to light. Failing to reduce the amount of light to which the 
complex is exposed could result in photo-induced electron transfer from the ruthenium(II) 
metal centre to the cobalt(III) metal centre. 
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Figure  4.4 Proposed synthesis of [(bpy)2Ru(pytp)Co(en)2](PF6)5 
4.2.2. Complexes Utilising a Pytp Bridging Ligand 
The ruthenium(II) complex [(bpy)2Ru(pytp)](PF6)2 was used in the formation of 
ruthenium(II)-cobalt(III) heterodinuclear complexes. This was achieved by stirring the 
ruthenium complex with either [Co(en)2(OTf)2]OTf or [Co(tren)(OTf)2]OTf in acetonitrile, in 
the dark. The final heterodinuclear complexes were then isolated as the PF6 salts. 
1H NMR 
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spectra showed the products to be relatively free from contamination, even though no attempt 
was made to purify them after isolation because of their potential instability. Additional 
experiments were conducted on the NMR scale so that the formation of the product could be 
monitored. Monitoring the reaction in this manner showed the 1H NMR peaks which 
corresponded to the starting material decreasing, while the 1H NMR peaks associated with the 
product grew (Figure  4.5). 
The rationale for synthesising these complexes was that ethane-1,2-diamine has a 
similar binding domain to the bidentate nitrogen mustards N,Nʹ-bis(2-chloroethyl)ethane-1,2-
diamine and N,N-bis(2-chloroethyl)ethane-1,2-diamine, while tris(aminoethyl)amine, being 
tetradentate, should be more stable towards substitution. In both cases the product will be a 
mixture of isomers. Firstly, this is due to the complex [(bpy)2Ru(pytp)](PF6)2 being a mixture 
of the Λ and ∆ forms. Secondly, the cobalt complexes can bind in either of two configurations. 
For the en complex these will be the Λ and ∆ forms, while for the tren complex the tertiary 
amine can be in either a cis or trans arrangement with the pyridyl nitrogen. 
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Figure  4.5 Aromatic regions of the 
1
H >MR spectra taken during the reaction between [(bpy)2Ru(pytp)]
2+
 
and [Co(tren)(OTf)2]
+
 in CD3C>; the top spectrum is primarily unreacted [(bpy)2Ru(pytp)]
2+
 while the 
bottom is primarily the heterodinuclear complex. 
The complex [(bpy)2Ru(pytp)Co(tren)](PF6)5 was characterised by 
1H, 13C, gCOSY, 
and HSQCad NMR techniques. In addition to the peaks we assigned to the two bpy ligands, 
the aromatic region of the gCOSY shows three discrete spin systems. These systems 
correspond to the four protons on the cobalt bound pyridine ring and the two sets of three 
protons on each side of the phenanthroline portion of the pytp ligand (Figure  4.6). 
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Figure  4.6 [(bpy)2Ru(pytp)Co(tren)]
5+ 
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Figure  4.7 Aromatic region of the gCOSY spectrum of [(bpy)2Ru(pytp)Co(tren)]
5+
 with the spin systems 
not corresponding to the bpy ligands highlighted 
c h d g e a   j f 
b,i 
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Assignment of the 1H NMR peaks associated with the two sides of the phenanthroline 
ring system was achieved by utilising the NOE experiment. Irradiation of the positions of the 
1H NMR peaks corresponding to the tren ligand results in the amplification of the signal peaks 
relating to nearby protons. A correlation between the tren peak at 4.6 ppm and the pytp peak at 
9.6 ppm means that the ring system corresponding to 9.6, 8.0 and 8.4 ppm are on the same 
side of the pytp molecule as the cobalt bound tren. The peak at 4.6 ppm was assigned to a 
single CH2 group next to an NH2 group. This means that the NOE experiment result can also 
be used to assign the orientation of the tren molecule as having the tertiary amine opposite the 
coordinated nitrogen of the triazine (Figure  4.8). 
 
Figure  4.8 3D representation of the coordination of Co(tren)
3+
 to pytp 
Having fully assigned the proton peaks correlating to the pytp ligand, HSQC was used 
to assign the 13C spectra. 
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Table  4.1 Selected 
1
H and 
13
C >MR peak assignments for [(bpy)2Ru(pytp)Co(tren)](PF6)5 
Peak Position (ppm) phen pyridyl phen 
9.85, 136.4 c   
9.59, 135.0   h 
9.33, 130.4  d  
8.88, 155.5  g  
8.69, 144.7  e  
8.49, 159.8 a   
8.41, 157.8   j 
8.23, 133.0  f  
8.08, 129.6 b   
8.04, 129.6   i 
 
The formation of the bis(en) complex (Figure  4.9) proceeded under the same reaction 
conditions as the tren complex and an orange-brown precipitate was isolated. 
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Figure  4.9 [(bpy)2Ru(pytp)Co(en)2]
5+
 
The 1H NMR spectrum of the complex revealed significant changes in position of the 
pytp peaks, in comparison to that of [(bpy)2Ru(pytp)]
2+, as well as additional peaks in the 
alkyl region (Figure  4.10). As no efforts were made to control the configuration of the two 
metal centres, we would expect the product to be a mixture of up to four isomers (ΛΛ, Λ∆, 
∆Λ and ∆∆). However, the 1H NMR spectrum does not show multiple sets of peaks. This 
suggests that there is either little difference in the electronic environment of each isomer or the 
product is selective for one of the pairs of enantiomers. Constructing models of the different 
isomers showed that there is a substantial distance between the two metal centres. This large 
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distance makes it unlikely that stereoselective binding is occurring and that there is actually a 
mixtures of isomers present. 
 
Figure  4.10 Aromatic regions of the 
1
H >MR spectra of [(bpy)2Ru(pytp)]
2+
 before (top) and after (bottom) 
coordination of a Co(en)2
3+
 fragment in CD3C> 
In both cases coordination of the cobalt complex resulted in a change of the UV-vis 
spectra. The value associated with λmax was slightly red shifted, while the absorbance below 
400 nm increased. In order to determine if these changes were due to the coordination of the 
cobalt(III) centre or just due to the overlapping of the peaks associated with the ruthenium 
centre and those of the cobalt centre, the UV-vis spectrum of a freshly prepared acetonitrile 
solution containing both [(bpy)2Ru(pytp)](PF6)2 and [Co(tren)(OTf)2](OTf) was recorded. In 
this case the spectrum was identical to that of the ruthenium(II) complex. The solution was 
then placed in the dark for twenty four hours and the spectrum was recorded again; this time 
the spectrum was identical to that of the ruthenium(II)-cobalt(III) complex. This is consistent 
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with the idea that it is the coordination of the cobalt metal centre that is responsible for the 
observed changes in the UV-vis spectra. 
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Figure  4.11 UV-visible spectra of [(bpy)2Ru(pytp)]
2+
 before (solid line) and after (dotted line) coordination 
of cobalt(III) in CH3C> 
4.2.2.1. Luminescence 
Many ruthenium(II) polypyridyl complexes have been observed to luminesce in the 
visible region.[129, 137] The generally accepted rationale is that luminescence such as this arises 
after a MLCT from the ground state to a singlet excited state (1MLCT). The excited state then 
crosses to a triplet state (3MLCT) via an intersystem crossing (ISC), and it is the relaxation of 
this triplet state back to the ground state that occurs with luminescence. 
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Figure  4.12 Fluorescent pathway for ruthenium(II) polypyridyl complexes 
The emission spectra of the complexes, both before and after coordination of the 
cobalt, were recorded (Figure  4.13). The complex with cobalt bound was observed to emit less 
light than the complex without. 
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Figure  4.13 Comparison of the emission spectra of [(bpy)2Ru(pytp)]
2+
 (upper, solid line) and 
[(bpy)2Ru(pytp)Co(tren)]
5+
 (lower, dashed line) in CH3C> 
hv 
hv 
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4.2.2.2. Lifetime study 
The mononuclear and heterodinuclear pytp complexes were sent to Dr Evan Moore at 
the University of Melbourne, for measurement of the excited state lifetimes. The samples were 
placed in dry aerated acetonitrile and exposed to an excitation wavelength of 440 nm; the 
emission at 625 nm was then monitored. 
The mononuclear complex was found to have a lifetime of 212 ns; while the 
heterodinuclear complex was found to have a lifetime of 72 ns. These values were calculated 
by fitting an exponential curve to the observed emission data (Figure  4.14). 
 
Figure  4.14 Lifetime measurements for [(bpy)2Ru(pytp)]
2+
 (blue) and [(bpy)2Ru(pytp)Co(tren)]
5+
 (red) 
In addition to the lifetime measurements, the quantum yields were calculated by using 
[Ru(bpy)3]Cl2 as a standard with a known quantum yield of 4.2 %.
[138] This involved 
measuring the relationship between the absorption at 440 nm and the integrated emission, and 
comparing this to the [Ru(bpy)3]Cl2 standard. From these measurements the mononuclear 
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complex was found to have a quantum yield of 1.11 % and the heterodinuclear complex a 
quantum yield of 0.21 %. 
 
Figure  4.15 Emission-absorption relationship for [Ru(bpy)3]
2+
 (green), [(bpy)2Ru(pytp)]
2+
 (blue) and 
[(bpy)2Ru(pytp)Co(tren)]
5+
 (red) 
All of these measurement are consistent with the coordination of the cobalt(III) metal 
centre resulting in a quenching of the luminescence. Furthermore, if we assume that the 
radiative and non-radiative decay paths are the same for each complex then the rate of electron 
transfer can be approximated from the formula kobs = krad + ket. If we assume that krad is equal 
to kobs in the mononuclear complex, then in the heterodinuclear complex ket = kobs – krad. This 
calculation gives a ket value of 9.6 x 10
6 s-1. 
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4.2.2.3. Photo-activated Ligand Release 
The purpose of synthesising these ruthenium(II)-cobalt(III) heterodinuclear complexes 
is to use them as an analogue for a photo-activated cytotoxin. Therefore the ability of the 
complex to release the ligands coordinated to the cobalt(III) metal centre must be assessed. In 
order to examine the photo-activated ligand release, the complex 
[(bpy)2Ru(pytp)Co(en)2](PF6)5 was dissolved in a 5 mm NMR tube with 50:50 mixture of 
deuterated acetonitrile and D2O. The sample was then placed in a water bath in front of a 200 
W incandescent lamp, and 1H NMR spectra recorded at regular intervals. 
Monitoring the changes between the 1H NMR spectra showed a new singlet peak at 
3.21 ppm growing in over time (Figure  4.16). We assigned this peak to the two CH2 groups on 
the free en ligand. This process was shown to be light dependent as placing the samples in the 
dark overnight did not result in any change being detected by 1H NMR methods. This supports 
the proposal that photo-activated electron transfer from the ruthenium(II) metal centre results 
in the reduction of cobalt(III) to cobalt(II) and triggers ligand release.  
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Figure  4.16 Photo-activated release of en from [(bpy)2Ru(pytp)Co(en)2]
5+
; the peak associated with the free 
en molecule is marked with an asterisk 
A similar experiment was performed with the [(bpy)2Ru(pytp)Co(tren)](PF6)5 complex 
under the same reaction conditions. In this case two new triplets were observed to form at 2.99 
and 2.73 ppm in the 1H NMR spectra. The integration of these signals increased with time 
(Figure  4.17). The multiplicity and chemical shifts are entirely consistent with release of the 
tren ligand from the cobalt centre. The independent experiments with the tren and en systems 
together demonstrate that photo-induced ligand release can be achieved. 
* 
* 
* 
* 
* 
* 
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Figure  4.17 Photo-activated release of tren from [(bpy)2Ru(pytp)Co(tren)]
5+
; the peaks associated with the 
free tren molecule are marked with an asterisk 
Further experiments were undertaken to examine whether the rate of ligand release 
depended on the O2 concentration. O2 dependent ligand release may provide a route to 
selective treatment of hypoxic cells like those found in poorly vascularised solid tumours. 
In these experiments, three 1H NMR samples were prepared in different manners. The 
first sample was prepared in exactly the same manner as above, the second had N2 bubbled 
through it for one minute in order to remove some of the O2, and the third was put through 
several freeze-pump-thaw cycles, the NMR tube was back filled with nitrogen before thawing 
so as to prevent excessive evaporation of acetonitrile from the solution. The three samples 
were then irradiated and the amount of en released was estimated by comparing the integral of 
the en singlet with the integral of the peak at 9.21 ppm corresponding to pytp bridging ligand 
of the unreacted starting material. Plotting these values revealed that the freeze-pump-thaw 
* * 
* * 
* * 
* * 
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sample released its ligands fastest, with the nitrogen bubbled samples being the second 
quickest (Figure  4.18). This suggests that the rate of ligand release may be oxygen dependent. 
0
5
10
15
20
25
30
35
40
45
0 100 200 300 400 500 600
Time (mins)
%
 L
ig
a
n
d
 R
e
le
a
s
e
d
 
Figure  4.18 Difference in rate of ligand release between freeze-pump-thaw (♦), >2 bubbled (▲) and air (■) 
4.2.3. Complex Utilising a Pztp Bridging Ligand 
The complex [(bpy)2Ru(pztp)](PF6)2 was reacted with [Co(en)2(OTf)2](OTf) in a 
similar manner to above. The reaction was much slower than the one with pytp as the bridging 
ligand. After three hours most of the starting material was still unreacted. We did not want to 
heat the reaction as a means to increase the reaction rate, because when we had heated similar 
reaction mixtures previously, the resulting solutions contained paramagnetic material. Instead, 
the formation of [(bpy)2Ru(pztp)Co(en)2](PF6)5 was achieved by stirring equimolar quantities 
of the reactants at room temperature in the dark for three days. 
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Figure  4.19 [(bpy)2Ru(pztp)Co(en)2]
5+
 
In comparison to the 1H NMR spectrum the starting material, the spectrum for the 
resulting complex shows major changes in the positions of the peaks associated with the 
pyrazine ring. The singlet at 9.99 ppm, assigned to the CH group in the 3 position, shifted 
downfield to 10.33 ppm, and the two doublets at 8.90 and 8.86 ppm also shifted downfield to 
9.41 and 9.01 ppm. The rest of the pztp protons were also shifted as a result of the cobalt 
coordination, while the bpy peaks only showed small changes. 
 
Figure  4.20 Aromatic regions of the 
1
H >MR spectra of [(bpy)2Ru(pztp)](PF6)2 (top) and 
[(bpy)2Ru(pztp)Co(en)2](PF6)5 (bottom) in CD3C> 
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As with the pytp complexes, the coordination of the cobalt(III) centre resulted in a 
slight red-shift of λmax and an increase in the absorbance in the near UV region. 
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Figure  4.21 UV-visible spectra of [(bpy)2Ru(pztp)]
2+
 before (solid line) and after (dotted line) coordination 
of the Co(en)2
3+
 fragment in CH3C> 
4.2.3.1. Photo-activated Ligand Release 
The examination of the photo-activated ligand release from the complex 
[(bpy)2Ru(pztp)Co(en)2](PF6)5 was conducted in the same manner as for 
[(bpy)2Ru(pytp)Co(en)2](PF6)5. Two samples were prepared; one with 5 iterations of freeze-
pump-thaw, back filling with argon before thawing, and the other with no effort made to 
remove oxygen from the system. In both cases a singlet corresponding to the CH2 groups on 
the free en appeared at 3.05 ppm. The generation of this singlet was quicker in the freeze-
pump-thaw sample, which is consistent with the oxygen dependence observed for the pytp 
complex. In addition to the appearance of the en singlet following irradiation, the recorded 1H 
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NMR spectra for both samples showed the reappearance of the peaks corresponding to 
[(bpy)2Ru(pztp)]
2+ (Figure  4.22). 
 
Figure  4.22 Aromatic regions of the 
1
H >MR spectra of [(bpy)2Ru(pztp)Co(en)2]
5+
 during irradiation in a 
50:50 D2O/CD3C> mixture, recorded from time = 0 (top) to time = 3 hours (bottom) 
The regeneration of the original 1H NMR spectrum was not seen in any of the pytp 
experiments. This could be due to either the ruthenium(III) complex being reduced back to 
ruthenium(II) after release of the cobalt metal centre and the cobalt(II) metal not 
recoordinating to the vacant binding domain, or the ligand release is occurring by some other 
process. In order to examine whether the reformation of [(bpy)2Ru(pztp)]
2+ was related to the 
irradiation, a sample of [(bpy)2Ru(pztp)Co(en)2](PF6)5 was placed in a 50:50 mix of 
acetonitrile and water and left in the dark for 17 hours. After this time the 1H NMR spectrum 
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of the sample was recorded. The recorded 1H NMR spectrum showed peaks consistent with a 
mixture of [(bpy)2Ru(pztp)Co(en)2]
5+ and [(bpy)2Ru(pztp)]
2+ being in solution (Figure  4.23). 
While the 1H NMR spectrum for the 17 hour sample showed an approximately equal amount 
of cobalt coordinated and uncoordinated species in solution, the irradiated sample with oxygen 
removed had no cobalt coordinated species in solution by 3 hours, and the irradiated sample 
with oxygen present had only a small amount of the cobalt coordinated species left after 3 
hours. This suggests that the electron transfer and subsequent ligand release is potentially 
thermally accessible. The potential thermal accessibility of the electron transfer could explain 
why we observed paramagnetic contamination in the products of the reactions involving 
heating the ruthenium(II) complexes with [Co(en)2Cl2]Cl. 
 
Figure  4.23 Aromatic region of the 
1
H >MR spectrum of [(bpy)2Ru(pztp)Co(en)2]
5+
 after 17 hrs in the dark 
in a 50:50 D2O/CD3C> mixture 
4.2.4. Complexes Utilising a Pytz Bridging Ligand 
The other bridging ligand used in our study was pytz. Unlike pytp and pztp, pytz has 
two identical binding domains and had to be synthesised before being coordinated to a 
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ruthenium(II) metal centre. The complex [(bpy)2Ru(pytz)Co(tren)](PF6)5 was formed in the 
same manner as the heterodinuclear pytp complex (Figure  4.24). 
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Figure  4.24 [(bpy)2Ru(pytz)Co(tren)]
5+ 
The product from the reaction was an intense blue colour and comparison of the 1H 
NMR spectra showed a changed aromatic region (Figure  4.25), as well as additional peaks in 
the alkyl region. 
 
Figure  4.25 Aromatic regions of the 
1
H >MR spectra of [(bpy)2Ru(pytz)]
2+
 (top) and 
[(bpy)2Ru(pytz)Co(tren)]
5+
 (bottom) in CD3C> 
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The coordination of the cobalt(III) metal centre resulted in a major change in the UV-
visible spectrum. The λmax in the visible region shifted from 514 nm to 570 nm. This red shift 
is similar to that observed with the diruthenium complex where λmax is shifted to 700 nm 
following coordination of the second ruthenium centre. 
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Figure  4.26 UV-visible spectra of [(bpy)2Ru(pytz)]
2+
 before (solid line) and after (dotted line) coordination 
of the Co(tren)
3+
 fragment in CH3C> 
4.2.4.1. Photo-activated Ligand Release 
Addition of water to a solution of [(bpy)2Ru(pytz)Co(tren)](PF6)5 resulted in an 
immediate colour change to a much less intense orange solution. On standing this solution 
gradually changed colour to green (Figure  4.27). 
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Figure  4.27 Change in colour of [(bpy)2Ru(pytz)Co(tren)](PF6)5 in acetonitrile following addition of water 
The aromatic region of the 1H NMR spectrum of the complex shortly after the addition 
of water is similar to that of the [(bpy)2Ru(pytz)]
2+ species. However, there are large broad 
peaks in both the aromatic and alkyl regions, which suggest the presence of paramagnetic 
species. The 1H NMR spectrum of the green solution still shows a broadened aromatic region 
similar to that of the orange solution. However, there are now two triplet peaks in the alkyl 
region, which we assign as being the free tren ligand. 
 
Figure  4.28 Aromatic region of the 
1
H >MR spectrum of [(bpy)2Ru(pytz)Co(tren)]
5+
 in CD3C> following 
addition of D2O (orange solution) 
Attempts to show photo-activation of the colour change were unsuccessful as addition 
of water resulted in the formation of the orange solution regardless of light levels. By 
comparison the diruthenium complex showed no change when exposed to the same 
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conditions. This indicates that the electron transfer between the two metal centres is easily 
realised and that, since cobalt(III) is needed as the second metal centre for ligand release to 
occur, the process still involves the formation of a cobalt(II) centre. The ease with which the 
ligand release occurs in this system makes it unsuitable for development as a photo-activated 
cytotoxin. However, the rapid ligand release could prove useful in cytotoxicity studies to 
assess the effect of coordinating a cytotoxic ligand to the cobalt(III) metal centre. 
4.3. Conclusion 
Through the use of cobalt(III) triflate compounds we have been able to synthesise 
several ruthenium(II)-cobalt(III) heterodinuclear complexes capable of undergoing ligand 
release. These complexes are all synthesised by reaction of the mono-ruthenium(II) complex 
with the appropriate cobalt(III) triflate complex. The coordination of the cobalt(III) metal 
centre results in a red shift of the UV-visible spectra, when compared to the mono-ruthenium 
complex, with the pytz complex showing the largest shift of 56 nm (Table  4.2). 
Table  4.2 λmax for mononuclear and heterodinuclear complexes 
 λmax (Ru) λmax (Ru-Co) 
pytp 440 445 
pztp 439 445 
pytz 514 570 
All of the ruthenium(II)-cobalt(III) heterodinuclear complexes synthesised show 
evidence of ligand release under various conditions. The pytp systems were observed to be the 
slowest ligand releasing complexes and showed evidence of re-coordinating to the cobalt(II) 
species generated following ligand release. In both the pytp and pztp systems, oxygen was 
seen to retard the rate of ligand release. 
While the pytp system required light in order for the ligand release to proceed, both the 
pztp and pytz systems showed the ability to undergo ligand release without light, although the 
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pztp system was greatly accelerated by it. This suggests that the electron transfer between the 
two metal centres may be thermally accessible. Further theoretical and physical studies will be 
required before this can be established. 
It needs to be mentioned that we conducted our studies using the PF6¯ salts because it 
made characterisation and subsequent investigation of the photo-activated ligand release 
easier. Other counter ions can also easily be obtained; for example the addition of tetrabutyl 
ammonium bromide to the complexes dissolved in acetonitrile results in the precipitation of 
the bromide salt. 
The ruthenium(II)-cobalt(III) heterodinuclear complexes described in this chapter have 
all been observed to exhibit ligand release from the cobalt metal centre. This means that 
complexes such as these are possible candidates for development as photo-activated 
cytotoxins. The synthetic strategies relating to the incorporation of cytotoxic ligands into these 
complexes are given in Chapter 5. 
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Chapter 5: Synthesis of 
Cobalt(III) Complexes and 
Cytotoxicity Studies 
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5.1. Introduction 
Having been able to demonstrate the photo-activated ligand release of both en and tren 
from a ruthenium(II)-cobalt(III) heterodinuclear complex, the next step is to look towards the 
coordination of cytotoxic ligands. This could be achieved either by the coordination of further 
non-cytotoxic analogues, such as ,ʹ-diethyl(ethane-1,2-diamine) which may better model 
the size and coordination geometry of a nitrogen mustard, or by forming nitrogen mustard 
complexes on the cobalt(III) metal centre (Figure  5.1). 
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Figure  5.1 Examples of ligands which could be bound to a cobalt(III) metal centre in the study of photo-
activated ligand release 
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Nitrogen mustards of this general kind can be synthesised by the reaction of an 
appropriate hydroxyethylamine with thionyl chloride (Figure  5.2).[45] However, doing this 
before coordination does have the potential to be problematic because the lone pair on the 
nitrogen can displace the chlorine atom to give a highly reactive aziridinium, as detailed in 
section 1.4.1. Thus decomposition of the mustard may compete with coordination. 
Furthermore, the later the reactive group is introduced into the molecule, the better. 
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Figure  5.2 Synthesis of a nitrogen mustard and subsequent formation of the reactive aziridinium ion 
In order to prevent the formation of the aziridinium ion, we used a synthetic strategy of 
coordinating the appropriate mustard precursors to the cobalt(III) metal centre, followed by 
reacting this complex with thionyl chloride. 
This strategy of coordinating hydroxyethyl amine to a cobalt(III) metal centre and then 
converting to the nitrogen mustard has its own potential problems, the most obvious of which 
is the possibility for the oxygen atom to also coordinate to the metal centre. Cobalt(III) 
complexes with coordinated alcohols have been previously observed to form.[139, 140, 141] One 
alcohol containing ligand which we were interested in using had been coordinated to a 
cobalt(III) metal centre. This ligand was -(2-hydroxyethyl)ethane-1,2-diamine (heen), and it 
was concluded that depending on the reaction conditions the ligand could be either bidentate, 
binding through just the amine groups, or tridentate, binding through the amine and hydroxyl 
groups.[142, 143] 
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The coordination of the ligand ,ʹ-bis-(2-hydroxyethyl)ethane-1,2-diamine (bheen) to 
a cobalt(III) metal centre has not previously been reported. However, there are several 
examples of bheen coordinating to different metal centres. 
The X-ray crystal structure for the complexation of bheen with zinc(II) and 
cadmium(II) metal ions has previously been reported.[144] In the case of zinc(II) metal ions the 
complex formed was a discrete M1L2 complex with coordination through the amines in a 
distorted tetrahedral geometry (Figure  5.3). The four oxygen atoms of the hydroxyethyl arms 
are not deprotonated and are positioned around the metal centre at an average distance of 3.00 
Å. 
 
Figure  5.3 X-ray crystal structure of [Zn(bheen)2]Cl2
[144]
 
The crystal structure of the cadmium(II) complex showed a M2L2 dimer, with the two 
cadmium metal centres being bridged by two chloride ions (Figure  5.4). The bheen ligand 
coordinated in a tridentate fashion with coordination occurring through the two amines and 
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one of the hydroxyethyl oxygen atoms. However, ESI-MS data indicated that this dimer is not 
the predominant species in solution and is instead produced during the crystallisation process. 
 
Figure  5.4 X-ray crystal structure of [(µ-Cl)2(Cd(bheen)Cl)2]
[144]
 
Oligomeric crystal structures containing bheen have also previously been prepared, 
Christou et al synthesised two such structures using iron(III) as the metal ion, one with 6 iron 
atoms and the other with 18.[145] In the complex with 6 iron atoms 3 of the 4 bheen molecules 
had both alcohol groups deprotonated and the fourth had one deprotonated alcohol. In the 18 
iron atom complex all the bheen alcohols were deprotonated (Figure  5.5). In both complexes 
the iron molecules formed a chain with the iron atoms being bridged by the deprotonated 
hydroxyl groups. 
These complexes show that bheen is versatile in respect to its number of binding 
atoms, charge and binding geometry and we therefore considered it likely that this ligand 
would show coordination to a cobalt(III) metal centre through the alcohol groups. 
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Figure  5.5 Part of the X-ray structure of an Fe(III)18 complex with bheen, showing the bridging of the iron 
atoms by the hydroxyl group on the ligand
[145]
 
In this chapter we will detail the synthesis of several ligands which could prove useful 
in the study of photo-activated cytotoxins. We will then describe the complexation of two of 
these ligands to a cobalt(III) metal centre. Of the two complexes formed one was found to be 
suitable for conversion to the cobalt(III) mustard complex, which was then converted to the 
triflate compound and used to produce a potential photo-activated cytotoxin. Finally the 
results of our cytotoxicity studies will be discussed. 
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5.2. Results and Discussion 
5.2.1. Ligand Synthesis 
5.2.1.1. N,Nʹ-diethyl(ethane-1,2-diamine) 
The ligand ,ʹ-diethyl(ethane-1,2-diamine) is a closer structural analogue for the final 
mustard ligands because the ethyl arms will approximate the steric bulk associated with the 
chloroethyl arms on the mustards. The ligand is synthesised from en in two steps. The first 
reaction is an acetylation, with the water produced by the reaction removed by distillation.[146] 
The second step is to reduce the amides to amines with lithium aluminium hydride, under an 
inert atmosphere, in dry ether (Figure  5.6).[147] 
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Figure  5.6 Synthesis of ,ʹ-diethyl(ethane-1,2-diamine) 
5.2.1.2. N,Nʹ-bis(2-hydroxyethyl)ethane-1,2-diamine 
Although the ligand ,ʹ-bis(2-hydroxyethyl)ethane-1,2-diamine is commercially 
available, it can be easily and cheaply synthesised in a single step.[148] The ligand is 
synthesised by reacting 2-chloroethanol with -(2-hydroxyethyl)ethan-1,2-diamine in the 
presence of sodium carbonate, with the product being purified by trituration in THF (Figure 
 5.7). 
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Figure  5.7 Synthesis of ,ʹ-bis(2-hydroxyethyl)ethane-1,2-diamine 
5.2.1.3. N,N-bis(2-hydroxyethyl)ethane-1,2-diamine 
,-bis(2-hydroxyethyl)ethane-1,2-diamine, like ,ʹ-bis(2-hydroxyethyl)ethane-1,2-
diamine, is commercially available. However, its expense led us to look for an established 
synthetic route to produce it. 
The literature method we followed[149] involved a two step synthesis. The first step was 
the reaction of -(2-bromoethyl)phthalimide with a nine fold excess of diethanolamine. The 
product then had to be separated from the excess diethanolamine by a silica gel column. The 
second step involved treating the product obtained from the first reaction with hydrazine to 
remove the phthalimide group and give the final product of ,-bis(2-hydroxyethyl)ethane-
1,2-diamine (Figure  5.8). 
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Figure  5.8 Synthesis of ,-bis(2-hydroxyethyl)ethane-1,2-diamine 
The main problem we found with this procedure was that, as written, it only produced 
about 0.25 g of ,-bis(2-hydroxyethyl)ethane-1,2-diamine, and we wanted to work on the 10 
g scale. Directly scaling up the reaction forty times was not practical as this would involve 1 
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litre of diethanolamine, the vast majority of which would need to be removed after the first 
step. We explored several alternatives such as using less diethanolamine or carrying out the 
reaction with equimolar amounts of reactants, using ethanol as the solvent. However, 
conditions suitable to the synthesis of large quantities of ,-bis(2-hydroxyethyl)ethane-1,2-
diamine could not be found, and further experiments with this ligand were abandoned. 
5.2.1.4. N,N,Nʹ,Nʹ-tetra(2-hydroxyethyl)ethane-1,2-diamine 
The nitrogen mustard ,-bis(2-chloroethyl)ethane-1,2-diamine is observed to be 
more cytotoxic than the ,ʹ-bis(2-chloroethyl)ethane-1,2-diamine mustard (IC50 against AA8 
cell line being 1.5 µM and 30 µM respectively).[45] It is reasonable to assume that having four 
reactive arms would result in the production of an even more cytotoxic mustard as the 
potential for crosslinking DNA would be increased. Therefore, the synthesis of ,,ʹ,ʹ-
tetra(2-hydroxyethyl)ethane-1,2-diamine was also investigated. 
The reaction involved reacting 1,2-dibromoethane with diethanolamine in the presence 
of a base.[150] The literature method on which we based our method used potassium carbonate 
as the base. However, we found that this resulted in only partial formation of the final product. 
By changing the base to triethylamine we found that the reaction proceeded in a higher yield 
and generated purer products. Unfortunately, attempts to complex this ligand with a cobalt 
metal centre gave a red solution and we were unable to characterise the products formed. This 
was likely due to the coordination of the alcohol arms to the cobalt metal. This, amplified by 
the number of arms, could result in a wide range of products being formed. 
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Figure  5.9 Synthesis of ,,ʹ,ʹ-tetra(2-hydroxyethyl)ethane-1,2-diamine 
5.2.2. Cobalt Complexes 
5.2.2.1. Cobalt(III) Complex of N-(2-hydroxyethyl)ethane-1,2-diamine 
We require the ligand -(2-hydroxyethyl)ethane-1,2-diamine (heen) to bind to the 
cobalt(III) metal centre in a bidentate fashion. While the binding of alcohol groups to a 
cobalt(III) metal centre has been observed several times in prior studies,[139, 140, 141] we were 
able to find one example where heen was coordinated to the cobalt(III) metal centre in a 
bidentate fashion. However, this report had limited characterisation of the final product (only 
elemental analysis and molar conductance measurements).[143] Ultimately, because we were 
already familiar with the experimental procedure for the synthesis of trans-
[Co(en)2(NO2)2]NO3, we decided to attempt the formation of [Co(heen)2(NO2)2](NO3) using a 
modification of this experimental procedure first (Figure  5.10). 
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Figure  5.10 Synthesis of [Co(heen)2(>O2)2](>O3) 
The reaction yielded orange crystals, some of which were suitable for characterisation 
by X-ray crystal diffraction (Figure  5.11). The structure showed that two heen ligands were 
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coordinated to the cobalt(III) centre through the amines, in a bidentate manner. The other two 
binding domains, trans to each other, were occupied by N-bound nitrite ligands. The two 
nitrite ligands were each involved in two hydrogen bonding interactions. One ligand bridges 
the secondary amines and the other bridges the primary amines; these interactions are shown 
as dotted lines in Figure  5.11. 
 
Figure  5.11 X-ray crystal structure of [Co(heen)2(>O2)2]>O3.H2O 
There is no direct hydrogen bonding between the cobalt complexes in the crystal 
lattice. However, a hydrogen bonding network exists with the cobalt complexes being bridged 
by solvent water molecules and nitrate counter ions (Figure  5.12). 
Chapter 5 Synthesis of Cobalt(III) Complexes and Cytotoxicity Studies 
Photo-activated Cytotoxins Alan Downward 132 
 
Figure  5.12 Hydrogen bonding network in the X-ray crystal structure of [Co(heen)2(>O2)2]>O3.H2O 
shown by dashed lines 
Since a single crystal is not always representative of the bulk product, additional 
analysis of the bulk product was conducted using 1H, 13C, gCOSY and HSQCad NMR 
techniques, as well as mass spectrometry and elemental analysis. The NMR spectra were able 
to be almost fully assigned (differentiation between two protons on the same carbon but in 
different electronic environments was not achieved) and showed that, as in the X-ray crystal 
structure, the two heen ligands were in equivalent electronic environments (Figure  5.13). 
Elemental analysis confirmed that the single water of crystallisation observed in the X-ray 
crystal structure was also present in the bulk samp
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Figure  5.13 
13
C and 
1
H >MR spectra of [Co(heen)2(>O2)2]
+
 in DMSO 
Attempts to replace the nitrite ligands with either chloride or triflate ligands by 
treatment with the appropriate acid were not successful. For example, following the attempted 
chloride replacement, the 1H and 13C NMR of the product showed a large increase in the 
number of peaks. Although this increase in complexity is not totally unexpected, given that the 
secondary amine is a stereogenic centre, the signals in these spectra could not be assigned. 
Mass spectrometry was able to identify two main ions. One had a mass charge ratio consistent 
with replacing a single nitrite ligand with a chloride ligand, and the other was consistent with 
the expected mass for the alcohol deprotonating and the adoption of a tridentate binding motif 
(Figure  5.14). 
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Figure  5.14 ESI-MS spectrum of the major peaks from the reaction of [Co(heen)2(>O2)2](>O3) and HCl 
On the basis of the ESI-MS result we concluded that coordination of the alcohol to the 
cobalt metal centre was occurring and that the alcohol would need to be converted to the alkyl 
chloride before the formation of the triflate salt. 
5.2.2.2. Cobalt(III) complex of N,Nʹ-bis(2-hydroxyethyl)ethane-1,2-
diamine 
Cobalt(II) nitrate was reacted with ,ʹ-bis(2-hydroxyethyl)ethane-1,2-diamine under 
the same reaction conditions used in the formation of [Co(heen)(NO2)2](NO3), with the 
intention of forming a similar complex (Figure  5.15). This resulted in the formation of an 
H
N
N
Cl
NO2
N
H
N
Co
OH
OH
H2
N
H
N
O
O
N
H2
NH
Co
Chapter 5 Synthesis of Cobalt(III) Complexes and Cytotoxicity Studies 
Photo-activated Cytotoxins Alan Downward 135 
orange-red precipitate, in contrast to the yellow product of the [Co(heen)(NO2)2](NO3) 
complex. 
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Figure  5.15 Proposed synthesis of [Co(bheen)2(>O2)2](>O3) 
Unlike [Co(heen)2(NO2)2](NO3), the orange-red precipitate which formed was 
insoluble in both DMSO and water. However, the addition of a small amount of acid to a 
suspension of the product in water would readily dissolve the precipitate, resulting in an 
orange solution which slowly changed to pink on standing. Dissolving the precipitate in 
concentrated HCl resulted in a green solution, which is indicative of two chlorides binding 
(trans-[Co(NH2)4Cl2]
+ is green).[75] 
The initially formed orange solution was analysed by 1H and 13C NMR techniques and 
mass spectrometry. The 13C NMR spectrum showed six unique carbon environments 
associated with the initial orange solution, and if left running overnight an additional six 
smaller peaks associated with the slowly formed pink solution. The 1H NMR spectrum 
associated with the orange solution was relatively simple, having only eight peaks. However, 
the spectrum associated with the solution after standing was much more complex and could 
not be assigned; this was in part due to the conversion being incomplete. 
The mass spectrum of the sample in water with a small amount of formic acid was 
recorded. The most prominent peak recorded had a mass-charge ratio of 299.07. In addition to 
this there was another prominent peak present with a mass-charge ratio of 597.16, almost 
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twice that of the major peak. A mass charge ratio of 299.07 is what would be expected for a 
cobalt(III) complex with one bheen ligand and two nitrites. The presence of the heavier peak 
could mean that the complex is a mixture of oligomeric products, with the 299.07 mass charge 
ratio species being the monomeric unit. 
 
 
Figure  5.16 ESI-MS spectrum of the product for the reaction between bheen and Co(II)(>O2)2 
Examination of the spectrum at higher mass-charge ratios revealed small peaks at 
895.23 and 1193.26. These compare well with the expected values for a singly charged trimer 
(895.11) and tetramer (1193.14), adding support to the proposal that oligomers were being 
formed. Unfortunately, because the complex was not stable in solution, crystals suitable for 
use in structure determination by X-ray crystallography could not be produced. 
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5.2.2.3. Synthesis of Cobalt(III) Bound Mustards 
The conversion of the hydroxyethyl group into a chloroethyl group was achieved 
through the use of thionyl chloride. The complex [Co(heen)2(NO2)2](NO3) was stirred in a 
solution of thionyl chloride, to which a small amount of DMF was added (the complex 
[Co(heen)2(NO2)2](NO3) is otherwise insoluble in thionyl chloride at room temperature). The 
reaction mixture was then stirred at room temperature for 30 minutes and the excess solvent 
removed (Figure  5.17). These reaction conditions are similar to those that have previously 
been reported by Broomhead in an analogous system.[151] 
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Figure  5.17 Reaction of [Co(heen)2(>O2)2](>O3) with thionyl chloride 
The 1H and 13C NMR spectra showed more peaks than expected, which we interpreted 
to mean that the product was not pure. ESI-MS results were consistent with the formation of 
several products. The major components of the mass spectrum were consistent with the 
complexes [Co(ceen)2(NO2)(Cl)]
+, [Co(ceen)2(NO2)2]
+, and [Co(ceen)(heen)(NO2)2]
+ being 
present. The varying amount of chlorine atoms in these complexes results in distinctive 
isotope patterns being associated with each species, which gives us additional confidence in 
the assignment. Recrystallisation of the crude product from water and ethanol gave pure 
[Co(ceen)2(NO2)(Cl)]Cl as the final product. 
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Figure  5.18 Predicted and measured ESI-MS spectra for the possible products from the reaction of thionyl 
chloride with [Co(heen)2(>O2)2](>O3) 
The ratio between the different products was found to be dependent on the age of the 
thionyl chloride used. Older thionyl chloride proved to be much less reactive and the reaction 
could be conducted by heating at reflux overnight. Using newer thionyl chloride resulted in 
the complex decomposing if heated. 
The attempted conversion of the [Co(bheen-H)(NO2)2]n to the corresponding mustard 
was carried out following the same procedure as used in the formation of 
[Co(ceen)(NO2)(Cl)]Cl. The reaction following from the addition of the DMF to the thionyl 
chloride suspension was much more vigorous than for the reaction with 
[Co(heen)2(NO2)2](NO3) and resulted in a deep green solution. The remaining thionyl chloride 
was then removed to give a thick green slurry. Attempting to recrystallise this slurry from 
ethanol resulted in a deep blue solution with a pale green precipitate. The blue solution would 
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turn pink upon the addition of water, which is the same colour change seen for the conversion 
of the tetrahedral complex [CoCl4]
2- into the octahedral complex [Co(H2O)6]
2+ (Figure 
 5.19).[75] 
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Figure  5.19 Interconversion of blue [CoCl4]
2-
 and pink [Co(H2O)6]
2+
 
The 1H NMR spectrum of the pale green precipitate showed three major peaks: two 
triplets and a singlet. This is the same 1H NMR pattern as would be expected for the free 
ligand. We therefore concluded that the ligand was dissociating from the cobalt(III) metal 
centre, and that the free metal was reduced from the +3 oxidation state to the +2 oxidation 
state, presumably oxidising water in the process. 
The 1H NMR spectrum of the precipitate obtained after heating [Co(bheen-H)(NO2)2]n 
at reflux overnight in thionyl chloride, without DMF, is identical to that of the original starting 
material. This lack of reactivity is most probably due to the complex being insoluble in thionyl 
chloride. 
5.2.2.4. Synthesis of Cobalt(III) Triflate Compounds 
In order to use the synthetic route we have developed for the preparation of 
ruthenium(II)-cobalt(III) heterodinuclear complexes, the mustard containing complex needs to 
be made soluble in acetonitrile. This solubility is achieved through the formation of the 
corresponding triflate salt. The conversion of cobalt(III) complexes into their triflate salts has 
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been well studied.[152, 153, 154, 155] This process generally involves either the nitrito or chlorido 
complex being treated with triflic acid under vacuum at a temperature of between 60 and 100 
°C.  
While this experimental procedure was successfully employed with both the en and 
tren cobalt complexes, this could not be realised for the nitrogen mustard complex 
[Co(ceen)2(NO2)(Cl)]Cl. We found that if the reaction was heated, either through an external 
heat source or by the exothermic nature of the reaction itself, the ligands would dissociate 
from the cobalt metal centre and the isolated product would be the triflate salt of the doubly 
protonated ligand (Figure  5.20). 
 
Figure  5.20 
1
H >MR spectrum of the protonated mustard -(2-chloroethyl)ethane-1,2-diamine in CD3C> 
In order to get around this problem, the reactions were conducted in a ice-salt bath. By 
keeping the temperature of the reaction low we were able to prevent the decomposition of the 
Cl
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+
N
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+
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complex. The product isolated from this reaction was green in colour, which is consistent with 
having both a chloride and triflate bound to the metal centre (trans-[Co(en)2(OTf)Cl](OTf), 
which is obtained by controlled solvolysis of [Co(en)2(Cl)2]
+ in triflic acid, is also green).[155] 
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Figure  5.21 [Co(ceen)2(OTf)(Cl)](OTf) 
If the reaction is conducted at room temperature instead of in a salt-ice bath then the 
purple triflato complex [Co(ceen)2(OTf)2](OTf) is formed. However, this complex is heavily 
contaminated with cobalt(II) and not suitable for further use. 
Another method that might have permitted us to both avoid the decomposition of the 
complex and not have a chloride ion on the final complex, was through the formation of the 
complex [Co(ceen)2(H2O)2](OTf)3. This reaction was conducted by heating aqueous triflic 
acid and the complex in a water bath.[154] This caused the mixture to effervesce quite 
noticeably, with the final isolated product being a very pale pink colour. The 1H NMR 
spectrum of the product was examined and assigned as being that of the free ligand. 
5.2.3. Synthesis of Photo-activated Cytotoxins 
The rate of exchange for a cobalt(III) bound chloride is much slower than for a 
similarly bound triflate (rate of aquation for [Co(NH3)5X]
2+ 1.7 x 10-6 and 2.7 x 10-2 s-1 
respectively).[49] While this decreased rate has the potential to significantly slow the formation 
of a ruthenium(II)-cobalt(III) heterodinuclear complex, the bidentate nature of the incoming 
Chapter 5 Synthesis of Cobalt(III) Complexes and Cytotoxicity Studies 
Photo-activated Cytotoxins Alan Downward 142 
ligand may facilitate replacement of the chloride ligand. If the reaction were too slow then 
silver(I) could be added to aid in the removal of the chloride. Ultimately, silver(I) was not 
needed as the reaction was able to progress without it. 
Mixing [Co(ceen)2(OTf)Cl](OTf) with [(bpy)2Ru(pytp)](PF6)2 on the NMR scale and 
monitoring the changes in the 1H NMR spectrum showed that the mustard containing complex 
was coordinating to the ruthenium complex. However, the observed 1H NMR was not as clean 
as for either the en or tren complex. This increase in complexity could be due to the 
asymmetry of the ligand resulting in a greater difference in the electronic environments of the 
various isomers, as well as there being a larger number of isomers possible. 
[(bpy)2Ru(pytz)](PF6)2 was mixed with [Co(ceen)2(OTf)Cl](OTf) in a minimal amount 
of acetonitrile in the dark for three hours. The blue product was precipitated out by drop wise 
addition of the reaction mixture to an aqueous solution of NH4PF6. Unfortunately the complex 
was not able to be characterised by 1H NMR techniques as there was too much noise in the 
aromatic region. However, the colour changes associated with this complex are the same as 
those for the coordination of the [Co(tren)]3+ fragment, suggesting that a heterodinuclear 
complex may have been produced. 
5.2.4. Cytotoxicity Studies 
In order to assess whether or not complexes similar to those formed in this study could 
potentially be used as photo-activated cytotoxins, cytotoxicity studies were carried out with 
the murine leukaemia cell line P388. These studies involved determination of the IC50 
(concentration at which cell growth is inhibited by 50%) by way of a twofold dilution series 
incubated for 72 hours. The inhibition of cell growth was assessed by using the yellow dye 3-
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(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide which is reduced to the purple 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenylformazan by a healthy cell (Figure  5.22). 
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Figure  5.22 Reduction of the dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
Before exposing the cell line to the mustard containing species, the mononuclear 
ruthenium and non-mustard containing heterodinuclear complexes were assayed. The various 
complexes showed a range of cytotoxicity; for example, while all complexes based on the 
‘LEGO system’ were active with IC50 values in the range of 30-50 µmol/L, the tetrazine 
complexes were much less cytotoxic with IC50 values of ~500 µmol/L. The IC50 value for the 
complex [(bpy)2Ru(pytp)Co(tren)]
5+ should be treated as an indication of the minimum value, 
as some of the complex could have been converted into the more active [(bpy)2Ru(pytp)]
2+ 
complex as a result of exposure to light. The cytotoxicity associated with the ‘LEGO system’ 
ligands was not unexpected as similar results had previously been reported by Liu et al against 
different cell lines.[156] 
The low cytotoxicity of the pytz and pztz complexes coupled with their rapid ligand 
release made them ideal candidates for examining any increased cytotoxicity associated with 
having nitrogen mustards as the ligands on the cobalt(III) metal centre. For this reason the 
heterodinuclear complexes [(bpy)2Ru(pytz)Co(tren)]
5+ and [(bpy)2Ru(pytz)Co(ceen)2]
5+ were 
also assayed. The complex containing the tren molecule did not show any cytotoxicity at the 
maximum tested concentration of 641 µmol/L. However, the complex containing the ceen 
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ligands had an IC50 value of 181 µmol/L. This value is approximately three times smaller than 
the non-cobalt containing complex. 
The complexes [Co(en)2(OTf)2](OTf) and [Co(ceen)2(OTf)Cl](OTf) were also assayed 
and found to have similar IC50 values of ~300 µmol/L. The lack of increased activity for the 
complex with ceen coordinated is presumably due to the ligands remaining bound to the cobalt 
metal centre, which would prevent the lone pair on the nitrogen atom from displacing the 
chlorine and forming a highly reactive and potentially cytotoxic aziridinium ion. 
Table  5.1 Cytotoxicity data for non-mustard containing complexes 
Complex IC50 (µmol/L) 
 P388 HL-60[156] 
[(bpy)2Ru(pytp)]
2+ 47 65.4 
[(bpy)2Ru(pytp)Co(tren)]
5+ 195  
[(bpy)2Ru(pztp)]
2+ 66 6.7 
[(tbpy)2Ru(pytp)]
2+ 166  
[(phen)2Ru(pytp)]
2+ 38 98.6 
[(bpy)2Ru(pytz)]
2+ 472  
[(bpy)2Ru(pztz)]
2+ 547  
[(bpy)2Ru(pytz)Co(tren)]
5+ >641  
[(bpy)2Ru(pytz)Co(ceen)2]
5+ 181  
[(bpy)2Ru(pytz)Ru(bpy)2]
5+ 660  
[Co(en)2(OTf)2](OTf) 303  
[Co(ceen)2(OTf)Cl](OTf) 349  
From these results we conclude that the incorporation of a nitrogen mustard in a 
ruthenium(II)-cobalt(III) heterodinuclear complex can result in a marked increase in 
cytotoxicity. This increased cytotoxicity is most likely due to an electron transfer between the 
two metal centres resulting in the formation of a labile cobalt(II) metal centre and the 
subsequent release and activation of the nitrogen mustard. 
5.3. Conclusion 
In order to synthesise complexes that could potentially act as photo-activated 
cytotoxins, several ligands closely related to the nitrogen mustards, ,-bis(2-
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chloroethyl)ethane-1,2-diamine and ,ʹ-bis(2-chloroethyl)ethane-1,2-diamine, were 
synthesised and their coordination to a cobalt(III) metal centre investigated. 
The most promising ligand investigated was -(2-hydroxyethyl)ethane-1,2-diamine, 
which readily forms the complex trans-[Co(heen)2(NO2)2](NO3) under the same reaction 
conditions as for the formation of trans-[Co(en)2(NO2)2](NO3). The hydroxyl groups on this 
complex can then be converted into the alkyl chloride by treatment with thionyl chloride and 
DMF. Following conversion to [Co(ceen)2(Cl)(OTf)](OTf), the complex can then be 
coordinated to a ruthenium(II) complex with a vacant bidentate binding domain. However, the 
complex [Co(ceen)2(Cl)(OTf)](OTf) is not stable and should be used as soon after being 
synthesised as possible. 
Cytotoxicity studies showed that by coordinating the ligand ceen to the cobalt centre of 
a ruthenium(II)-cobalt(III) heterodinuclear complex, utilising pytz as the bridging ligand, a 
marked increase in cytotoxicity is achieved. This result shows the promise of systems such as 
these as potential chemotherapeutic agents. 
 
Chapter 6 Future Work 
Photo-activated Cytotoxins Alan Downward 146 
Chapter 6: Future Work 
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6.1. Introduction 
At the conclusion of our study, there are a number of avenues for future experiments 
which could still be pursued. In this chapter we present an overview of some of these potential 
studies. In some cases we have already done some preliminary experiments towards this 
research and details of these will be given where appropriate. 
6.2. Altering the Ruthenium Bound Ancillary Ligands 
Many dye sensitised solar cells use a ruthenium(II) metal complex which absorbs light 
and, through a MLCT, injects electrons into the semiconductor conduction band.[59] In order to 
tune the efficiency and wavelength at which this occurs, the energy levels associated with the 
electron transfer need to be altered. One way to achieve this is through varying the non-
bridging ligands bound to the ruthenium metal. Altering these ligands results in changes in the 
electron transfer associated with the bridging ligand and can greatly improve the performance 
of the solar cell by permitting it to operate at longer wavelengths and with a higher efficiency. 
It has also been observed that the degree of metal-metal communication in bridged 
diruthenium complexes is influenced by the non-bridging ligands. For example the ∆Λ form 
of the azobis(2-pyridine) diruthenium complex has a log Kc value of 8.28 when the non-
bridging ligands are bpy, and 8.79 when the non-bridging ligands are 4,4ʹ-dimethyl-2,2ʹ-
bipyridine (Kc is the comproportionation constant and represents the degree of metal-metal 
communication).[157] The large bathochromic shift associated with the coordination of the 
second ruthenium metal centre is also increased by approximately 11 nm when Mebpy is used 
as the non-bridging ligand.  
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6.2.1. 4,4ʹ-dicarboxy-2,2ʹ-bipyridine (dcbpy) 
The ligand dcbpy is often used in dye sensitised solar cells to help tune the energy 
levels of the electron transfer. In a photo-activated cytotoxin, the carboxylic acid groups on the 
dcbpy ligand could be deprontonated, which would decrease the charge on the complex. This 
change in charge could also have an effect on the interaction of the molecule with biological 
systems or the mode of entry into cells. 
Dcbpy is an ideal ligand for future study and one that we were interested in using in 
our own work. However, the high cost associated with this ligand prohibited its use until we 
were made aware of an as of yet unpublished method for its synthesis by Paul Kruger.[158] 
The first step proceeds as per the standard literature method, with 4-picoline being 
coupled by Pd/C to give 4.4ʹ-dimethyl-2,2ʹ-dipyridine. The traditional literature method for the 
oxidation of 4.4ʹ-dimethyl-2,2ʹ-dipyridine to dcbpy involves the use of chromium, and care 
needs to be taken to ensure the product is free from contamination and to appropriately 
dispose of the chromium. Kruger’s method is to use nitric acid at 180 °C in a sealed bomb. 
This reaction proceeds in about a fifty percent yield and the pure product is isolated by 
filtration (Figure  6.1). 
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Figure  6.1 Synthesis of dcbpy 
We were successfully able to use the dcbpy synthesised by this method to form 
[Ru(dcbpy)2(Cl)2]. However, reacting this with phendione and then subsequently using the 
product of that reaction to form [(dcbpy)2Ru(pytp)](PF6)2 (Figure  6.2) gave a product which 
was highly contaminated. While column chromatography on silica gel was able to remove 
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some of these impurities, a pure sample could not be obtained. We feel that this could have 
been remedied through the use of additional purification steps; however, the scale on which 
we were working did not make this feasible. 
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Figure  6.2 [(dcbpy)2Ru(pytp)]
2+ 
6.2.2. 1,10-phenanthroline 
While the differences between the ligands bpy and phen are generally considered to be 
slight, they are not identical, and we decided to synthesise the complex [(phen)2Ru(pytp)]
2+ 
(Figure  6.3). 
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Figure  6.3 [(phen)2Ru(pytp)]
2+
 
The complex [(phen)2Ru(pytp)]
2+ was synthesised in the same manner as the bpy 
analogue and the UV-vis spectrum was recorded. The result was a slight blue shift, with 
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λmax=435 nm. A more detailed analysis of this complex was not carried out as it was decided 
that this would be better left to a more thorough study concentrating solely on the effects of 
changing the auxiliary ligands. 
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Figure  6.4 UV-vis spectra for [(bpy)2Ru(pytp)]
2+
 (solid line) and [(phen)2Ru(pytp)]
2+
 (dashed line) in 
CH3C> 
In addition to any photophysical changes, the cytotoxicity of the phen complexes could 
vary greatly from that of the bpy complexes. This is potentially due to the ruthenium(II) bound 
phen complex, [Ru(phen)3]
2+, being capable of weakly intercalating with DNA whereas the 
analogous bpy complex, [Ru(bpy)3]
2+, is not.[159] 
It should also be mentioned that attempting to make the ruthenium(II) phen complexes 
of either pytz or pztz was not successful. This is probably due to the phen ligand either 
preventing or decomposing the desired complex. It should be mentioned that although the 
complex [(bpy)2Ru(pytz)Ru(bpy)2]
4+ was first reported in 1985,[128] the complex 
[(phen)2Ru(pytz)Ru(phen)2]
4+ has never been reported.  
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6.3. Changing the Bridging Ligand 
One of the most obvious avenues for future study involves altering the bridging ligand 
between the two metal centres. A wide range of bridging ligands which have been successfully 
used in the formation and study of diruthenium complexes are described in the literature 
(Figure  6.5). By utilising these ligands in the formation of ruthenium(II)-cobalt(III) 
complexes, we would be able to compare the observed behaviour of the heterodinuclear 
complex with that of the corresponding homodinuclear complex. 
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Figure  6.5 Potential future bridging ligands 
A new systematic MSc study, utilising ligands known to form dinuclear ruthenium(II) 
complexes with various degrees of metal-metal communication, has recently commenced. The 
goal of this study is to establish if there is a relationship between the degree of metal-metal 
communication in the diruthenium complex and the ease with which electron transfer occurs 
in the heterodinuclear complex. 
As a result of previous studies involving ruthenium(II) polypyridyl complexes, there 
were several potential bridging ligands already available in the department and we conducted 
tests with two of these on the NMR scale, as detailed below. 
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6.3.1. Tetrapyrido[3,2-a:2ʹ,3ʹ-c:3ʹʹ,2ʹʹ-h:2ʹʹʹ,3ʹʹʹ-j]phenazine 
(tpphz) 
The complex [(tbbpy)2Ru(tpphz)](PF6)2 was synthesised in a similar manner as the 
pytp and pztp complexes used in our study, by reaction of [Ru(tbbpy)2(phendione)]
2+ with 
1,10-phenanthroline-5,6-diamine. This complex was then mixed with [Co(tren)(OTf)2](OTf) 
in a 3 mm NMR tube. The heterodinuclear ruthenium(II)-cobalt(III) complex was then 
observed to form and addition of water to the solution resulted in the gradual release of the 
cobalt bound ligands. 
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Figure  6.6 Tetrapyrido[3,2-a:2ʹ,3ʹ-c:3ʹʹ,2ʹʹ-h:2ʹʹʹ,3ʹʹʹ-j]phenazine (tpphz) 
6.3.2. 2,3-di(pyridin-2,yl)quinoxaline (dpq) 
The complex [(tbbpy)2Ru(dpq)](PF6)2 was reacted in an 3 mm NMR tube with 
[Co(en)2(OTf)2](OTf). The reaction mixture was observed for several days and during that 
time there was no evidence of binding cobalt(III) to the vacant domain. However, despite the 
lack of evidence for the formation of a heterodinuclear complex, free en was observed to build 
up in solution. 
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Figure  6.7 2,3-di(pyridin-2-yl)quinoxaline 
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The accumulation of en suggests several possibilities. Firstly, that the complex 
[Co(en)2(OTf)2](OTf) is not stable in acetonitrile over several days. Alternatively, the 
cobalt(III) metal centre is being reduced by the ruthenium complex to the labile cobalt(II) state 
and subsequently releasing its ligands. This reduction could occur either by slow coordination 
to the ruthenium(II) complex followed by comparatively rapid electron transfer, or by 
intervalent charge transfer from the ruthenium. 
The formation of the complex [(bpy)2Ru(pztp)Co(en)2](PF6)5 was achieved by reacting 
the ruthenium complex with [Co(en)2(OTf)2](OTf) over a period of three days, and during this 
time no free en was observed. This suggests that the most likely of these explanations is that 
the cobalt complex is slowly coordinating to the ruthenium and then being reduced, resulting 
in ligand release. As long as the rate for the reduction step is faster than the rate for 
coordination, the heterodinuclear complex will not be observed by 1H NMR as there will not 
be an appreciable amount in solution. 
This observation is interesting, as it is the only time that ligand release was observed to 
occur without the addition of water. The Kc values of the diruthenium complex 
[(bpy)2Ru(dpq)Ru(bpy)2] are 1800 for the meso compound and 1120 for the rac 
compound.[160] For comparison, the Kc value for the [(bpy)2Ru(pytz)Ru(bpy)2] complex is 3 x 
108 (this measurement was made using a mixture of the meso and rac isomers).[53] These Kc 
values can be interpreted to suggest that the ease of electron transfer in ruthenium(II)-
cobalt(III) heterodinuclear pytz complex is greater than in the dpq complex. However, the 
complex [(bpy)2Ru(pytz)Co(tren)](PF6)5 is stable in acetonitrile at room temperature. Further 
study of the dpq system as well as related systems is desirable as it could provide insight into 
this result. 
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6.4. Controlling the Configuration of Complexes 
During our study we made no attempt to control the configration of the complexes we 
formed. Additional studies attempting this could prove useful, as the degree of communication 
between two bridged ruthenium(II) metal centres has been shown to vary depending on the 
orientation of the ligands around the metal centres.[80, 157, 161] For example Λ∆-
[(bpy)2Ru(azobis(2-pyridine))Ru(bpy)2]
4+ has an observed log Kc of 8.28 while the ΛΛ and 
∆∆ forms have a log Kc of 8.45 (Figure  6.8). An approximately 6 nm difference in the λmax of 
the MLCT transfer absorption was also observed.[157] 
 
Figure  6.8 meso and rac forms of [(bpy)2Ru(azobis(2-pyridine))Ru(bpy)2]
4+ 
The separation of the meso and rac isomers from each other in these studies was 
achieved through the use of column chromatography on Sephadex with bulky anions. Because 
of the stereochemical arrangement around the ruthenium(II) metal centres there is a difference 
in the gap between the meso and rac forms; the meso form has a ‘v’ shaped groove while the 
rac form has the bpy ligands parallel to each other (Figure  6.9). This difference in the size and 
shape of the gap means that the ability of the anion to associate with these molecules is also 
different. This means that after a sufficient elution time the complexes can be separated. 
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Figure  6.9 Representation of the differences in groove shape between the meso (left) and rac (right) forms 
of [(bpy)2Ru(azobis(2-pyridine))Ru(bpy)2]
4+
 
While a similar strategy might be feasible for our heterodinuclear complexes, there are 
several foreseeable complications. Firstly, because the two metal centres are non-equivalent, 
the number of unique isomers is greater than the heterodinuclear case. The second 
complication relates to the stability of the heterodinuclear complex. Since the Sephadex 
columns are done under aqueous conditions, the possibility of the complexes decomposing 
cannot be ignored. As was previously shown, the nature of the bridging ligand greatly affects 
the stability of the final complexes and their rate of ligand release. This means that the column 
would have to be conducted with minimal light exposure and even then only with select 
complexes. 
However, despite these potential problems it is possible to easily introduce some 
degree of stereo control through the use of enantiomeric ruthenium(II) complexes such as 
[Ru(bpy)2(Py)2](L)2. The Λ and ∆ forms of these complexes can be separated by precipitation 
with a chiral salt, such as disodium (+)-O,Oʹ-dibenzoyl-D-tartrate (Figure  6.10). This means 
that by using resolved ruthenium(II) complexes, the final complex will be restricted to only 
two possible orientations depending on the how the cobalt(III) complex coordinates. 
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Figure  6.10 disodium (+)-O,Oʹ-dibenzoyl-D-tartrate 
Further control of the overall stereochemistry is potentially possible by treating the 
cobalt(III) complexes in a similar manner; [Co(en)3]
3+ can be resolved through the use of d-
tartrate.[162, 163] The major problem with a strategy such as this is that there is no guarantee that 
the configuration of the product will be retained during the formation of the triflate salt. For 
example treatment of trans-[Co(en)2(Cl)2]Cl with triflic acid results in the formation of the cis 
product,[152, 153] meaning that any attempt to control the binding geometry of the cobalt end of 
the molecule, by a process of resolving the complex before coordination to the bridging 
ligand, may not actually result in any additional stereochemical control for the final complex. 
Even if no changes in the stability and rate of activation are observed between the 
various isomers of these complexes, it is still worthwhile to pursue ways of controlling the 
orientation of the ruthenium(II) centre. This is because, following activation and subsequent 
loss of the cobalt complex, the remaining ruthenium fragment is capable of interacting with 
DNA. It has previously been shown that these interactions are dependent on the configuration 
of the ruthenium metal centre.[164, 165] 
6.5. Synthesis of the Bridging Ligands on Cobalt 
The synthetic strategy utilised during our study involved the formation of a 
ruthenium(II) bound bridging ligand to which a cobalt(III) complex was then coordinated. 
This approach was problematic in that appropriate conditions for the formation of the final 
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heterodinuclear complex were not immediately obvious. One way to circumvent this problem 
involves forming the bridging ligand on the cobalt(III) metal centre and then coordinating the 
ruthenium fragment. 
The complex [Co(en)2(phendione)](ClO4)3 is well known and easily synthesised from 
[Co(en)2(phen)]Br3. There are numerous examples of [Co(en)2(phendione)](ClO4)3 being used 
as a reactant in the synthesis of additional complexes, such as [Co(en)2(dppz)](ClO4)3.
[166, 167] 
However, when we attempted to synthesise [Co(en)2(phtp)](ClO4)3 by a similar process the 
resulting 1H NMR spectrum had too many peaks in the aromatic region, and no peaks that 
could be assigned to the en ligands. The ESI-MS spectrum of the sample had only one peak 
that we were able to assign, which we ascribed to the free phtp ligand. 
From this we concluded that although the formation of phtp did seem to occur, the 
final product was not what we desired and we abandoned this line of study. However, further 
study in the formation of complexes such as these could prove useful as similar cobalt(III) 
complexes have been shown to exhibit cytotoxic activity.[156, 166] Unfortunately, such 
complexes could probably not be used in the synthesis of photo-activated cytotoxins, as the 
attachment of the ruthenium would most likely involve heating the reaction mixture; 
something that we found to be detrimental to the formation of ruthenium(II)-cobalt(III) 
heterodinuclear complexes. 
6.6. Development of New Cytotoxins 
One of the major problems we encountered in synthesising a potential photo-activated 
cytotoxin, related to the formation of the cobalt(III) bound nitrogen mustard triflate 
compound. The standard literature procedures call for heating either the nitrito or chlorido 
complex in neat triflic acid. [152, 153, 154, 155] However, we found that this resulted in 
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decomplexation of the ligand from the cobalt metal centre and resulted in the isolation of the 
doubly protonated ligand. 
While we did develop a new experimental procedure for the formation of the triflate 
compound, this reaction was very sensitive. Insufficient cooling at almost any point during the 
reaction results in some of the ligand dissociating from the cobalt metal centre, causing the 
final product to be contaminated with both the free ligand and cobalt(II) ions. One way that it 
might be possible to prevent the dissociation of the ligand is to develop new cytotoxins that 
coordinate more strongly to the cobalt(III) metal centre. This additional coordination strength 
could be achieved through the development of either tri or tetradentate cytotoxic ligands. The 
coordination of ligands such as -(2-aminoethyl)ethane-1,2-diamine (dien), ,ʹ-(ethane-1,2-
diyl)dipropane-1,3-diamine (3,2,3-tet), and tren (Figure  6.11) to a cobalt(III) metal centre has 
been well studied.[168, 169, 170] The introduction of a nitrogen mustard moiety onto ligands such 
as these could enable the formation of more stable cytotoxin containing cobalt(III) triflate 
compounds. 
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Figure  6.11 The ligands dien (left), 3,2,3-tet (centre) and tren (right) and their potential nitrogen mustard 
analogues 
Chapter 6 Future Work 
Photo-activated Cytotoxins Alan Downward 159 
6.7. Electrochemical Studies 
Several of the mononuclear cobalt(III) and ruthenium(III) complexes that have been 
synthesised for use as chemotherapeutic agents are activated in vitro, by a reductive pathway. 
As mentioned in section 1.6, Denny et al synthesised a series of cobalt(III) complexes, such as 
[Co(acac)2(bceen)] (Figure  6.12), which relied on natural biological processes for activation. It 
is also believed that the mechanism by which the ruthenium(III) complexes NAMI-A and 
KP1019 are activated involves reduction to the ruthenium(II) complex. 
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Figure  6.12 [Co(acac)(bceen)]
+ 
The oxidation and reduction potentials for the multiple metal centres in our photo-
activated cytotoxin could be determined through electrochemical studies. Such information 
would give an indication as to whether or not the complexes could be prematurely reduced to 
an active state by biological systems. Studies on the degree of metal-metal communication in 
diruthenium complexes use the measured oxidation potentials of the complexes to evaluate Kc. 
In a complex with a good degree of metal-metal communication, the oxidation potentials of 
the two ruthenium(II) metal centres have been shown to be non-equivalent (Figure  6.13); this 
is due to the metal centre that is oxidised first being able to ‘communicate’ this oxidation to 
the other metal centre. The difference between these two oxidation potentials correlates to the 
degree of interaction between the two metal centres (Kc=exp((E≨-E≩)F/RT). 
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Figure  6.13 Representation of the cyclic voltammograms of a diruthenium(II) complex with no metal-
metal communication (left) and a diruthenium(II) complex with metal-metal communication (right) 
In a similar way electrochemistry could provide valuable insights into the nature of the 
ruthenium(II)-cobalt(III) heterodinuclear complexes, and possibly help describe the ease with 
which the two metal centres can interact. 
6.8. Photochemical and Theoretical Studies 
The lifetime measurements taken for the complexes [(bpy)2Ru(pytp)]
2+ and 
[(bpy)2Ru(pytp)Co(tren)]
5+ provide a valuable insight into the mechanism by which the 
intravalent charge transfer occurs and any future study should, where possible, include similar 
measurements as part of the complex characterisation. These studies could also be expanded to 
include the measurement of excited state adsorption spectra. 
In order to gain a better understanding of the electron transfer pathways involved in the 
observed photo-activated ligand release, theoretical and computational studies should also be 
undertaken. Such studies would provide a valuable insight into the energy levels associated 
with the various complexes reported in this thesis, and ideally would give rise to an 
explanation for the various observed results, such as the rate at which ligand release occurs. 
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The primary goal of our study was the production of a ruthenium(II)-cobalt(III) 
heterodinuclear complex with a potential application as a photo-activated cytotoxin. Ideally, 
the final complex would involve a ruthenium(II) metal centre bound to a bridging ligand, with 
the other binding domain coordinated to a cobalt(III) metal centre with potentially cytotoxic 
ligands coordinated. Irradiation of the complex would then result in an electron being 
transferred from the ruthenium metal through the bridging ligand to the cobalt metal, oxidising 
the ruthenium to ruthenium(III) and reducing the cobalt to cobalt(II). Because cobalt(II) is a 
labile metal, the cytotoxic ligands could then be rapidly displaced by water (Figure  7.1). 
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Figure  7.1 Schematic of a photo-activated cytotoxin: Following irradiation the donor metal (D) transfers 
an electron through the bridging ligand (L) into the acceptor metal (A) which triggers release of the bound 
cytotoxins 
In order to achieve this, several synthetic challenges needed to be overcome. The first 
was the selective binding of the metal centres to the appropriate end of the bridging ligand. 
The initial synthetic strategy pursued is described in Chapter 2 and involved varying the 
geometry and coordination number of the binding domains (Figure  7.2). The research into 
these bridging ligands followed on from the work conducted by Zibaseresht[87] and was based 
on using functionalised terpyridines as the bridging ligand. Unfortunately, this line of research 
had to be abandoned due to a range of synthetic problems. 
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Figure  7.2 Example of a terpyridine based bridging ligand with a different coordination geometry and a 
different number of donor atoms at each binding domain 
The next series of bridging ligands, as detailed in Chapter 3, did not have a vastly 
different binding domain for each metal centre, but instead achieved selectivity through 
synthesising the ligand on the ruthenium(II) metal centre. These ligands were intermediates in 
the formation of Jurgen Sauer’s ‘Lego’ system[114] and were synthesised by the condensation 
reaction between a hydrazonamide and a 1,2-dicarbonyl compound (Figure  7.3). 
N
N
O
O
N
N N
N
N
N
H2N
H2N
NN
+
 
Figure  7.3 Synthesis of pytp 
Binding the phendione to a ruthenium(II) metal centre before carrying out the 
condensation reaction did not prevent the reaction from occurring. This gave an easy route for 
forming ruthenium(II) complexes with a vacant binding domain. Additionally, it should be 
noted that attempting to bind a ruthenium(II) metal centre to the free ligand results in a 
mixture of products as the metal is capable of binding to either of the two binding domains. 
The final series of bridging ligands we investigated in Chapter 3 were symmetrical, 
with no difference between the two binding domains. These ligands required care when 
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binding the ruthenium(II) metal centre, so as to minimise the formation of the undesired 
diruthenium complex. 
The coordination of the ruthenium(II) complexes synthesised in Chapter 3 to non-
cobalt metal centres was also investigated and we were able to demonstrate binding to 
copper(I), copper(II), silver(I) and zinc(II), through the use of 1H NMR and ESI-MS 
techniques. 
In Chapter 4 the synthesis of ruthenium(II)-cobalt(III) heterodinuclear complexes, with 
the non-cytotoxic ligands en and tren coordinated to the cobalt metal centre, was described. 
These complexes had to be formed using the triflate salts of the cobalt complexes; making 
both reactants soluble in acetonitrile at room temperature. This solubility at room temperature 
was important since all attempts to synthesise these complexes at higher temperatures failed. 
By exposing these heterodinuclear complexes to light in the presence of water, we 
were able to demonstrate photo-activated ligand release. This ligand release was monitored by 
1H NMR spectroscopy. Following irradiation of the complexes, peaks in the recorded 1H 
NMR spectra attributed to the non-bound ligand could be observed to increase in size. The 
different bridging ligands were associated with different rates of ligand release. Of the 
bridging ligands trialled, pytp based systems released their ligands the slowest, over a period 
of days, while pytz took only minutes to achieve complete ligand release. The rate of ligand 
release was also retarded by atmospheric oxygen; this decrease in the rate of ligand release 
was observed in both pytp and pztp bridged systems (the effect of oxygen on pytz was not 
investigated because of the rapid ligand release associated with such systems). This oxygen 
dependent decrease in the rate of ligand release is a very promising result as cancerous 
growths tend to have hypoxic regions; this would increase the selectivity of a photo-activated 
cytotoxin based on these complexes for these regions. 
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In Chapter 5 we discussed how it might be possible to move from the non-cytotoxic 
analogues (en and tren) used in Chapter 4 to a cytotoxin containing system. The cytotoxins we 
selected for use were nitrogen mustards. The reason for using nitrogen mustards is that they 
are less cytotoxic when bound to a metal centre than as the free ligand. Our strategy for the 
synthesis of the cobalt(III) bound mustards began with the coordination of the alcohol 
precursor to the cobalt(III) metal centre. The resulting complex was then treated with thionyl 
chloride to convert the alcohols into alkyl chlorides. The final step, before complexation with 
a ruthenium complex, was to react the complex with triflic acid to form the triflate compound 
(Figure  7.4). 
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Figure  7.4 Formation of a cobalt(III) bound cytotoxin 
The problems we discovered with this approach were that sometimes the alcohol group 
would also coordinate to the metal centre and that even in complexes where this did not occur, 
the mustard containing complex was not as stable as its non-cytotoxic analogue and was prone 
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to dissociation during the treatment with triflic acid. The first of these problems could 
potentially be solved by the use of a protecting group, such as a silyl ether, which would 
prevent the alcohol from being able to coordinate to the metal centre. The second problem was 
alleviated, to some extent, by carrying out the reaction with triflic acid in a salt-ice bath. 
However, this resulted in the final complex having a chloride still bound to the metal centre 
and the stability was still lower than the non-cytotoxic analogue. The product from the 
reaction of this complex with the complexes [(bpy)2Ru(pytp)]
2+ and [(bpy)2Ru(pytz)]
2+ 
showed evidence of binding, although the product was not able to be fully characterised. A 
cytotoxicity assay against the murine leukaemia cell line P388, showed that the complex we 
believe to be [(bpy)2Ru(pytz)Co(ceen)](PF6)5 was about three times more cytotoxic than the 
[(bpy)2Ru(pytz)Co(tren)](PF6)5 complex. 
Ultimately this thesis provides a synthetic strategy which, with minor modification, 
can be used for the synthesis and study of photo-activated cytotoxins. Unfortunately, we were 
not able to produce a fully characterised photo-activated cytotoxin, but the 1H NMR 
experiments which demonstrate photo-activated ligand release from a ruthenium(II)-cobalt(III) 
heterodinuclear system provide a proof of concept. 
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1H NMR spectra were recorded on either a Varian INOVA 500 spectrometer at 23°C, 
operating at 500 MHz or a Varian UNITY 300 NMR spectrometer at 23°C operating at 300 
MHz. gCOSY, HSQCAD and gHMBC experiments were all performed on a Varian INOVA 
500 spectrometer at 23°C, operating at 500 MHz. 13C NMR spectra were recorded on either a 
Varian INOVA 500 spectrometer at 23°C operating at 125 MHz or a Varian UNITY 300 
NMR spectrometer at 23°C operating at 75 MHz. The INOVA was equipped with a variable 
temperature and inverse-detection 5 mm probe or a triple-resonance indirect detection PFG 
probe. The UNITY was equipped with a variable temperature direct broadband 5 mm probe. 
Chemical shifts are expressed in parts per million (ppm) on the δ scale and were referenced to 
the appropriate solvent peaks, TMS or TMPS. DMSO-d6 referenced to CD3(CHD2)SO at δH 
2.50 (1H) and (CD3)2SO at δC 39.43 (
13C). Acetonitrile-d3 referenced to CHD2CN at δH 1.94 
(1H) and CD3CN at δC 1.24 (
13C). Methanol-d4 referenced to CHD2OD at δH 3.31 (
1H) and 
CD3OD at δC 49.05 (
13C). TMS and TMPS were both referenced to δH 0 (
1H) and δC 0 (
13C). 
Infrared spectra were obtained using a Shimadzu 8201PC Series FTIR using diffuse 
reflectance method in solid KBr. 
High Resolution Electrospray Ionisation Mass Spectra were recorded on a Micromass 
LCT spectrometer using a probe voltage of 3200 V, an operating temperature of 150°C and a 
source temperature of 80°C. The carrier solvent was 1:1 CH3CN/H2O at 20 µL min
-1. 
Typically, 10 µL of a 10 µL mL-1 solution was injected. Leucine enkephalin was used as the 
lock mass internal standard. 
UV-visible spectra were recorded on a Varian CARY Probe 50 UV-vis 
spectrophotometer or a Varian CARY 100 UV-vis spectrophotomer. 
X-Ray crystal data was collected on a Bruker-Nonius APEX II system using graphite 
monochromatised Mo Ka (l = 0.71073 A) radiation at the temperature indicated in the tables 
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that may be found in Appendix 1. The data collection, cell determination and data reduction 
were all performed with the APEX software.[171] All structures had intensities corrected for 
Lorentz and polarisation effects and for absorption using SAINT. All structures were solved 
by direct methods using SHELXS and refined on F2 using all data by full-matrix least squares 
procedures using SHELXL-97. Unless otherwise stated, all non-hydrogen atoms were refined 
with anisotropic displacement parameters 1.2 and 1.5 times the isotropic equivalent of their 
carrier carbon atoms. Some of the refinements reported may change a little upon preparation 
for final publication. The crystal structure pictures were generated using Olex2.[172] 
Steady state absorption measurements were performed using an absorption 
spectrometer (Cary Bio50, Varian). Steady state emission spectra were acquired with an 
emission spectrometer (Cary Eclipse, Varian). Quantum yield measurements were performed 
using the optically dilute method, using [Ru(bpy)3]Cl2 in aqueous solution as a standard (Φref 
= 4.2%). Time resolved emission lifetime experiments were performed using a nanosecond 
laser setup. The 355 nm tripled output of a Q-switched Nd:YAG (Continuum NY-61-10, 
Coherent) was used to drive an OPO system (Casix BBO, Shanghai Uniwave Technologies) 
which was tuned to 440 nm, and this output was focused on the sample using all quartz optics. 
Emission was collected perpendicular to the excitation, collimated then refocused onto the 
entrance port of a 0.3 m triple grating monochromator (SpectraPro 300i, Acton Instruments) 
for spectral selection at 630 nm. The detector was a PMT tube (R928P, Hamamatsu), the 
output of which was sampled directly using a 500 MHz digital oscilloscope (TDS520, 
Tektronix). The instrument response function (IRF) for this setup was measured using 
scattered excitation to be ca. 8 ns at FWHM. Each resulting trace contained at least 1000 data 
points, and was averaged over 1000 shots. Data analysis was performed using a commercially 
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available software package (Igor, Version 6.1.2.1, Wavemetrics). The quality of the fit was 
assessed using the reduced chi-squared χ2 function and by an inspection of the weighted 
residuals. 
Elemental analyses were performed by the Campbell Microanalytical Laboratory at the 
University of Otago. 
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8.1. Chapter 2 
4ʹ-p-tolyl-2,2ʹ-6ʹ,2ʹʹ-terpyridine (ttp) 
i)[99] A mixture of 183 g acetamide, 118g ammonium acetate, 12.4g 
p-tolylaldehyde and 25 g 2-acetylpyridine was heated at reflux for 2 hours. 
After this time the mixture was cooled to 120 °C and a solution of 90g 
NaOH dissolved in water was added. The mixture was kept at 120 °C without stirring for a 
further 2 hours before being cooled to room temperature. A brown solid ‘glass’ was separated 
from the rest of the reaction mixture, washed with water and dissolved in 60 ml of acetic acid. 
The hydrobromide salt was then precipitated out with 60 ml 47% HBr, filtered off and 
dissolved in 200 ml water. KOH was added until the pH of the solution was 10. The resulting 
suspension was extracted with 3 portions of 200 ml CH2Cl2. Following evaporation of the 
solvent the residue was recrystallised from 400 ml ethanol to give 7.46g of white needles. 
These needles were a mixture of the desired 4ʹ-p-tolyl-2,2ʹ:6ʹ2ʹʹ-terpyridine and 6ʹ-p-tolyl-
2,2ʹ:4ʹ,2ʹʹ-terpyridine. 
The mixture of these two product was dissolved in 380 ml of EtOH:CH2Cl2 (1:1), to 
which a solution of 4.5 g (NH4)2Fe(SO4)2·6H2O in 76 ml H2O was added. The mixture was 
left to stand for 5 hours at room temperature before the CH2Cl2 was removed under reduced 
pressure. A solution of 4.27 g KPF6 in 38 ml H2O was then added to form a purple precipitate. 
This precipitate was filtered off and washed with 3 portions of 100 ml toluene. The precipitate 
was then dissolved in 100 ml CH3CN and 100 ml H2O. KOH is added until the aqueous layer 
is pH > 12. H2O2 was then added drop wise until there was only one layer with a heavy orange 
precipitate and a flocculent pale lavender precipitate, which could not be removed with more 
H2O2. The solution was then filtered and the lavender layer scrapped off. The remaining 
N
N N
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precipitate was then boiled with charcoal in 50 ml chloroform, before being refiltered. The 
filtrate was then taken to dryness giving 4.98g of 4ʹ-p-tolyl-2,2ʹ:6ʹ2ʹʹ-terpyridine as a bright 
white powder. Yield 4.98 g (15%) 
ii)[100] 4.84 g of 2-acetylpyridine was dissolved in 100 ml ethanol, to which 2.4 g of p-
tolylaldehyde was added. To this reaction mixture was then added 3.08 g KOH and 58 ml of 
aq. NH3. The solution was stirred at room temperature for 4 hours, after which it was filtered 
and the precipitate washed three times with 10 ml cold ethanol. The product was further 
purified by recrystallisation from ethanol. Yield 1.223 g (19%) 
1H NMR (500 MHz; solvent CDCl3): δ 8.742 (s, 2 H), 8.732 (m, 2 H), 8.675 (d, 2 H), 
7.884 (m, 2 H), 7.831 (d, 2 H), 7.356 (m, 2 H), 7.318 (d, 2 H), 2.430 (s, 3 H). 
 
4ʹ-(p-bromomethylphenyl)-2,2ʹ:6ʹ,2ʹʹ-terpyridine (Br-ttp) 
The -bromosuccinamide and benzoylperoxide were both purified 
before being used in this reaction.[173] 
0.84 g of ttp, 0.46 g of -bromosuccinimide and a catalytic amount of 
dibenzoyl peroxide were heated at reflux in 50 ml dry benzene under an argon atmosphere for 
4 hours. The solution was then cooled to room temperature and the crude product obtained by 
vacuum filtration. The product was then purified by recyrstallisation from an ethanol:acetone 
mix (2:1). Yield 0.86 g (83%). 1H NMR (300 MHz; solvent CDCl3): δ 8.735 (s, 2 H), 8.7272 
(m, 2 H), 8.674 (d, 2 H), 7.901 (m, 4 H), 7.541 (d, 2 H), 7.367 (m, 2 H), 4.570 (s, 2 H). 
 
1,4,8,11-tetraazacyclotetradecane (cyclam)
[174]
 
54.7 g of nickel(II) perchlorate was dissolved in 400 ml water. With 
N
N N
Br
NH
NH
HN
HN
Experimental 
Photo-activated Cytotoxins Alan Downward 173 
adequate stirring 26 g of 1,5,8,12-tetraazadodecane was added to the solution, which was then 
cooled to 5 ºC in an ice bath. 30 ml of 30% glyoxal was then added to the cooled solution, 
which was left to stand at room temperature for 4 hours. The solution was then returned to the 
ice bath and 11 g of NaBH4 slowly added over a 1 hour period. The mixture was then heated 
to 90 ºC for 15-20 minutes and then quickly filtered through a large medium glass frit. The 
filtrate was then transferred to a single necked flask with 29 g of NaCN, which was heated at 
reflux for 2 hours before being cooled to room temperature. 15 g of NaOH was then added and 
the solution concentrated on a rotary evaporator until a semi-solid remains. 100 ml of CHCl3 
was added and the mixture filtered through a large glass frit. The precipitate was washed twice 
with 100 ml of CHCl3. The organic layer was separated from the aqueous and dried over 
Na2SO4, before being taken to dryness under vacuum. The yellow solid was recrystallised 
from 800 ml of chlorobenzene. The white product was obtained by filtration and washed with 
50 ml ether before being air dried. Yield 12.31 g (41%). 1H NMR (300 MHz; solvent CDCl3): 
δ 2.757 (m, 8 H), 2.688 (s, 8 H), 2.402 (br s, 4 H), 1.727 (m, 4 H). 
 
(10bα,10cα)-decahydro-1H,6H-3a,5a,8a,10a-tetraazapyrene 
(bisaminal-cyclam)
[111]
 
4 g of cyclam and 3.3 g of glyoxal were dissolved in 300 ml of CH3CN. 
The solution was stirred at room temperature for 1 hour after which the temperature was 
increased to 50-60 ºC and stirring continued for a further 2 hours. The solution was then 
cooled to room temperature and the solvent removed under vacuum. The residue was 
dissolved in CHCl3, dried over Na2SO4 and filtered. Evaporation of the filtrate gave the 
product as a yellow oil, which can be solidified by trituration with ether. Yield 3.5 g (78%). 1H 
N N
N N
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NMR (300 MHz; solvent CDCl3): δ 3.532 (t, 2 H), 3.080 (s, 2 H), 2.948 (m, 6 H), 2.735 (d, 2 
H), 2.344 – 2.072 (m, 8 H), 1.224 (m, 2 H). 
 
4ʹ-[p-{(10bα,10cα)-decahydro-1H,6H-3a,5a,8a,10a-
tetraazapyrenium-3a-methyl}phenyl]-2,2ʹ:6ʹ,2ʹʹ-terpyridine 
bromide 
A solution of 0.12 g bisaminal-cyclam in 10 ml THF was 
added to another solution of 0.25 g Br-ttp in 10 ml THF. The combined solution was stirred at 
room temperature until the solvent had fully evaporated. The resulting white precipitate was 
washed with THF, and the insoluble white solid filtered off. Yield 0.26 g (70%). 1H NMR 
(500 MHz; solvent D2O): δ 7.87 (d, 2 H, H6, H6ʹʹ), 7.28 (d, 2 H, H3, H3ʹʹ), 7.25-7.22 (m, 2 H, 
H4, H4ʹʹ), 7.00 (s, 2 H, H3ʹ, H5ʹ), 6.94-6.92 (m, 2 H, H5, H5ʹʹ), 6.87 (d, 2 H, H3ʹʹʹ, H5ʹʹʹ), 6.79 (d, 2 
H, H2ʹʹʹ, H6ʹʹʹ), 4.69-4.66 and 4.19-4.16 (AB, 2H, H7A, H7B), 4.05 (br s, 1 H, H015), 3.88-3.67 (1 
H, H02(ax)), 3.50 (br s, 1 H, H016), 3.36-3.34 (1 H), 3.23 (1 H, H014(ax)), 2.94-2.88 (6 H, 
including H03(eq), H05(ax), H012(eq)), 2.76-2.74 (2 H, including H014(eq)), 2.53-2.50 (2 H, H02(eq), 
H03(ax)), 2.37-2.35 (2 H, including H05(eq)), 2.15-2.13 (2 H, H012(ax), H06(eq)), 1.95-1.93 (1 H, 
H013(eq)), 1.60-1.58 (1 H, H013(ax)), 1.37-1.35 (1 H, H06(ax)). 
13C NMR (75 MHz; solvent D2O): δ 
153.71, 153.30, 147.90 (2 C, C6, C6ʹʹ), 146.26, 137.79, 137.54, 133.21 (2 C, C3ʹʹʹ, C5ʹʹʹ), 126.47, 
125.93 (2 C, C2ʹʹʹ, C6ʹʹʹ), 124.29, 121.44 (2 C, C3, C3ʹʹ), 116.72 (2 C, C3ʹ, C5ʹ), 82.62 (C016), 
69.50 (C015), 61.39 (C7), 59.84 (C014), 53.98 (C03), 53.29 (C05), 51.91 (C012), 51.35 , 47.86 
(C02), 46.52, 41.90, 18.40 (C013), 17.95 (C06). ESI-MS: m/z (fragment) 272.6939 ([M+H-
Br]2+), 544.3924 ([M-Br]+). 
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[(ttp)Ru(ptmtb)](PF6)3 
To a solution of 0.02 g [Ru(ttp)Cl3] in MeOH was added an 
equimolar amount of ptmtb and 10 drops -methylmorpholine. The 
solution was heated at reflux for 1h under Ar. The deep red solution 
was cooled to room temperature before it was filtered to remove 
any unreacted materials and excess methanolic solution of 
ammonium hexafluorophosphate was added to the filtrate to 
precipitate the product complexes. The dark red precipitate was 
dissolved in CH3CN, then the solution was taken to dryness under 
vacuum and the residue was purified by column chromatography (SiO2 eluting with CH3CN-
saturated KNO3 solution-H2O, 14 :0.5 :1). An excess of NH4PF6 was added to the major red 
fraction and the solution was reduced in volume under vacuum. The precipitate was collected 
by filtration over Celite, before it was dissolved in CH3CN, and evaporated to dryness in 
vacuo to give [(ttp)Ru(ptmtb)](PF6)3 as a red powder. Yield 0.043 g, 78%. 
13C NMR (75 
MHz; solvent CD3CN) δ 159.21, 159.10, 156.69, 156.28, 153.42, 149.43, 147.56, 141.99, 
140.10, 139.02, 135.40, 134.88, 134.82, 131.27, 129.66, 129.48, 129.30, 128.67, 128.54, 
128.42, 125.63, 125.53, 122.68, 122.35, 84.35, 71.13, 62.23, 61.10, 55.43, 55.06, 53.28, 53.21, 
49.87, 47.69, 43.46, 21.43, 19.83, 19.67. ESI-MS: m/z (fragment) 557.2206 ([M-2(PF6)]
2+), 
323.1544 ([M-3(PF6)]
3+). IR (KBr): /cm-1 = 3651 w, 2949 w, 2843 w, 1655 w, 1607 m, 1524 
w, 1477 m, 1466 m, 1431 m, 1406 m, 1384 m, 1356 w, 1246 w, 1196 w, 1144 w, 1086 w, 
1030 w, 845 ssh, 789 s, 754 m, 735 w, 656 w, 557 ssh, 492 w, 480 w, 448 w, 421 w. UV-vis 
(CH3CN): λmax = 285.0, 295.0, 305.0, 490.0 nm. 
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[(ttp)Ru(mptmtb)](I)(PF6)3 
To the complex [(ttp)Ru(ptmtb)](PF6)3, (0.5368 g, 0.38 
mmol) in CH3CN (50ml) was added CH3I (0.5ml). The solution 
was stirred at room temperature for 72 hours. The remaining CH3I 
and solvent were removed on a rotary evaporator to give a red 
solid. Yield 0.5547g, 95%.1H NMR (500MHz; solvent CD3CN) δ 
9.086 (d, 4 H), 8.729 (t, 4 H), 8.419 (d, 2 H), 8.185 (d, 2 H), 8.01-
7.9 (m, 6 H), 7.646 (d, 2 H), 7.5-7.48 (m, 4 H), 7.249 (m, 4 H), 
5.288 (d, 1 H), 4.81 (d, 1 H), 4.35 (s, 2 H), 3.8-2.8 (m, 20 H, 
cyclam), 3.411 (s, 3 H), 2.64 (s, 3 H). ESI-MS: m/z (fragment) 637.27 ([M-(PF6)-(I)]
2+), 
376.49 ([M-2(PF6)-(I)]
3+). 
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8.2. Chapter 3 
1,10-phenanthroline-5,6-dione 
6.13 g of 1,10-phenanthroline and 6.25 g of KBr were placed in a 250 
ml round bottomed flask. A cooled 0 °C mixture of 60 ml H2SO4 and 30 ml HNO3 was then 
slowly added. After addition of the acid mixture the solution was heated at reflux for 3 h 
before being cooled to room temperature. The condenser was then removed from the round 
bottom flask and the solution allowed to stand for 5 to 10 mins. The solution was then poured 
over 600 ml of ice and carefully neutralised with NaOH until either neutral or slightly acidic. 
The bright yellow product was obtained by extraction with CHCl3. Yield 6.27 g (87%). 
1H 
NMR (500MHz; solvent CDCl3) δ 9.131 (dd, 1 H), 8.517 (dd, 1 H), 7.600 (dd, 1 H). 
 
1,10-phenanthroline-1-oxide
[125]
 
6 ml of 30% H2O2 is added to a solution of 10 g 1,10-phenanthroline in 
60 ml glacial acetic acid. The solution was heated at 70 – 75 °C for 3 h before addition of 
another 6 ml H2O2; heating was then continued for another 3 h. The solution was then 
concentrated to ~15 ml on a rotary evaporator, 15 ml of H2O added and the concentration 
continued until ~10 ml. The concentrated solution was then neutralised with a sodium 
carbonate-water paste before being extracted multiple times with several portions of 
chloroform. The extracts were taken to dryness and then further dried overnight in a 50 °C 
oven. The dried product was ground into a fine powder and reextracted with chloroform. The 
extracts were dried over sodium sulfate; boiled with decolourising charcoal and evaporated to 
give the crude product which was then recrystallised from chlorobenzene. Yield 5.53 g (51%). 
N N
O O
N N
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1H NMR (500MHz; solvent D2O) δ 8.671 (d, 1 H), 8.297 (d, 1 H), 7.823 (d, 1 H), 7.526 (d, 1 
H), 7.414 (dd, 1 H), 7.287 (t, 1 H), 7.146 (d, 1 H), 7.061 (d, 1 H) 
 
2-cyano-1,10-phenanthroline 
[125]
 
3 ml benzoyl chloride was added drop wise over 15 mins to a solution 
of 2.98 g 1,10-phenanthroline-1-oxide and 3 g KCN in 50 ml H2O. The solution was then 
stirred for an additional 15 mins. The resulting precipitate was collected by suction filtration 
and washed with water. The crude product was then recrystallised from ethanol. Yield 1.920 g 
(61 %). Mp 240-242 °C (lit: 237-238 °C). 1H NMR (500MHz; solvent CDCl3) δ 9.276 (d, 1 
H), 8.404 (d, 1 H), 8.316 (d, 1 H), 7.965 (m, 2 H), 7.851 (d, 1 H), 7.740 (dd, 1 H) 
 
1,10-phenanthroline-2-carbohydrazonamide
[126]
 
0.97 g 2-cyano-1,10-phenanthroline and 8 ml hydrazine hydrate 
were placed in 10 ml ethanol and stirred at room temperature for 3 h. Evaporation of the 
ethanol and remaining hydrazine gave the final product. Yield 1.09 g (98 %). 1H NMR 
(500MHz; solvent DMSO) δ 9.126 (dd, 1 H), 8.434 (dd, 1 H), 8.399 (d, 1 H), 8.288 (d, 1 H), 
7.982 (m, 2 H), 7.790 (dd, 1 H), 6.138 (s, 2 H), 5.599 (br s, 2 H) 
 
Pyridine-2-carbohydrazonamide 
2.2 g 2-cyanopyridine and 1.5 g hydrazine hydrate were placed in a 
round bottomed flask with a minimal amount of ethanol, to aid dissolution. The flask was 
stoppered and the solution stirred overnight. The yellow precipitate was filtered from the 
solution and washed with ether. Yield 1.69 g (60 %). 1H NMR (500MHz; solvent CDCl3) δ 
8.517 (d, 1 H), 8.011 (d, 1 H), 7.691 (t, 1 H), 7.265 (t, 1 H), 5.273 (s, 2 H), 4.544 (br s, 2 H) 
N N
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Pyrazine-2-carbohydrazonamide 
2.2 g 2-cyanopyrazine and 1.5 g hydrazine hydrate were placed in a 
round bottomed flask with a minimal amount of ethanol, to aid dissolution. The flask was 
stoppered and the solution stirred overnight. The yellow precipitate was filtered from the 
solution and washed with ether. Yield 2.04 g (72 %). 1H NMR (500MHz; solvent CDCl3) δ 
9.282 (s, 1 H), 8.525 (d, 1 H), 8.450 (m, 1 H), 5.118 (s, 2 H), 4.709 (br s, 2 H). 
 
Phtp
[114]
 
0.5 g 1,10-phenanthroline-5,6-dione and 0.57 g 1,10-
phenanthroline-2-carbohydazonamide were heated at reflux for 6 h in 40 ml of ethanol. The 
bright yellow product was collected by vacuum filtration and washed with cold ethanol before 
being dried for 16 h at 80 °C. The final product was then recrystallised from DMF. Yield 0.75 
g (77%). 
 
Pytp
[114]
 
0.32 g of pyridine-2-carbohydrazonamide and 0.5 g of 1,10-
phenanthroline-5,6-dione were refluxed for 6 hours in 40 ml EtOH. The 
solution was cooled and the yellow product filtered off and dried for 16 hours at 80 oC under 
reduced pressure. Yield 0.51 g (69 %). 1H NMR (CDCl3) δ 9.78 (1 H), 9.75 (1 H), 9.38 (1 H), 
9.35 (1 H), 9.00 (1 H), 8.88 (1 H), 8.02 (1 H), 7.89 (1 H), 7.85 (1 H), 7.56 (1 H). 
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Pztp
[114]
 
0.6 g of pyridine-2-carbohydrazonamide and 0.9 g of 1,10-
phenanthroline-5,6-dione were refluxed for 6 hours in 40 ml EtOH. The 
solution was cooled and the yellow product filtered off and dried for 16 hours at 80 oC under 
reduced pressure. Yield 1.3 g (97%). 1H NMR (CDCl3) δ 10.060 (s, 1 H), 9.780 (s, 1 H), 9.701 
(d, 1 H), 9.369 (d, 2 H), 8.935 (d, 1 H), 8.842 (d, 1 H), 7.880 (m, 2 H). 
 
3,6-di(pyridin-2-yl)-1,4-dihydro-1,2,4,5-tetrazine
[122]
 
1 g of 2-cyanopyradine was placed in a round bottomed flask 
with 2 ml ethanol and 2 g of hydrazine hydrate. The solution was then heated at reflux for 4-5 
hours. The solution was then cooled to room temperature and the orange precipitate isolated 
by vacuum filtration. Yield 0.71 g (80%). 1H NMR (500MHz; solvent DMSO) δ 8.978 (s, 2 
H), 8.640 (d, 2 H), 7.946 (m, 4 H), 7.534 (t, 2 H) 
 
Pytz
[122]
 
1.71 g of 3,6-di(pyridin-2-yl)-dihydro-1,2,4,5-tetrazine was 
dissolved in 200 ml of glacial acetic acid and 140 ml of water. The solution was placed in an 
ice bath and to this was slowly added a solution of 16.8 g NaNO2 dissolved in 50 ml H2O. 
Once the entire solution had been added the mixture was stirred at 0 ºC for 1 hour before being 
neutralised with ammonia. The final bright pink product was isolated by filtration. Yield 1.33 
g (78%). 1H NMR (500MHz; solvent DMSO) δ 8.947 (s, 2 H), 8.621 (d, 2 H), 8.168 (t, 2 H), 
7.742 (t, 2 H) 
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3,6-di(pyrazin-2-yl)-dihydro-1,2,4,5-tetrazine
[121] 
5.65 g of 2-cyanopyrazine was placed in a round bottomed 
flask with 90 ml THF and 9 ml c. HCl. To this solution was added 10.6 g of hydrazine hydrate 
and then the combined solution was heated at reflux for 5 hours. The solution was then cooled 
to room temperature and the orange precipitate isolated by vacuum filtration. Yield 5.76 g 
(88%). 1H NMR (500MHz; solvent DMSO) δ 9.389 (s, 2 H), 8.867 (m, 2 H), 8.833 (m, 2 H), 
7.035 (s, 2 H) 
 
Pztz
[122]
 
0.7 g of 3,6-di(pyrazin-2-yl)-dihydro-1,2,4,5-tetrazine was 
dissolved in 100 ml of glacial acetic acid and 70 ml of water. The solution was placed in an ice 
bath and to this was slowly added a solution of 6.9 g NaNO2 dissolved in 20 ml H2O. Once the 
entire solution had been added the mixture was stirred at 0 ºC for 1 hour before being 
neutralised with ammonia. The final bright pink product was isolated by filtration. Yield 0.43 
g (61%). 1H NMR (500MHz; solvent CDCl3) δ 9.897 (s, 2 H), 8.905 (s, 2 H), 8.854 (s, 2 H) 
 
[(bpy)2Ru(pytz)](PF6)4 
0.200 g of pytz (0.84 mmol) was placed in 10 ml of 
methanol. 0.300 g of [Ru(bpy)2Cl2].2H2O (0.6 mmol) was dissolved 
in 20 ml of methanol. The pytz solution was heated to reflux and the 
ruthenium solution then slowly added to the refluxing solution. The 
combined reaction mixture was then heated at reflux for an additional 5 hours before being 
cooled to room temperature. The solution was concentrated to give a dark slurry and purified 
by column chromatography over silica gel using CH3CN: saturated aqueous KNO3 solution: 
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water (7:2:2) as elutant. The major purple-red band was collected and the product precipitated 
out by addition of saturated methanolic NH4PF6. Yield 0.2368 g (42%). 
1H NMR (500MHz; 
solvent CD3CN) δ 8.947 (d, 1 H), 8.787 (d, 1 H), 8.656 (d, 1 H), 8.595 (d, 1 H), 8.492 (m, 3 
H), 8.237 (m, 2 H), 8.152 (m, 4 H), 8.010 (d, 1 H), 7.918 (t, 1 H), 8.365 (d, 1 H), 7.773 (d, 1 
H), 7.705 (t, 1 H), 7.580 (m, 3 H), 7.508 (t, 1 H), 7.435 (m, 2 H). ESI-MS: m/z (fragment) 
795.12 ([M-(PF6)]
+), 325.08 ([M-2(PF6)]
2+). UV-vis (CH3CN): λmax = 514 nm. 
 
[(bpy)2Ru(pytz)Ru(bpy)2](PF6)4 
0.5 g of [Ru(bpy)2Cl2].2H2O (1 mmol) and 0.236 
g pytz (1 mmol) were heated together at reflux in a 
solution of 18 ml ethylene glycol and 2 ml water for 3 
hours. The solution was then cooled to room temperature 
and an additional 20 ml of water added. The product was precipitated out by addition of a 
saturated methanolic solution of NH4PF6. Yield 0.39 g (48%). 
1H NMR (500MHz; solvent 
CD3CN) δ 8.743 – 8.442 (m, 10 H), 8.304 – 8.011 (m, 12 H), 7.835 – 7.437 (m, 18 H). UV-vis 
(CH3CN): λmax = 700 nm (Lit 688 nm)
[128] 
 
[(bpy)2Ru(phendione)](PF6)2.H2O 
1 g of [Ru(bpy)2Cl2].2H2O and .4 g 1,10-
phenanthroline-5,6-dione were heated at reflux in 50 ml of 
ethanol. The solution was concentrated to ~20 ml followed by 
addition of 50 ml H2O. The product was precipitated by addition of 1 ml saturated methanolic 
solution of NH4PF6. The precipitate was collected by vacuum filtration and washed with 0 °C 
ethanol. Yield 0.54 g (30 %). 1H NMR (CD3CN) δ 8.518 (m, 6 H), 8.095 (t, 4 H), 7.986 (s, 2 
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H), 7.845 (d, 2 H), 7.753 (d, 2 H), 7.613 (t, 2 H), 7.433 (t, 4 H). Anal. Calc. for 
C32H22F12N6O2Ru.H2O (931.57): C 41.26, H 2.60, N 9.02%; found: C 41.49, H 2.63, N 9.08. 
 
[(bpy)2Ru(pytp)](PF6)2 
0.5 g [(bpy)2Ru(phendione)](PF6)2.H2O was 
dissolved in 15 ml of CH3CN. 0.076 g of pyridine-2-
carbohydrazonamide was dissolved in 5 ml of EtOH 
and then added to the acetonitrile solution. The reaction mixture was heated at reflux for 1 h 
after which it was filtered over celite and taken to dryness. The pure product was obtained by 
column chromatography on silica gel, eluting with an EtOH and 10% NaCl H2O solution 
(50:50). The major red band was collected and the ethanol removed under vacuum. The 
addition of a few drops of a methanolic saturated solution of NH4PF6 precipitated out the 
product which was filtered and washed with 0 °C water, 0 °C EtOH and ether. Yield 0.30 g 
(52 %). 1H NMR (500MHz; solvent CD3CN) δ 9.806 (dd, 1 H, phen), 9.721 (dd, 1 H, phen), 
8.963 (d, 1 H, py), 8.927 (d, 1 H, py), 8.543 (m, 4 H, bpy), 8.302 (dd, 1 H, phen), 8.263 (dd, 1 
H, phen), 8.140 (m, 1 H, py), 8.127 (m, 2 H, bpy), 8.030 (m, 2 H, bpy), 7.957 (m, 2 H, py), 
7.848 (d, 2 H, bpy), 7.717 (d, 1 H, py), 7.682 (m, 2 H, bpy), 7.475 (m, 2 H, bpy), 7.269 (m, 2 
H, bpy). ESI-MS: m/z (fragment) 869.38 ([M-(PF6)]
+), 362.32 ([M-2(PF6)]
2+). UV-vis 
(CH3CN): λmax = 440.0 nm. 
 
[(bpy)2Ru(pztp)](PF6)2.2H2O 
0.5 g [(bpy)2Ru(phendione)](PF6)2.H2O was 
dissolved in 15 ml of CH3CN. 0.08 g of pyridine-2-
carbohydrazonamide was dissolved in 5 ml of EtOH and then added to the acetonitrile 
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solution. The reaction mixture was heated at reflux for 1 h after which it was filtered over 
celite and taken to dryness. The pure product was obtained by column chromatography on 
silica gel, eluting with an EtOH and 10% NaCl H2O solution (50:50). The major red band was 
collected and the ethanol removed under vacuum. The addition of a few drops of a methanolic 
saturated solution of NH4PF6 precipitated out the product which was filtered and washed with 
0 °C water, 0 °C EtOH and ether. Yield 0.24 g (42 %). 1H NMR (500MHz; solvent CD3CN) δ 
10.069 (m, 1 H), 9.817 (m, 1 H), 9.724 (m, 1 H), 8.961 (m, 1 H), 8.904 (m, 1 H), 8.542 (m, 4 
H), 8.313 (m, 1 H), 8.277 (m, 1 H), 8.126 (m, 2 H), 8.031 (m, 2 H), 7.964 (m, 2 H), 7.848 (m, 
2 H), 7.703 (m, 2 H), 7.476 (m, 2 H), 7.269 (m, 2 H), . Anal. Calc. for 
C37H25F12N11P2Ru.2H2O (1050.70): C 42.30, H 2.78, N 14.66%; found: C 42.57, H 2.96, N 
14.56. UV-vis (CH3CN): λmax = 439 nm. 
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8.3. Chapter 4 
 [(bpy)2Ru(pytp)Co(tren)](PF6)5 
0.0586 g of [(bpy)2Ru(pytp)]
2+ and 0.0377g 
[Co(tren)(OTf)2](OTf) were placed in a 25 ml round 
bottom flask. The flask was wrapped in aluminium foil and 2 ml of acetonitrile added. The 
flask was then stoppered and the solution stirred for 3 hours at room temperature. The product 
was precipitated out as the PF6¯ salt by drop wise addition to a stirred solution of 60 ml water 
and 3 ml of saturated solution of NH4PF6 in methanol. Yield 0.0515g 
1H NMR (500MHz; 
solvent CD3CN) δ 9.856 (dd, 1 H, phen), 9.589 (dd, 1 H, phen), 9.333 (dd, 1 H, py), 8.880 (d, 
1 H, py), 8.693 (t, 1 H, py), 8.562 (m, 4 H, bpy), 8.490 (dd, 1 H, phen), 8.409 (dd, 1 H, phen), 
8.232 (m, 1 H, py), 8.143 (m, 2 H, bpy), 8.092 – 8.032 (m, 4 H, phen, bpy), 7.846 (m, 2 H, 
bpy), 7.750 (dd, 1 H, bpy), 7.689 (dd, 1 H, bpy), 7.490 (m, 2 H, bpy), 7.294 (m, 2 H, bpy), 
5.299 (br s, 2 H, tren, NH2), 4.637 (m, 2 H, tren), 4.364 (br s, 2 H, tren, NH2), 4.115 (m, 2 H, 
tren, NH2), 3.637 (m, 4 H, tren), 3.166 (m, 6 H, tren). 
13C NMR (75 MHZ; solvent CD3CN) δ 
165.166, 159.777 (phen), 158.013 (bpy), 157.818 (phen), 157.785, 155.528 (py), 154.595, 
153.096 (bpy), 152.991 (bpy), 152.466, 151.849, 148.527, 147.127, 144.772 (py), 139.280 
(bpy), 139.259 (bpy), 139.217 (bpy), 139.187 (bpy), 136.405 (phen), 135.046 (phen), 132.958 
(py), 130.379 (py), 128.679 (bpy), 128.630 (bpy), 128.583 (bpy), 127.814, 127.766, 125.403 
(bpy), 65.248 (tren), 61.879 (tren), 47.867 (tren), 44.969 (tren). Anal. Calc. for 
C44H44F30N14P5CoRu.H2O (1653.74): C 31.96, H 2.68, N 11.86%; found: C 31.70, H 3.50, N 
11.05. ESI-MS: m/z (fragment) 1509.31 ([M-(PF6)]
+), 362.32 ([M-2(PF6)]
2+). UV-vis 
(CH3CN): λmax = 445 nm. 
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[(bpy)2Ru(pytp)Co(en)](PF6)5 
0.0586 g of [(bpy)2Ru(pytp)]
2+ and 0.0377g 
[Co(en)(OTf)2](OTf) were placed in a 25 ml round 
bottom flask. The flask was wrapped in aluminium 
foil and 2 ml of acetonitrile added. The flask was then stoppered and the solution stirred for 3 
hours at room temperature. The product was precipitated out as the PF6¯ salt by drop wise 
addition to a stirred solution of 60 ml water and 3 ml of saturated solution of NH4PF6 in 
methanol. Yield 0.0515g 1H NMR (500 MHz; solvent CD3CN) δ 9.851 (m, 1 H), 9.781 (m, 1 
H), 9.304 (d, 1 H), 8.830 (d, 1 H), 8.714 (t, 1 H), 8.554 (m, 4 H), 8.470 (m, 1 H), 8.412 (m, 1 
H), 8.268 (m, 1 H), 8.144 (m, 2 H), 8.061 (m, 4 H), 7.842 (m, 2 H), 7.742 (t, 1 H), 7.688 (t, 1 
H), 7.489 (m, 2 H), 7.300 (m, 2 H), 3.156 (m, 4 H), 3.758 (m, 4 H). Anal. Calc. for 
C42H42F30N14P5CoRu.H2O (1627.70): C 30.99, H 2.60, N 12.05%; found: C 30.32, H 3.26, N 
11.59. UV-vis (CH3CN): λmax = 445 nm. 
 
[(bpy)2Ru(pztp)Co(en)](PF6)5 
0.0364 g of [(bpy)2Ru(pztp)]
2+ and 0.0377g 
[Co(en)(OTf)2](OTf) were placed in a 25 ml round 
bottom flask. The flask was wrapped in aluminium foil and 2 ml of acetonitrile added. The 
flask was then stoppered and the solution stirred for 24 hours at room temperature. The 
product was precipitated out as the PF6¯ salt by drop wise addition to a stirred solution of 60 
ml water and 3 ml of saturated solution of NH4PF6 in methanol. Yield 0.0199g 
1H NMR (500 
MHz; solvent CD3CN) δ 9.634 (s, 1 H), 9.170 (d, 1 H), 9.130 (m, 1 H), 8.708 (d, 1 H), 8.313 
(t, 1 H), 7.847 (m, 4 H), 7.788 (dd, 1 H), 7.728 (m, 1 H), 7.678 (dd, 1 H), 7.435 (m, 2 H), 
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7.383 – 7.314 (m, 4 H), 7.137 (m, 2 H), 6.915 (m, 1 H), 6.777 (m, 2 H), 6.602 (m, 1 H), 6.511 
(m, 1 H). UV-vis (CH3CN): λmax = 445 nm. 
 
[(bpy)2Ru(pytz)Co(tren)](PF6)5 
0.1 g of [(bpy)2Ru(pytz)]
2+ and 0.07g 
[Co(tren)(OTf)2](OTf) were placed in a 25 ml round bottom 
flask. The flask was wrapped in aluminium foil and 2 ml of 
acetonitrile added. The flask was then stoppered and the solution stirred for 3 hours at room 
temperature. The product was precipitated out as the PF6¯ salt by drop wise addition to a 
stirred solution of 60 ml water and 3 ml of saturated solution of NH4PF6 in methanol. Yield 
0.0809 g. 1H NMR (500 MHz; solvent CD3CN) δ 8.042 (d, 1 H), 8.809 (d, 1 H), 8.770 (d, 1 
H), 8.732 (d, 1 H), 8.661 (d, 1 H), 8.557 (d, 1 H), 8.481 (m, 2 H), 8.393 (t, 1 H), 8.303 (m, 1 
H), 8.249 (t, 1 H), 8.158 (m, 1 H), 8.101 (m, 1 H), 7.817 (m, 2 H), 7.754 (m, 2 H), 7.703 (m, 2 
H), 7.597 (m, 2 H), 7.468 (m, 2 H), 7.275 (d, 1 H), 5.268 (br s, 2 H), 4.509 (m, 2 H), 4.357 (m, 
2 H), 4.007 (m, 1 H), 3.596 (m, 5 H), 3.294 (m, 1 H), 3.098 (m, 1 H). UV-vis (CH3CN): λmax = 
570 nm. 
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8.4. Chapter 5 
>,>ʹ-diethylethane-1,2-diamine 
5 g LiAlH4 was dissolved in 200 ml of ether. To this was added a slurry of N,Nʹ-
(ethane-1,2-diyl)diacetamide in 50 ml of ether. The solution was heated at reflux overnight 
under N2; any unreacted LiAlH4 was then decomposed by the slow addition of water. The 
solution was then filtered and the precipitate washed with ether. The ether layer of the filtrate 
was combined with the ether washings and evaporated to give N,Nʹ-diethylethane-1,2-diamine 
as an oil. Yield 3.0845 g (39%) 1H NMR (500 MHz; solvent CDCl3) δ 2.671 (s, 2 H), 2.595 
(q, 2 H), 1.426 (br s, 2 H), 1.048 (t, 3 H) 
 
>,>ʹ-bis(2-hydroxyethyl)ethane-1,2-diamine 
8.5 g of 2-chloroethanol was added to a suspension of 8 g Na2CO3 in 10.4 g 2-(2-
aminoethylamino)ethanol. The solution was stirred at 120 °C for 29 hours before being cooled 
to room temperature. 150 ml of methanol was then added and the solution filtered. The 
methanol was then evaporated from the filtrate to give a viscous yellow oil. The oil was 
titurated in 150 ml boiling THF for 30 minutes after which the supernatant fluid was decanted 
off and placed in the fridge overnight. The product was then obtained by filtration as a white 
solid (2.4 g). Repeating the trituration of the yellow oil gave a second crop of product (1.1 g). 
Yield 3.5 g (24%) 1H NMR (500 MHz; solvent CD3OD) δ 3.653 (t, 4 H), 2.757 (s, 4 H), 2.729 
(t, 4 H) 
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,,ʹ,ʹ-Tetrakis(2-hydroxyethyl)ethane-1,2-diamine
[150]
 
3 g diethanolamine and 2 g 1,2-dibromoethane were dissolved 
in 50 ml of ethanol. 1 ml of triethyl amine was then added and the 
solution heated at reflux for 40 hours. The solution was cooled to room temperature and 
filtered. Any unreacted starting material was then removed under vacuum to give the product 
as a yellow oil. Yield 3.47 g (92%) 1H NMR (500 MHz; solvent CDCl3) δ 5.322 (s, 4 H, OH), 
3.659 (t, 8 H), 2.652 (s, 4 H), 2.615 (t, 8 H) 
 
[Co(heen)2(>O2)2](>O3).H2O 
11.64 g Co(NO3)2.6H2O and 6 g NaNO2 were dissolved in 20 ml 
H2O and placed in a bubbler. To this was added 8.3 g heen dissolved in 10 
ml H2O and 3 ml conc. HNO3. A vigorous stream of air was drawn through the solution for 1 
hour after which the solution was placed in the freezer overnight. The yellow-orange 
crystalline product was then isolated by filtration. Yield 11.7 g (67%) 1H NMR (500 MHz; 
solvent DMSO) δ 6.672 (m, 2 H, NH, NH2), 5.125 (s, 1 H, OH), 5.082 (m, 1 H, NH2), 3.706 
(m, 1 H, HOCH2), 3.519 (m, 1 H, HOCH2), 2.936 (m, 1 H), 2.817 (m, 1 H), 2.671 (m, 1 H, 
CH2NH2), 2.322 (m, 1 H), 2.241 (m, 1 H, CH2NH2), 2.171 (m, 1 H). 
13C NMR (126 MHz 
solvent DMSO) 56.455 (HOCH2), 53.094 (HOCH2CH2), 51.175 (NHCH2) 42.706 (CH2NH2). 
Anal. Calc. for C8H24N7O9Co.H2O (439.27): C 21.87, H 5.97, N 22.32%; found: C 22.18, H 
6.01, N 22.69. 
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[Co(ceen)2(>O2)Cl]Cl 
1.8 g of [Co(heen)2(NO2)2](NO3).H2O was placed in a 50 ml round 
bottomed flask. 20 ml of SOCl2 was then slowly added with stirring. 1 ml 
of DMF was then added drop wise to facilitate dissolution of the solid. 
The reaction mixture was stirred for 30 minutes after which the thionyl chloride was removed 
under a stream of nitrogen. The resulting dark pink slurry was recrystallised from a mixture of 
water and ethanol. Yield 1.23 g (71%) 13C NMR (126 MHz solvent DMSO) δ 52.488, 51.476, 
42.705, 40.094. Anal. Calc. for C8H22N5Cl4O2Co (421.04): C 22.82, H 5.27, N 16.63%; found: 
C 22.73, H 5.44, N 16.49. 
 
[Co(ceen)2(OTf)Cl]OTf 
[Co(ceen)2(NO2)Cl]Cl was placed in a 25 ml round bottom flask 
and cooled in a salt-ice bath. HOTf was then added drop wise with 
stirring, until the solid was just covered. The reaction mixture was stirred 
under vacuum in the salt-ice bath for 45 minutes. 100 ml of ether was placed in a second salt-
ice bath to which the reaction mixture was slowly added by drop wise addition. Trituration 
aids solidification of the product which was isolated by filtration and then dried under vacuum 
to give a green solid. 1H NMR (500 MHz; solvent CD3CN) δ 5.723 (br m, 2 H), 5.179 (br s, 1 
H), 4.011 - 3.908 (m, 2 H), 3.122 (m, 3 H), 3.006 (m, 2 H), 2.715 (m, 1 H). 
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8.5. Chapter 6 
4,4ʹ-dimethyl-2,2ʹ-bipyridine 
10 g of 4-methylpyridine was flushed with nitrogen for 30 minutes, after 
which 0.5 g of 10% Pd/C was added and the mixture heated at reflux for 1 week. 50 ml of 
chloroform was then added and the solution filtered through celite. The chloroform was then 
removed from the filtrate under vacuum and the remaining solution was filtered again to give 
the product as a white solid. Yield 2.23 g (22.6%). 1H NMR (500 MHz; solvent CDCl3) δ 
8.459 (d, 2 H), 8.150 (s, 2 H), 7.055 (d, 2 H), 2.362 (s, 6 H) 
 
2,2ʹ-bipyridine-4,4ʹ-dicarboxylic acid 
0.046 g of 4,4ʹ-dimethyl-2,2ʹ-bipyridine was placed in a 23 ml 
Teflon bomb with 8 ml H2O and 0.5 ml c.HNO3. The solution was stirred for 10 minutes 
before being sealed and heated to 200 °C for 36 hours. The sample was then slowly cooled 
back to room temperature at a rate of 5 °C/hr. Filtration gave the product as a white crystalline 
solid. Yield 0.0239 g (39%). 1H NMR (500 MHz; solvent DMSO) δ 8.905 (m, 2 H), 8.825 (m, 
2 H), 7.906 (m, 2 H) 
 
[Co(en)2(phen)]Br3 
1 g of 1,10-phenanthroline was dissolved in 6 ml of ethanol. 
1.43 g of [Co(en)2Cl2]Cl and 3 g of NaBr were dissolved in 5 ml of water. The ethanolic 
solution of 1,10-phenanthroline was the added to the aqueous solution, which was then heated 
on a water bath until dark yellow. The mixture was then cooled in ice and the precipitate 
filtered off and recrystallised from water. Yield 0.70 g (21%). 
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[Co(en)2(phendione)](ClO4)3 
0.95 g of [Co(en)2(phen)]Br3 and 0.54 g of NaBr were 
placed in a round bottom flask and then placed in an ice bath. 6 ml of H2SO4 was then slowly 
added, followed by the slow addition of HNO3. The mixture was then heated at reflux for 40 
minutes after which the heat was reduced and the condenser removed for 5 mins. The solution 
was then cooled to 0 °C and added drop wise to a solution of 2.13 g NaClO4.H2O in 40 ml 
water, which was placed in the freezer overnight. The product was obtained by filtration and 
washed twice with 5 ml of 0 °C HCl, and 5 ml EtOH before being dried under vacuum. 1H 
NMR (500MHz; solvent D2O) δ 9.046 (d, 1 H), 8.943 (m, 1 H), 8.864 (t, 1 H), 8.706 (t, 1 H), 
8.292 (m, 1 H), 8.210 (m, 1 H), 5.991 – 5.578 (m, 8 H), 3.292 (m, 2 H), 3.184 (m, 2 H), 3.037 
(m, 4 H). 
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Appendix 1: X-Ray Crystal Data 
[Ru(6ʹ-p-tolyl-2,2ʹ:4ʹ,2ʹʹ-terpyridine)2Cl2] 
Identification code  [Ru(6ʹ-p-tolyl-2,2ʹ:4ʹ,2ʹʹ-terpyridine)2Cl2] 
Empirical formula  C48 H46 Cl2 N6 O2 Ru 
Formula weight  910.88 
Temperature  108(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 11.1012(4) Å α= 110.958(2)°. 
 b = 13.8935(4) Å β= 93.182(2)°. 
 c = 16.8503(8) Å γ = 111.078(2)°. 
Volume 2213.43(15) Å3 
Z 2 
Density (calculated) 1.367 Mg/m3 
Absorption coefficient 0.520 mm-1 
F(000) 940 
Crystal size 0.25 x 0.15 x 0.10 mm3 
Theta range for data collection 1.32 to 35.73°. 
Index ranges -17<=h<=17, -21<=k<=22, -25<=l<=26 
Reflections collected 57750 
Independent reflections 18228 [R(int) = 0.0432] 
Completeness to theta = 25.04° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1 and 0.895017 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7819 / 1 / 521 
Goodness-of-fit on F2 1.078 
Final R indices [I>2sigma(I)] R1 = 0.0615, wR2 = 0.1757 
R indices (all data) R1 = 0.0722, wR2 = 0.1901 
Largest diff. peak and hole 4.241 and -1.029 e.Å-3 
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pytp.2HCl.H2O 
Identification code  pytp.2HCl.H2O 
Empirical formula  C18 H14 Cl2 N6 O 
Formula weight  401.25 
Temperature  118(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 8.3203(2) Å α= 112.3820(10)°. 
 b = 9.8047(3) Å β= 93.764(2)°. 
 c = 11.3191(4) Å γ = 93.041(2)°. 
Volume 848.93(4) Å3 
Z 2 
Density (calculated) 1.570 Mg/m3 
Absorption coefficient 0.406 mm-1 
F(000) 412 
Crystal size 0.24 x 0.19 x 0.17 mm3 
Theta range for data collection 1.95 to 30.99°. 
Index ranges -12<=h<=12, -14<=k<=14, -16<=l<=16 
Reflections collected 24101 
Independent reflections 5311 [R(int) = 0.0324] 
Completeness to theta = 30.99° 98.4 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9595 and 0.9435 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 5311 / 2 / 256 
Goodness-of-fit on F2 1.139 
Final R indices [I>2sigma(I)] R1 = 0.0332, wR2 = 0.0941 
R indices (all data) R1 = 0.0396, wR2 = 0.1086 
Largest diff. peak and hole 0.514 and -0.297 e.Å-3 
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[(bpy)Ru(pztp)](PF6)2.2CH3C> 
Identification code [(bpy)2Ru(pztp)](PF6)2 
Empirical formula  C41 H31 F12 N13 P2 Ru 
Formula weight  1096.80 
Temperature  136(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P -1 
Unit cell dimensions a = 11.8919(7) Å α= 81.000(4)°. 
 b = 12.3372(7) Å β= 77.789(4)°. 
 c = 15.9036(10) Å γ = 66.668(4)°. 
Volume 2087.1(2) Å3 
Z 2 
Density (calculated) 1.745 Mg/m3 
Absorption coefficient 0.558 mm-1 
F(000) 1100 
Crystal size 0.35 x 0.11 x 0.02 mm3 
Theta range for data collection 1.31 to 26.51°. 
Index ranges -14<=h<=14, -15<=k<=15, -19<=l<=19 
Reflections collected 38662 
Independent reflections 8631 [R(int) = 0.1187] 
Completeness to theta = 26.51° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9889 and 0.8286 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 8631 / 0 / 612 
Goodness-of-fit on F2 1.001 
Final R indices [I>2sigma(I)] R1 = 0.0655, wR2 = 0.1564 
R indices (all data) R1 = 0.1494, wR2 = 0.2207 
Largest diff. peak and hole 1.044 and -0.846 e.Å-3 
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Glycolated [(bpy)2Ru(Phendione)](PF6)2 
Identification code  Glycolated [(bpy)2Ru(phendione)](PF6)2 
Empirical formula  C36 H30 F12 N6 O4 P2 Ru 
Formula weight  1001.67 
Temperature  136(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P21/c 
Unit cell dimensions a = 13.3982(11) Å α= 90°. 
 b = 22.3433(19) Å β= 98.509(6)°. 
 c = 13.6758(12) Å γ = 90°. 
Volume 4048.9(6) Å3 
Z 4 
Density (calculated) 1.643 Mg/m3 
Absorption coefficient 0.569 mm-1 
F(000) 2008 
Crystal size 0.13 x 0.12 x 0.04 mm3 
Theta range for data collection 2.19 to 25.05°. 
Index ranges -15<=h<=15, -26<=k<=26, -16<=l<=16 
Reflections collected 75165 
Independent reflections 7157 [R(int) = 0.4831] 
Completeness to theta = 25.05° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9776 and 0.9297 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7157 / 0 / 550 
Goodness-of-fit on F2 0.738 
Final R indices [I>2sigma(I)] R1 = 0.0738, wR2 = 0.1720 
R indices (all data) R1 = 0.3318, wR2 = 0.2288 
Largest diff. peak and hole 0.650 and -0.504 e.Å-3 
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 [Co(heen)2(>O2)2](>O3).H2O 
Identification code  [Co(heen)2(NO2)2](NO3).H2O 
Empirical formula  C8 H26 Co N7 O10 
Formula weight  439.29 
Temperature  136(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 9.3740(9) Å α= 69.965(4)°. 
 b = 9.5745(9) Å β= 87.315(4)°. 
 c = 11.5103(10) Å γ = 62.039(4)°. 
Volume 849.16(14) Å3 
Z 2 
Density (calculated) 1.718 Mg/m3 
Absorption coefficient 1.079 mm-1 
F(000) 460 
Crystal size 0.56 x 0.19 x 0.01 mm3 
Theta range for data collection 2.48 to 25.05°. 
Index ranges -11<=h<=11, -11<=k<=11, -13<=l<=13 
Reflections collected 16406 
Independent reflections 3013 [R(int) = 0.0320] 
Completeness to theta = 25.05° 99.9 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9851 and 0.5833 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3013 / 0 / 245 
Goodness-of-fit on F2 0.975 
Final R indices [I>2sigma(I)] R1 = 0.0222, wR2 = 0.0564 
R indices (all data) R1 = 0.0240, wR2 = 0.0575 
Largest diff. peak and hole 0.279 and -0.246 e.Å-3 
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Appendix 2: P388 IC50 Data 
PC388 IC50 data for [(bpy)2Ru(pytp)]
2+
: 
Submitted concentration: 69 mg/ml 
% Cell 90.45 92.09 87.06 69.94 73.99 25.43 20.23 27.30 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: 47 µmol/L 
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PC388 IC50 data for [(bpy)2Ru(pytp)Co(tren)]
5+
: 
Submitted concentration: 65 mg/ml 
% Cell 85.84 80.31 92.10 101.79 86.78 75.07 38.75 24.44 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: 195 µmol/L 
PC388 IC50 data for [(bpy)2Ru(pztp)]
2+ 
Submitted concentration: 56 mg/ml 
% Cell 93.81 85.69 83.59 77.92 29.95 24.35 11.59 14.83 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: 66 µmol/L 
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PC388 IC50 data for [(tbpy)2Ru(pytp)]
2+ 
Submitted concentration: 69 mg/ml 
% Cell 88.94 100.89 88.08 93.57 76.19 46.13 19.88 1.37 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: 166 µmol/L 
PC388 IC50 data for [(phen)2Ru(pytp)]
2+ 
Submitted concentration: 67 mg/ml 
% Cell 93.92 91.02 78.84 23.16 23.04 35.77 24.89 6.09 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: 38 µmol/L 
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PC388 IC50 data for [(bpy)2Ru(pytz)]
2+ 
Submitted concentration: 73 mg/ml 
% Cell 92.09 93.05 88.10 95.49 92.49 97.88 40.41 -18.85 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: 472 µmol/L 
PC388 IC50 data for [(bpy)2Ru(pztz)]
2+ 
Submitted concentration: 53 mg/ml 
% Cell 82.82 95.92 92.18 92.84 88.46 82.66 76.15 25.83 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: 547 µmol/L 
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PC388 IC50 data for [(bpy)2Ru(pytz)Co(tren)]
5+
 
Submitted concentration: 81 mg/ml 
% Cell 107.40 98.09 95.95 99.69 109.65 98.97 93.60 88.35 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: >641 µmol/L 
PC388 IC50 data for [(bpy)2Ru(pytz)Co(ceen)]
5+
 
Submitted concentration: 94 mg/ml 
% Cell 110.43 90.53 83.22 78.23 70.85 52.73 35.24 5.25 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: 181 µmol/L 
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PC388 IC50 data for [(bpy)2Ru(pytz)Ru(bpy)2]
4+
 
Submitted concentration: 111 mg/ml 
% Cell 116.92 116.88 108.79 114.61 114.14 122.06 93.16 23.62 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: 660 µmol/L 
PC388 IC50 data for [Co(en)2(OTf)2](OTf) 
Submitted concentration: 36 mg/ml 
% Cell 101.10 107.22 96.36 95.25 93.28 75.73 41.86 10.50 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: 303 µmol/L 
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PC388 IC50 data for [Co(ceen)2(OTf)Cl](OTf) 
Submitted concentration: 35 mg/ml 
% Cell 112.22 107.22 94.85 71.74 89.99 77.26 61.54 27.24 
Log ID50 1.989 2.290 2.591 2.892 3.193 3.494 3.796 4.097 
 
 
IC50: 349 µmol/L 
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